Editors’ Note: This is the transcript version of the podcast. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below if you need any clarification. We hope you enjoy!

This week we are breaking down behind the scenes look at when Canada legalized Cannabis and the forward look to global trade negotiations. 

We discuss:

  • How Canadians legalization violated international treaties
  • Why Consumption Lounges could be a massive opportunity 
  • How future global regulations might not include the United States 

About Nathan Mison:

Nathan Mison is a Founding Partner of Diplomat Consulting. As the former Vice President of Government and Stakeholder Relations at Fire & Flower, he was one of the first employees for the company, helping guide it through legalization and into its place as Canada’s largest independent cannabis retail company. Nathan is the co-chair of the National Cannabis Working Group for the Canadian Chamber of Commerce, a board member of the Alberta Cannabis Council. founding member of NorthCanvas, an ancillary cannabis incubator, a member of the Alberta Cannabis Stakeholder Group and a founding member of the Alberta Cannabis Retailers Association. He has a BA in Political Science and Philosophy from the University of Alberta and has volunteered his time as the Past President of the Valley Zoo Development Society and is the co-founder of Politics on Tap.

This show is presented to by 8th Revolution:

At Eighth Revolution (8th Rev) we provide services from capital to cannabinoid and everything in between in regard to the hemp & cannabis industry. Our forward-thinking team can diagnose, analyze & optimize every detailed nuance of your company to keep your business safe, smart, and profitable. Our flexibility and experience combined with ongoing research create unique insights into how to best grow your market share. Contact us directly at [email protected]

Bryan Fields: @bryanfields24

Kellan Finney: @Kellan_Finney 


[00:00:00]Nathan Mison: What’s

[00:00:02]Bryan Fields: up guys. Welcome back to the episode of the dime I’m Brian Fields. And with me as always is Kellen Finney. And this week we’ve got a very special guest Nathan Meissen, president and founder of diplomat consulting and co-chair of the national cannabis working group for Canadian chamber of commerce.

[00:00:18] Nathan, thanks for taking the time.

[00:00:20]Nathan Mison: How are you doing today? I’m pretty great. And life is pretty good. Lots of fun things going on in the world. So it’s a lots of time and lots of change in the cannabis sector and beyond. So going to be a part of it, excited, dive into a bunch

[00:00:32]Bryan Fields: of topics. Kellen, how are you doing?

[00:00:34]Nathan Mison: I’m doing well.

[00:00:35]Kellan Finney: It was a lot of snow on the ground out here in Colorado, and I’m really excited to talk internet.

[00:00:40]Bryan Fields: Yeah, I guess for the record, Nathan, you’re located north of the border. So I don’t know if that goes for either the east or the west Kellen. Do you have a. I think he’s in

[00:00:48]Kellan Finney: Toronto, it’s east, if he’s in Vancouver, it’s west,

[00:00:51]Nathan Mison: that’s right. And the rest of the country doesn’t matter in Canada. So don’t worry. It’s just all blank space. Then the rest of Canada is the only two places that [00:01:00] matter. We can also put Montreal in there as well. So yeah. They’re welcome

[00:01:04]Kellan Finney: to have an east coast versus west

[00:01:06]Nathan Mison: coast, a cold

[00:01:08]Kellan Finney: thing

[00:01:08]Nathan Mison: going on.

[00:01:09] No, it’s funny because Canadians where we would have to make everything a little bit more difficult. It’s central Canada, which we’re Ontario and Western Canada. Cause the east Canada is that Atlantic. So we even add another layer. So we make it more boring in true Canadian fashion while apologizing for it.

[00:01:29] So I’m sorry that I brought that to the table.

[00:01:32]Bryan Fields: Amazing. So Nathan Farr listeners can give a little background about you and how you got into the Canada.

[00:01:37]Nathan Mison: Yeah, so thanks very much. It’s been an exciting ride having a great opportunity to help in the cannabis space from legacy. So legacy cannabis is defined in Canada.

[00:01:47] So Vancouver, Canada had a very unique circumstance. We were moving towards legalization in Canada. But what Vancouver did was actually approved municipal retail. For cannabis prior to actual [00:02:00] legalization. So you had a groundswell of stores that actually were popping up that were selling cannabis that was not regulated federally and that is classified as legacy Canada or cannabis.

[00:02:10] So I was helping some of the legacy cannabis retailers come into the legal sector, which as you can imagine, was an incredible transition and difficult to do because when you’re used to no taxation and knew no rules, except at a municipal level, coming into a regulatory environment that a municipal provincial and federal level that is as difficult as opening a nuclear power plant was a little bit hard for those retailers to decide that they wanted to carry it through.

[00:02:35] But it really spurred the opportunity of what was coming in Canada. And because we were the first G seven and the first , I always viewed this as an opportunity. If Canada didn’t screw it up is that this could be our internet because it was such an economic opportunity that was manifesting here first, where the world would look at us first and then spread it out.

[00:02:58] And we’ve seen that the case, like when we [00:03:00] started legalization in 20 17, 2 countries in the world, we’re talking federal legalization, Uruguay in Canada. Now 59 nations around the world are going through legalization. And the interesting thing from a Canadian was that we had to build our own domestic supply chain.

[00:03:15] So there’s lots of interesting opportunities for Canadian expertise to come abroad. And I wanted to be a part of that because I thought there was some really interesting ways for us to help re write rules at a muni at a city. Providence state level and at a federal level that made sense.

[00:03:30] So I joined with fire and flower. As one of the founders, I was the first employee in Western Canada for them. And I think employee number four overall in, for four years, they have gone from, literally selling ether. Like this is coming. You have to believe it’s coming to 101 stores across Canada, four stores in the United States.

[00:03:50] And they’re in, are now partnered with circle. K. So the 16,000 stores worldwide that circle K has potentially in the future could have fire and flower. So being a part of a company that went [00:04:00] through that kind of growth with that kind of parent that a comma came on board was an incredible opportunity to help write the regulatory framework at the city provincial and federal level.

[00:04:10] And so I was very involved in helping do that running their government relations, regulatory affairs, And communication sides for fire and flower. And they really afforded me the opportunity to help set up a number of the provincial associations as well as the federal association. So that’s you threw it out there.

[00:04:26] Why I became the co-chair of the national cannabis working group of the Canadian chamber of commerce. I was the past chair of the Alberta cannabis council and the Ontario cannabis policy committee. So they really afforded that up. So that opportunity for us to help write the rules, which cannabis retail, or was written on that it’s a spurred some incredible passion in me about what the economic sector and the opportunity that it can be.

[00:04:48] And I don’t know if you guys saw the Deloitte report that was just dropped on Monday out of Canada, we had talked about some pretty fricking big numbers and some pretty exciting opportunities that maybe this is our [00:05:00] internet, if we don’t screw it up. So I think there’s lots of opportunities to represent that, you know at a municipal provincial state and international.

[00:05:09] That doesn’t happen very often. So it’s been a crazy ride and to see the explosion and acceptance of cannabis, pretty exciting.

[00:05:15]Bryan Fields: Yeah. It’s gotta be exciting. And I want to stay with kind of the original framework that you were putting together. Obviously we’ve talked about when you’re leaning on other previous policies like New York who can lean on California and Denver to do the right ways when you were in that room for the first time.

[00:05:30] And you’re saying it’s only you and another country. There’s no other countries you can lean on for framework of her references. So that has to be another layer of complexity and challenges because you’re not only fighting the stigma of the unknown. You don’t have anyone to lean on and say, look, they’ve done it successfully.

[00:05:43] This is what we call.

[00:05:43]Nathan Mison: And big up Uruguay, right? But your way is not Canada. So Canada doing it was going to be the basis of probably what everybody else like since Canada went through the legalization process and just talked about it and went from two countries in the world to 59, it was the first [00:06:00] Commonwealth nation that did it. There’s now 24 Commonwealth nations that are going through cannabis legalization. Right now. They’re probably gonna use common law based on the Commonwealth practice of Canada law to be able to do it. And I think it’s a really good point.

[00:06:14] When you do something domestically, the unintended consequences internationally are so profound. Sometimes that it impacts the follow-up. So just a quick example on that. The federal liberal party led by prime minister, Justin Trudeau, who pushed this initiative forward. This is probably one of the most significant social policy or economic policies.

[00:06:37] When people look back at he’ll be known for, right? This is building a worldwide economy that has built on, but it was fricking hard to do that because you got to push that down through three orders of government, right? Till you get the federal to legalize, then you have to have the province, build the distribution system and the retail environment.

[00:06:55] And then you have to have the cities decide how they’re going to zone it. Can it be close to [00:07:00] daycares, schools, libraries, all of that stuff. But it was, I think one of the really unique things is we were in violation of three international treaties when we actually legalized cannabis Including the controlled substance treaty, which is a little bit of a big deal when it comes to international policy, because that’s how you move drugs across the country are across the world, including pharmaceuticals.

[00:07:24] So China and Russia who had fairly significant negative feelings of cannabis, if they wag their finger at Canada and said that we were in violation, pharmaceutical drugs, could have been to stop being sent to Canada because of our legalization. So what happened is we legalized then the federal government was like, we didn’t legalize, right?

[00:07:45] Like it pretend we didn’t do anything and then get the province and the municipalities to do it all because they didn’t want to piss off the international consequences of what it would mean. And it’s interesting how sometimes how, political sensitivities and cover [00:08:00] our own ass when it comes to big decisions that sometimes politicians make that have huge consequences, both economically and society turn out to be really good things.

[00:08:10] So their decision of the Canadian federal government to lower its eyes actually meant we had to build a domestic supply chain because we were establishing a completely new domestic market for cannabis legalization from production to retail. But everybody forgets about lawyers, accountants, building.

[00:08:29] Who’s going to wrap the windows, who’s going to do security. What are the computers that are going to hold that data system, who is doing point of sales? Who’s doing merchant of financing, all of those other pieces, but what’s really crazy about that is that’s now businesses that Canadians can actually.

[00:08:45] And export to the world because let’s be honest, cultivation on retail is tough to take to the world because you have regulatory environments, advisors, and ancillary businesses. They can go wherever the hell they want. So the economic [00:09:00] opportunity, and now that we’re finally lifting our eyes up and saying, oh yeah, we did legalize.

[00:09:04] Okay. You can pay attention to us again. Is creating some really exciting opportunities for Canadian businesses and Canadians to offer that that opportunity abroad. And that’s a really exciting possibility to create a regulatory framework that looks like. We’re domestic businesses know how to work in internationally and scaling is not something that Canadian businesses are known very well for internationally.

[00:09:27] So it’s a really exciting time where if we, again, don’t screw it up, this could be our internet kind of thing. I have a quick question.

[00:09:34]Kellan Finney: How much of an impact did working at fire and flower have on your ability

[00:09:40]Nathan Mison: to speak

[00:09:42]Kellan Finney: accurately in these conversations when you guys are drafting the regulations and putting these

[00:09:48]Nathan Mison: rules in place?

[00:09:48] So I think it’s a great question because, When you’re building relationship with regulators and politicians, they of course know you’re coming in with a slant, right? Like they know that you’re advocating for a [00:10:00] municipal you a mutually beneficial solution that perhaps gives you a preference over others.

[00:10:07] But if you think about how they’re going to sell it, how it fits in with Arizona, And how it actually benefits all of the sector. There is opportunities to see significant advancement in that and because the sector was so new, and because it was start stop at the beginning of cannabis legalization, like there was nine stores in Alberta and then it was like, whoa, we don’t have enough domestic supply.

[00:10:31] We’re not going to approve any more retails stores for eight or for nine months. To have the supply catch up. Now we’re like, there’s too much supply. And now there’s too much retail stores. So it was interesting because you were telling people like, Hey, this is coming. And they’re like, wow, we don’t believe you.

[00:10:47] No. There’s not enough supply. There’s 9 million square foot facilities that have been built. There’s an extra 1.2 billion grams in Canada of cannabis right [00:11:00] now that cannot be stolen because our domestic market can’t handle it 1.2 billion cramps. It’s a really good point.

[00:11:06] You have to advocate for the middle, show them that you understand their points of view and give them speaking points that is a win for them and a willing for your company and the sector you’re looking to establish. And I think, the fact that fire and flower was so generous in letting me and financial contribution and setting up a lot of the associations that represented the cannabis sector at a provincial and national level.

[00:11:33] It allowed us to have a diverse voice while still having intrinsic ties to one player. And I think that was been very beneficial as well. Regulators often just want a solution. And if you’re willing to put in the work to help them get there, they’re willing to listen. Even though that they know that there might be a little bit of biases in there,

[00:11:55]Bryan Fields: I want to stay on that topic because it’s so interesting. And I never really thought about like the international, pure [00:12:00] pressure that would have been sued if they turned and started wagging their finger. So is that a consideration before that’s legalized? Do you think that’s like a post, oh, I didn’t realize that this was going to be received so negatively.

[00:12:11]Nathan Mison: Oh no, that’s a great question. I, it’s interesting in the fact that it’s a great question. So there’s two different elements in most policy development, right? Politicians and bureau. So we all know that the bureaucracy might’ve been running around in circles, but their hand above their heads screaming, like they were on fire, that we were in violation to that stuff.

[00:12:32] And the political class could be like, we made a promise, let’s get it over the line. Cause we’re pandering the 18 to 35 year olds and we’re going to make this happen, hell or high water. And the guys who are running around in circles that are screaming, they can take care of the international consequences because I don’t even know if I’ll be here in the future.

[00:12:48] I think you have to find that happy balance between the two. There was some movement in other jurisdictions to already see cannabis move. Australia was talking about it and New Zealand was talking about it. Germany was talking [00:13:00] about it. South Africa was talking about it.

[00:13:02] Mexico was talking about it. So I think that’s a really, that was very beneficial. And again, I think it’s also quickly just important in the Canadian context to understand cannabis legalization came through the judicial. It was patients suing for access to better medicinal cannabis. And because we have common law under the Commonwealth, that is judicial precedent in all Commonwealth nations.

[00:13:26] So when the south Africans legalized cannabis through their Supreme court ruling, it was based on the Canadian Supreme court case. So they knew that the ball could have been rolling at that point. So I think it was like, oh shit, this could be a consequence. The ball’s already out of the thing.

[00:13:46] We made a promise. Let’s go get those 18 to 35 year olds. And hopefully the bureaucrats can steer us out of the darkness if we get in too much trouble. Yeah.

[00:13:54]Bryan Fields: So that’s such a complicated puzzle pieces of such situations and [00:14:00] personalities and political understandings that I’ll never even be able to probably come from.

[00:14:04]Nathan Mison: And the thing is just as a quick aside on that is the world health organizations in the United nations in 2020, I’m sorry. Late 2019 did amend the controlled substance treaty to actually exempt CBD and ad declassify, classify cannabis from a class, a felony, right? Or as a class, a inhibitor.

[00:14:27] The also had been advocating at some of the organizations with the treaties that specifically if the Russians and the Chinese got really mad at us, there was movement to change some of that international treaties. And I’m sure that went into the calculus behind the scenes with bureaucrats who were running around and screaming that firefighter world’s on fire.

[00:14:47] So it was intellect to your point. It’s a complicated web, and it’s a bold statement for a country to go first in that environment and then have everybody chasing it. It’s it’s [00:15:00] interesting because the rules are so strict in Canada because it was easier to sell strict rules that you could roll back.

[00:15:08] And that’s one of the environments that we now find ourselves in.

[00:15:12]Bryan Fields: Yeah. It’s a lot easier to loosen the restrictions than it is to be like, put them on first and then be like whoa. We got to tighten this up because you’ve got to walk back that experience and change the customer perception as well as the business operations.

[00:15:23] So staying, yeah. One

[00:15:25]Nathan Mison: was a great example of that Colorado with the animals, right? Like the fact that there was no edible cap at the beginning, people were buying a thousand milligram cakes and then all of a sudden it’s oh my God, we shouldn’t give a thousand milligrams. It was like, we have to lower that a political rule that, and a bureaucratic rule is always give easier to give to the citizenry, then take something away.

[00:15:45] So make it as strict as possible where you can lose it in time. And I think they use some of the Colorado example specifically in that circumstance on our Caltech cannabis policy,

[00:15:54]Kellan Finney: In Florida definitely did where they wouldn’t didn’t even allow you to buy canvas flower to smoke. Which [00:16:00] is the industry,

[00:16:00]Nathan Mison: It’s wild.

[00:16:03]Bryan Fields: Do you think there was an economic influence or an economic kind of major point behind it is saying, Hey, if we do go first, we can capture like a bigger opportunity to position the businesses for potential exposure. If and when the other countries follow suit or you think it was Hey, we think this is a good idea.

[00:16:18] We should do it because it can help the citizens.

[00:16:21]Nathan Mison: I think that’s a great question. And the answer is categorically. No, they did not care about the economics, because again, this was a health Canada led thing because of a Supreme court ruling. And that’s been one of the worst things that’s actually happened for the cannabis sector, because when you have to go up against people who believe reefer madness, that you have to go up with people who are trenched in the tropes of the past.

[00:16:47] One of the ways to crack that. Hey, this is generating $43 billion of economic impact and 151,000 direct and indirect jobs in the last three and a half years, and has continued to grow during COVID as perhaps one [00:17:00] of Canada’s greatest COVID economic success stories. But that. An interesting thing, then I think this is a really important thing to keep in mind is there is not one provincial or federal economic mandate at one ministry or ministerial purview for the economics of cannabis, a sector that is now larger than dairy forestry, mining and automotive production has nobody who gives a shit about the jobs that it creates in this country.

[00:17:28] And I think that is one of the fascinating needing lessons that other countries have learned is if you see what Mexico did, South Africa, Australia, New Zealand, Germany, they’ve all added an economic mandate. And that’s something that Canada has given to the world because we didn’t have to do it. And the politicians realized, Hey, this creates a lot of jobs and a lot of revenue, a lot of government revenue, we should maybe build in the economics into it at the beginning as well.

[00:17:54] So I think that’s a lesson that Canada gave to the look to the world as going first, because we really [00:18:00] screwed that up here.

[00:18:03]Bryan Fields: Let’s talk about one of the challenges of advocating for some of those political stances. I know you, you have your fair share of experiences and probably some stories about maybe some vaping and some of the taxes that go into it.

[00:18:14]Nathan Mison: Yeah. Going into, ministers, board rooms and them telling you that there’s no illegal eight products in the place that you’re advocating for. And you’re like, oh, minister, please tell me more. And then they’re categorically tell you a legal cannabis is not in this jurisdiction. And you perhaps open up a large app that you can order cannabis from illegally and you order vape products for them and to be delivered to that ministerial boardroom and then hit refresh over and over.

[00:18:49] So the minister can literally see the dot, moving closer and closer to be delivering a legal cannabis to his office in a legislative building is pretty [00:19:00] emphatic on your advocacy point. It’s really fun to have those stories because it puts a real world example to the level of ignorance, arrogance and education that the cannabis sector had to provide to people who are so oblivious to actually what.

[00:19:17] The sector is trying to displace and crate too. And I think, that’s a simple example where it was literally somebody telling you like it doesn’t exist. Then it’s we legalized to this place, a sector that had an 80 year headstart that contributes six and a half billion dollars to the economy each year from your own federal stats organization.

[00:19:39] And you’re telling me it doesn’t exist because we’re in this province. Come on. So I think there’s lots of things that, you know, that it seems ridiculous in con in hindsight, but it shows the work that the cannabis sector has had to do to provide even that baseline of education. For the [00:20:00] people who are making the decisions on how the sector actually operates and legislated under that they have zero idea about what the sector is, what it is, how it works, what you’re working towards.

[00:20:11] And that’s probably a lesson that as the state’s pushes forward on legalization or other jurisdiction, the, there has to be some education on the difference between illegal and legal, so that policymakers understand why you’re making a move in that direction and the economic opportunities that came for that because Canada failed in that regard.

[00:20:33] And that’s probably a lesson that we can again, share to the world because it made advocacy much harder. Isn’t that

[00:20:40]Bryan Fields: frightening though? Like the fact that the people who are making the rules have no idea what’s going on. I love going back to the example of governor Ricketts of Nebraska. If you legalize cannabis, it will kill your kids.

[00:20:50] And I just can’t get that out of my head. How in this day and age to see say something like that, unless he’s a hundred percent tunnel visioned in, or someone’s [00:21:00] provided him a talking script and he’s this is what my lobbyist want me to say. This is what I mean.

[00:21:05]Nathan Mison: Oh, my God. Wait. It’s also interesting.

[00:21:09] The changes in attitude when money starts to come involved, when Illinois tax revenue showed that they were making more money off cannabis than they were on alcohol, it was testing out. Many states started to be like, Hey whoa, wait what they, what was that? You were saying more money than alcohol.

[00:21:29] We like more money or, form a police officers who at one time in my own country said that cannabis was the same as murder. And they now own cannabis companies. Like it’s interesting how things can evolve through the process. So what I think is, as we move through normalization and societal acceptance, some of those.

[00:21:48] Statements that are made, that people will look back and realize, oh man, I was really stupid or ignorant saying that hopefully they have enough self-confidence in themselves to realize that was a really stupid thing they said, [00:22:00] because it’s not the same, but it does leave an interesting conversation from a policy point of view.

[00:22:05] And I would imagine that considering who you guys are, that’s an interesting one. I’ve always thought it would be really interesting to do an economic analysis on a cost of government on a cross-comparison between alcohol and cannabis as a new brand. I would love for somebody to fund. I would imagine I’m probably going to get some unique feedback from maybe some of the people in the alcohol and cannabis sector, if you want to do a true cost to society on a neighbor and let’s actually have a foundation of information that we can cross reference against each other to make good policy decisions.

[00:22:37] Because I don’t know about you. I don’t see a lot of people fighting at the end of the night when they’re high over a pack of Doritos that perhaps you might see in with other indie or taking up hospital beds goes over consumption. So I think there’s some really interesting things that as the sector continues to evolve, we can see some good research, good ballsy development.

[00:22:56] The only thing that’s

[00:22:57]Bryan Fields: happening there is those people are falling asleep on the [00:23:00] couch.

[00:23:03]Nathan Mison: Yeah, that’s right. Netflix and chill actually means Netflix and sleep, they still call them. Yes. I also don’t think

[00:23:10]Kellan Finney: that we probably don’t need to conduct the experiment as far as the cost on society, when you compare alcohol to cannabis.

[00:23:17] I think it’s pretty cut and dry personally, as far as, I don’t know anyone that’s ever blacked out on cannabis and made really poor decisions, so

[00:23:26]Nathan Mison: we’ll just leave it there. But it would still be interesting, but so that’s a good, but it’s an interesting point.

[00:23:30] And it comes back to the story about the vape, right? Like vape doesn’t, isn’t illegal in my province. It doesn’t exist. When you’re facing with that level of. Misunderstanding. We sometimes have to show the cost comparison because they understand one side because it has 80 to a hundred years of familiarity and they have no reference to the other side.

[00:23:53] So we have to draw that direct comparison so that there’s an apples to apples conversation so that we can make better [00:24:00] policy from a common level of understanding.

[00:24:03]Kellan Finney: And that understanding has to come from a third party. Unbiased

[00:24:07]Nathan Mison: organization makes sense.

[00:24:09]Bryan Fields: Yes. There’s like bunch of layers of challenges here, right?

[00:24:12] From a political standpoint. And maybe Nathan, you can probably weigh in better than I can. I’m just make some assumptions here is that if you’re a political figure who’s pushing for certain policy and let’s say out big alcohol is one of your biggest fans. They might not want to see cannabis take some of their market share because when I’ve seen some of the estimates for here in New York and some of the potential numbers are just mind blowing to begin, I don’t even know how they’re making those numbers because right.

[00:24:35] There’s adoption for current cannabis consumers, which they don’t know how many people, they don’t know what’s going on in a black market standpoint, but also the users who are now consuming alcohol on a regular basis that might migrate over and capture some of that market share. I don’t know how you can put a number on that.

[00:24:49] And if I’m an alcohol company out, I’m frightened by the concept because the hangovers terrible, right? It’s quote unquote makes you feel bad. You don’t want to get up in the morning and worked out, but from a cannabis [00:25:00] standpoint, it alleviates that burden. So there has to be some fear from alcohol side that like they might lose market share and.

[00:25:07]Nathan Mison: So a couple of things that I think I, I agree with most of the things, but look at the play of alcohol companies into the cannabis sector, constellation with canopy, Molson, with trust Boston brewing with looking to enter into the cannabis space in Canada. There is a natural affiliation to that.

[00:25:26] And I think, we’ve heard some of the decelerated consumptions of beer in United States with a younger population of 18 to 13 or 18 to 35. But that’s a demographic that consumes cannabis at a higher level than other demographics. You can start making unique financial decisions on how to play in both worlds to both demographics, to continue to move it forward.

[00:25:49] And I think you really raised an interesting a point and I, one of the greatest opportunities that the Canadian cannabis market has, but I think a worldwide market abs is the establishment of a cannabis, [00:26:00] tourism and hospitality environment. So the number in Canada is 21.5 to 25% of Canadians consume cannabis based on, based on a number of different numbers.

[00:26:10] So in a country of 39 million people that’s not an insignificant population base, but it’s interesting if you think about it from a policy point of view, people aren’t fighting for the 75 to 79%, of which, by the way, the statistics are the statistics on. Most of that demographic would be interested in trying cannabis, but through ingestibles right, 66% of first-time cannabis users want to have an adjustable experience and that’s not like a combustible, that’s a drink.

[00:26:42] That’s a mocktail that has a nice letter, a distillate. That’s a food based experience. But as a measure dosing that they can have. That and to the conversation that we’re having before about that parallel between alcohol and cannabis, that they can make a direct comp or parallel to, [00:27:00] oh, if I have one shot of something, I feel the effects in eight to 12 minutes.

[00:27:04] Okay. If I have this mock tail with this Iceland, I feel the effects and eight to 12 minutes in the same environment that I can have a drink. That’s when we start to see a greater societal use of cannabis, I think in that regard and considering COVID has completely beat up the tourism and hospitality.

[00:27:25] So I can, I know the statistics in Canada. I unfortunately don’t know it in the states, but I’ll give you one in here. So the Canadian tourism and hospitality contributed $105 billion to the Canadian economy per year, prior to COVID it’s now down to 50 billion, right? A $55 billion. And the crazy thing about that number, and now I’m really policy peaking.

[00:27:47] So I do apologize for it is that is an over-representation of a sector that hires the most underemployed 18 to 20 five-year-olds. So you beat up a sector that is the bridge to get younger [00:28:00] people into the job market as well, by losing more than 48 or sorry, 55% market share. What an interesting opportunity in Canada, we’ll say as an example, to have a differentiated experience when the light bulb gets turned back on and people can start to travel that 29% of worldwide consumers want a cannabis experience when it when they arrive in that jurisdiction, why can’t we fill some of that $55 billion by creating a cannabis experience where 29% of the world travelers come to Canada, where the alcohol companies own some of the cannabis companies that are providing.

[00:28:40] That people can feel the effect with light. They do in alcohol, in an environment at pubs festivals, music, venues, stolen and so forth. So there’s a direct parallel. And I think that’s perhaps one of the most exciting developments that are coming for the cannabis sector. I think it’s really exciting that New York has talked about consumption loans, licenses as [00:29:00] well as Michigan.

[00:29:01] And I think it’s a really interesting opportunity for north America who has three of the biggest nations in it, right? The only three nations in it that are all in different stages of federal legalization to add that as something that they should be perhaps talking about as well. But I think to have a long winded way alcoholism has a law as a way to help steward and advocate for that kind of regulatory change with the relationships politically that they’ve already.

[00:29:30] And both cannabis on to get the cannabis or a sector further along on that adoption. I agree.

[00:29:38]Kellan Finney: I think that cannabis and alcohol need to hold hands and walk off into the sunset together. I know Brian’s shaking his head so excited to hear what he has to say after

[00:29:46]Bryan Fields: this. Yeah. Maybe in the situations where the big alcohol companies partner with the cannabis companies, then sure.

[00:29:53] It’s time. But I think alcohol companies

[00:29:55]Nathan Mison: take

[00:29:56]Kellan Finney: your experience, right? If you’re constellation and you then have the someone [00:30:00] enters, you get a hundred percent conversion rate when someone enters your pump, do you know what I mean? If they’re going to buy a beer or if they’re going to buy a THC drink, versus if you’re only selling the beer and then maybe it’s a, every other alcohol industry should take a, every other alcohol companies should be taking notes right now.

[00:30:16] You know what I mean? All right, go ahead.

[00:30:20]Nathan Mison: So

[00:30:20]Bryan Fields: I agree. I agree with that. That’s totally fine. But what about the alcohol companies don’t have exposure to that? To the cannabis companies? Those were the ones who were like, absolutely not. We need some more time. We need to build our strategy. We need to have more board meetings to discuss the same concept we’ve talked about for probably 10 years.

[00:30:37] And when we make that acquisition, then Nathan it’s time to open up the cannabis. The consumption lodges,

[00:30:44]Nathan Mison: th there are like the bureaucrats that were young are running around in circles with their hands above their head, screaming, fire, and fire before right now. But I think one of the things that’s interesting, and I think this is going to be a very different experience between the Canadian tourism and hospitality [00:31:00] sector and the United States tourism and hospitality sector.

[00:31:03] Canada will not allow cohabitation of India. You will not be able to have cannabis and alcohol in the same jurisdiction. You just won’t buy because there is not because in Canada we legalized medicinal. That then became adult use recreation. This lives at health Canada as the primary regulatory agency federally.

[00:31:28] And there is not peer reviewed research on how the two inebriates work together. We cannot make decisions that will allow those two things to happen together until we do 10 years of research innovation endocannabinoid measurements on how alcohol matches together with CBD, CBN, THCA, all of that stuff, it just won’t happen.

[00:31:50] And what’s interesting is, and this is where the Americans are going to have to make an interesting decision when they’re regulatory is the world’s going to follow Canada in that regard, [00:32:00] not the state. So in nations that will legalize pharmaceutical first and then go to adult regions like Australia, New Zealand, South Africa, Germany.

[00:32:11] So that’ll be a really interesting circumstance. Non-alcoholic. Infused with cannabis. Sure. DDT a full wine that has cannabis in it. Yup. But the two things together, you will not have them go habitated in the same locations, which is good. I could see it going where

[00:32:30]Kellan Finney: I’ve seen a couple of consumption lounge designs out in California here in Denver with the recent passing and like the way the loophole around that is they just literally put two locations next to each other and then they have to bypass between a door.

[00:32:43] And you can’t carry your cannabis, drink to

[00:32:45]Nathan Mison: your bar. You can’t carry alcoholic, drink back, but like you can

[00:32:48]Kellan Finney: go to the consumption lounge, hang out, maybe have a Doobie with your friends and then go back

[00:32:53]Nathan Mison: to the bar where the show

[00:32:55]Kellan Finney: is playing. I’ve seen it approach from that sense. But also I’ve even brought up the [00:33:00] fact that like Lagunitas and some of these other more established breweries have tried, have experimented with putting cannabinoids in their beer and the regulators, the alcohol regulators were like, absolutely not even with CBD, they literally pulled the plug on it

[00:33:13]Nathan Mison: faster than you could even

[00:33:14]Kellan Finney: imagine, and probably has to do with those laws that are those, the

[00:33:18]Nathan Mison: lack of studies that you were just mentioning.

[00:33:20] And even to your point, you’ll never have. That’s an interesting Canadian difference through the states as well, which is a good thing for your tourist market. Because as we know, flower represents one 66% of the cannabis sales currently of current sales. You’ll never have it in Canada. You will never have smoking indoors in Canada where somebody is smoking a pipe, a Hoka joint.

[00:33:44] It just won’t happen. And it shouldn’t it’s better for the

[00:33:48]Kellan Finney: industry as a whole that we’re not encouraging people to inhale things that

[00:33:52]Nathan Mison: are on fire, fundamental

[00:33:53]Kellan Finney: level. This is why I think the hospitality is such a attractive opportunity from a market segment perspective,

[00:33:59]Nathan Mison:[00:34:00] especially steward.

[00:34:00] Under tapped or uncapped demographic, which by the way, is the vast majority of the society that if we could bring them in it’s new market share new opportunity and politically motivated people who could actually represent, Hey, this cannabis thing, isn’t too bad. Maybe you’ve got out of the way, cause I’m not smoking it.

[00:34:21] I would like to go have a drink down at a pub or wherever it is. So that you could actually add that. So I think that’s a really exciting opportunity and I think 2020. Is going to see big advancements on that area in Canada and beyond on the cannabis, tourism and hospitality. And if I can hopefully play a small part in bashing my head against a wall to make through to get that happen I’ll be excited to see what we can achieve on that regard.

[00:34:46]Bryan Fields: I love the consumption lounge idea, and I think from educational side, you bring in consumers were maybe a little more fearful to walk into a normal dispensary and ask those questions. And you take them through the experience. When you go out to California and you have the wine experience and the, they’re [00:35:00] taking you through the grapes and how it was processed and all those beautiful things, maybe learn one or two different things and you feel good.

[00:35:05] You go back home and you brag to your family. I only drank, peanuts from Oregon. You can do the same thing in Canada where you go through that experience, and say, oh I got these great genetics and these strains are world.

[00:35:15]Nathan Mison: Local food, local cannabis, local chefs only in that jurisdiction is a cannabis.

[00:35:22] So we call them farm gates in Canada. They are moving in that regard, which is a similar model to the wineries, but they haven’t bolted on consumption yet. That is probably the come and in, in Canada we have the Niagara region for wine or the the Kalona area, the Okanagan valley for wine, just like you guys have California, Oregon.

[00:35:41] And you’ll see that cannabis opportunities, because again, the benefit is from a policy point of view is, oh, we did that for wine. And it was incredibly successful and bought a ton of tourists here with more money. I understand that parallel. So it’s easier for the politician or the policy maker [00:36:00] to see that and advance that.

[00:36:01] Cause to get us further to that, the more that we can find. Parallels to get the cannabis sector further ahead, the better, because that’s how we actually advanced the cause. And considering this is the third year of the cannabis act in Canada, October 17th, 2021 was the third year. And it has embedded in the act, something that was in hindsight, incredibly intelligent, which was a full legislative review of the act.

[00:36:27] We can actually advocate for the change that we want to actually lessen. Some of that stringent onus that we started with, that we talked about earlier, but we can start having conversations about Hey, can we do infuse restaurants with a dosing station or the creation of a cannabis chef or a cannabis mixologist.

[00:36:46] Now the act is open. Can we push that? We can get into that point of view. And that’s a really exciting opportunity for us to see regulatory change to get us to that environment. So it’s going to be a big year,

[00:36:58]Bryan Fields: so I want to slightly switch [00:37:00] gears on the topic standpoint. Canada’s perception of us and how they’re handling the process or the rollout of

[00:37:08]Nathan Mison: cannabis.

[00:37:08] That’s a great question. So Canadian license holders, which are the cultivators are pleased for the love of God, hurry up and federally do it so that we can push our 1.2 billion, extra grams of cannabis down there into your market. While Oregon, Washington and Colorado are like, please, for the love of God, lets federal legalization happens so that we can push our hundreds of thousands of bounds to the rest of the country.

[00:37:35] That’s an interesting circumstance. We’ll figure out how that plays out in the markets. I think bolting that on to the. Movement as well is a really interesting one because you have potentially cannabis potentially be a part of the U S MCA negotiations in the future. So you have a north American purview.

[00:37:54] Hell. Even if we just start at hemp, which we’ve approved across, now you have a north American CBD[00:38:00] and non-psychoactive cannabinoid market. That’s a really interesting point of view. I think Canadian companies and regulators have started to lose faith that federal legalization is imminent. I think, the political discourse in the states is pretty fragmented.

[00:38:16] So Canadians are looking at other jurisdictions and I say this a lot on conversations with the states and I feel bad cause I feel like I’m always like the negative Nancy of opportunity for Americans. But the fact that there’s going to be a worldwide standard. For cannabis, it probably based around EU GMP production because of the size of the European market and because the federal government isn’t involved in that conversation, it could potentially lock Canadian or American cannabis in America.

[00:38:49] Canada is starting to look at Germany, France, Europe, as a significant place to divert their attention to because the Americans [00:39:00] are trapped in their own border, but there, so I think that’s a really well, so again, it’s that Germany. They do because because we legalize the same way because it’s medicinal first.

[00:39:16] So it’s pharmaceutical grade based on EU GMP standards of production. And because the states hasn’t legalized in the same manner would that same kind of regulatory environment. And the benefit is that’s medicinal to medicinal, not recreational to recreational. So you can have medicinal products that is pharmaceutical grade flow between countries of which there’s potentially 58 around the world that are going through that process while the states is trying to figure out what it is.

[00:39:49] So you’re going to see much more attention from Americans are from Canadians regulators and. Companies to those jurisdictions, I will flag one, just one quick thing for an [00:40:00] interesting point of view. So Canada has had a fairly protectionist experience when it comes to cannabis domestic supply from outside sources to the point where Jamaica and Columbia has threatened the Canadian domestic market with protectionism at the WTO for for not fulfilling its world international treaty obligations between nations.

[00:40:22] So that is actually starting to pop off, which is going to be a really interesting thing to watch when it comes to domestic or international flow of cannabis. Because could you imagine the world trade organization leaning in on trade agreements for cannabis and the states as an asphalt, that, that table, that’s a weird thing to happen.

[00:40:40] So there’s some really interesting stuff internationally. And the states being where they’re at is really hurting their commercialization opportunities. I

[00:40:48]Kellan Finney: just have one quick question. What does the U S MCA, what does that acronym that you threw in there for our

[00:40:52]Nathan Mison: listeners United States, Mexico, Canada agreement.

[00:40:55] That’s not as sexy as it was when it was called NAFTA. That is the new NAFTA. They didn’t [00:41:00] like the name NAFTA because the feedback was us have to be in front of the other countries when they renamed it. So I literally, that was the reason for it. So it is now the United States, Mexico Canadian agreement.

[00:41:12] That is the new year for NAFTA. It’s

[00:41:14]Bryan Fields: good that we didn’t let our ego get in the way when we were naming an agreement. Being left out of those sorts of like conversations, just because we can’t get our act together is so complicated because like you were saying, Nathan, like here in the states, we’re, it’s a state, it’s a state led story.

[00:41:29] And what we don’t have as a federal level is a somewhat of an understanding of a plan moving forward. Or at least that there is, it doesn’t seem like there’s a clear one. When Canada’s looking to, let’s say, expand their operations and they’re limited with which direction they can go. They can either be passive and wait for the U S which is challenging, or they can take that to Europe.

[00:41:46] It’s a bad sign for us because there’s good opportunities as well. But from an exposure standpoint, right? The economies of scale, just based on the sheer location, that’s gotta be another layer of hurdle that the U S operators is going to fall before. [00:42:00]

[00:42:00]Nathan Mison: Yeah, for sure. I completely agree. And, but I think, America will do what America has always done very well and better than most other nations on.

[00:42:09] Build great brands and have great access to capital. So when they do come to market, it’ll be like gobble, right? You’ll have foreign entrance into those markets by acquiring other nations. They, especially, because when you go through federal legalization, you can see some of the bigs who are listed financially on large stock exchange, where they can’t get involved with cannabis because they would avail themselves off of the proceeds of crime.

[00:42:37] Move off the sideline. The other one too, that I think is under talked about, is family trusts that have vice clauses in them. You have big hedge funds and big family trusts who are sitting on the sidelines, but not watching the cannabis sector because they’re not allowed to, because it is a vice because it is not legal.

[00:42:53] I think when the, when that light turns it’ll be just acquisition, like how look [00:43:00] cookies just opened a location this week in Spain. So you’re already seeing brands move in a true way that Americans are great at Americans build better brands than almost any other nation on earth. So you’ll export brands.

[00:43:15] You’ll figure out how to work in that jurisdiction. And then you’ll acquire those domestic companies when the bandaid is ripped off or get put on that analogy is a weird one. But yeah, however that would work. It’d be a

[00:43:26]Bryan Fields: wild time when that goes down.

[00:43:29]Nathan Mison: It will be very, it’ll be very interesting because all of the money who’s been sitting on the side, we’ll just push.

[00:43:37] And the interesting thing that when you have all the money sitting on the outside is you don’t have all the places to put it. So the valuations and the stupidity that are going to come on, the other side of that is going to be pretty problematic because Canada can show you when you have speculated companies.

[00:43:56] The problem is when you get high valuation, You have to show [00:44:00] profitability and sustainability at a certain point. Then when those come crashing down together, it’s not always a good thing. So that’ll be an interesting thing to see when when that happens. And I look forward to enjoying the ride and crying on the way down.

[00:44:12]Bryan Fields: What is one idea or concept about Canadian cannabis policy that Americans wouldn’t know?

[00:44:19]Nathan Mison: That the provincial governments in almost every jurisdiction is the only wholesaler and supplier for retail. So you only have one person to buy from in most jurisdictions and in Canada, who is the government who takes money on the front end from the cultivator and the back end from the retailer to the point where that Deloitte report that came out, that we referenced earlier, show $43.5 billion of economic contribution to the Canadian economy since legalization and 15 billion of that went to tax policy.

[00:44:53] Our taxation, that is a big nut. And that’s because the government was smart, depending on [00:45:00] what insider you are and put themselves in. So you can’t go anywhere else. They’ve given themselves government monopoly where they get the set up prices and negotiate the cut on what they’ll buy for. So it’s a pretty tough,

[00:45:13]Bryan Fields: you think that’ll be the same way long-term or you think that eventually the companies will look to push?

[00:45:18]Nathan Mison: No, we’ve been pretty proud that we’ve already seen some significant change. Alberta, the jurisdiction where I live in just close there. Government monopoly e-commerce website. So in the province that I lived in, they were the only e-commerce and delivery website. They’ve now closed that so that private companies can actually have act test that e-commerce and delivery.

[00:45:38] So I think there will continue to be changes. And it’s not like the government can’t get its touch and get out of the business of being a wholesaler and distributor without taking the capital cost of it. We have lots of other sectors that we could probably point to. I dunno, like alcohol that you do the exact same thing in where you still take taxation on the top, but private sector has got to be the [00:46:00] wholesaler and distributor.

[00:46:00] So I think it’ll get there, but it made sense when it was easier to give it to citizenry than take it away. So they controlled supply at the begin. And they control the revenue because nobody knew what the hell this was gonna look like. Cause we were the first G 20 country in the world to do it. So it was a safer alternative to tell the citizens you control it.

[00:46:22] Yeah, it makes

[00:46:22]Kellan Finney: sense. Honestly, especially with an emerging market like that. And who knows how police service could have been from a startup company, that’s trying to figure it out on the fly and they don’t have that professionalism that comes with the government organization. I think it’s smart from the beginning and it’s cool that they’re able to change it now.

[00:46:39] Yup.

[00:46:40]Nathan Mison: Yup. Some of us employed are with consulting contract, so that’s also a good thing too.

[00:46:45]Bryan Fields: It probably looks really nice on an Excel sheet. They’re like, see, we’re making twice as much.

[00:46:50]Nathan Mison: Yeah. Yeah. 43.1% is the taxation on cannabis and the province that I live in. How do you displace an illegal market? When the [00:47:00] consumer, without markup at a retail level pays 43.1% before the product is even on the shelf for sale.

[00:47:07] That’s insane. It’s

[00:47:10]Bryan Fields: hard to understand that, like hearing you say that, like you just think about it from like a numerical standpoint, it’s still hard to understand. That’s

[00:47:16]Nathan Mison: crazy. That’s crazy. I I can call her

[00:47:19]Kellan Finney: even here in Colorado, like there’s dispensaries or storefronts that I’ll pay 20, 30% taxes on, but the cannabis is still cheaper now than it was 10 years ago in the legacy market.

[00:47:32] Like

[00:47:32]Nathan Mison: significantly cheaper, like insanely cheaper compared to at least in Colorado, right? Industrial agriculture’s industrial agriculture is a whole hell of a thing, right? Like when you open your and millions of square feet and acres and acres of outdoor grow, you all of a sudden have a cheaper product because now there’s more of it.

[00:47:51] So that’s a good thing for consumers, a bad thing for the growers. So that has to be the counterbalance between the two, but they [00:48:00] don’t have to worry about the

[00:48:00]Kellan Finney: feds rolling in now. That would be the kind of point, I guess

[00:48:05]Nathan Mison: they’re not going to go. I think that they’re talking 25% taxation at a federal level as well.

[00:48:10] So that’ll be interesting to see how that works out if that bill goes forward. So the taxation policy is going to be very interesting to watch it, the states. And I would recommend that American companies look at Canada cause there’s some really good stats based analysis that we would love to share so that hopefully we can help arm you with some of that policy and research to advocate for better decision making.

[00:48:31] So one of the things that you asked, what people can know about the Canadian space, that American companies don’t. We’ve done a lot of this. Give us a call because we’d love to share with you so that we can make better policies and we hopefully prevent you from falling on your face as it really hurts to fall on your face and then step up and try and fix it.

[00:48:50] So if we can work together to create a better example of what a cannabis market can be Canadian companies are happy to share that a lesson with with American compatriots

[00:48:59]Bryan Fields: since you’ve been in the [00:49:00] cannabinoid industry, what has been the biggest misconception?

[00:49:03]Nathan Mison: That’s a really interesting conversation.

[00:49:04] So I, that I didn’t support. Because I work for a licensed producer or a retailer that was seen as like one of the real white collar corporate cannabis companies that was so out in front and significant development people didn’t see that we were advocating for the entire sector. They saw that we were just advocating for better fallacies for for fire and flower and for corporate cannabis and not understanding that, to build a better sector that displaces the elect the illegal.

[00:49:35] I was advocating for as many of legacy people to come into the market as easy as possible because we want their better cannabis and you’re going to displace the elicit sector by bringing people in as quick as possible and easy as possible. And I think that was a real challenge that I got beaten up a whole bunch from people who thought, I wasn’t supportive of the whole sector.

[00:49:55] It was just the big corporate. And that was not the case [00:50:00] as I’m sure, there can be some vitriol from certain segments these days on social media and stuff like that. You could get beat up pretty good about it, but, considering argue with politicians for a living, I’m pretty lucky to have thick skin.

[00:50:11] So I only cry inside, not on the outside. That’s the only thing that matters. Yeah.

[00:50:17]Bryan Fields: If you can set up your experience in the cannabinoid space, any main takeaway or lesson learned to pass on the next generation?

[00:50:26]Nathan Mison: It’s an economic opportunity that is unfettered. My kids are going to grow up in a world where cannabis is going to be larger than alcohol and accepted by more people and utilize more diversity.

[00:50:40] Hurry up and get us there instead of fighting for beliefs from 50 years ago, that would be one of the things I would love to see. Okay. That’s well said.

[00:50:50]Bryan Fields: All right, prediction time. I wrote this one on the fly, so I apologize for mumbling it. How do we get the NAFTA [00:51:00] or formerly known NAFTA agreement to allow for cannabis sales across us, Canada and Mexico.

[00:51:07] And does it need federal legalization to occur?

[00:51:12]Nathan Mison: Great question. I am very involved with the Canadian chamber of commerce. I believe that the chambers of commerce, because they represent everybody in the supply chain, cultivators retailers and ciliary businesses is a great way to do it. I believe that the political relationships that he have with traditional economic actors representing it towards politicians who are thinking that it’s just a cannabis company coming in there and whining for better policy that they can take advantage of to the point of the past.

[00:51:41] And I would start with non-psychoactive cannabinoids, like CBD CBN, THC, because they’re already approved in all three locations. So start there and then let’s work to a neighbor is when. The next USM CA review is in 2023. Let’s roll up our sleeves and let’s get her done, right? [00:52:00] Let’s have a north American perspective.

[00:52:02] It’s on the books. You pass the farming act. We have it federally legislated and the Mexicans federally legislated. Have you heard one person talk about it? Why not? Why not? It’s just a simple question to ask. So if we put it out there, maybe we can force it to actually be a part of the conversation and from a political politician point of view, it’s an agricultural product, not an, a neighborhood.

[00:52:26] So maybe they feel safer doing it.

[00:52:28]Bryan Fields: Convinced governor Ricketts county.

[00:52:30]Kellan Finney: First we did pass the farm bill, but that did not seem to do much for CBD as far as rescheduling it or saying it’s safe or really anything it’s still in that gray area. You know what I mean? So

[00:52:42]Nathan Mison: what,

[00:52:42]Kellan Finney: we should probably figure out what we’re going to do with CBD first, and then we can move forward, but I think it does require federal legalization, honestly, at least on the U S as part, because.

[00:52:52]Nathan Mison: U S is going to just look like an outlier

[00:52:54]Kellan Finney: sitting on a table with two countries that have robust established matured [00:53:00] markets, where even when we talk about representatives, not knowing that they’re still illegal the products on the market.

[00:53:06] I can’t even imagine the ignorance that the U S representatives approach that conversation with never even having a real marketplace to, to have cannabis sales from a federal perspective. You know what I mean? And so I don’t think there is a conversation. I think the point is moot

[00:53:23]Nathan Mison: or it’s like this.

[00:53:25] Yes. Buyers and cover my eyes. So please go ahead and talk about it. Like I, I think that’s probably where that, but like jury. Is going through adult use recreation, France is going throughout and use recreation. Like these are not small other nations. These are traditional American allies who are going through that process and you’re surrounded on both borders.

[00:53:49] So it has to get there where you’re not taking a political risk anymore, and it’s a huge economic opportunity. So I think it’ll when the light [00:54:00] bulb turns, it’ll go very quickly. The question is what is the policy that you get that you have to live within? Because I think when you rush the consequences of rushing are more scary than taking the time.

[00:54:11] So that would be the one thing that I would worry about when America turns that light our, when flips that switch, what the policy will come out the other side, because the cannabis sector might advocate for the next five to 10 years, the roll back, some of the things that were embedded in the legislation during the.

[00:54:29] I agree with what you

[00:54:30]Kellan Finney: said, except the only caveat is you do have to do something. We can’t just hang out with your patient.

[00:54:37]Nathan Mison: Twenty-five years. Eventually have to take a step forward. We can’t just talk about, and there are five bills in both houses there isn’t stuff to talk about. You know what I mean?

[00:54:49] Like there’s and I think it’s isn’t the majority of American states are

[00:54:54]Bryan Fields: 63% or 68. I think it was 68.

[00:54:58]Nathan Mison: And by the way, this is the [00:55:00] most popular public policy position in the United States for the citizenry is cannabis legalization at a certain time, maybe a politician is going to be like, wait a second.

[00:55:10] So 70% of people like this, why aren’t I jumping on that? Cause I like 70% of American voting for me. So I think, sometime hopefully we’ll combine that political opportunism with common sense policy make,

[00:55:23]Bryan Fields: it seems like a layup, right? Just to think about that. Statistical standpoint, you got to feel pretty good going in knowing seven out of 10, like it, I’m not going to feel good laying here, but what I never thought about until you said it, Nathan was the international peer pressure, that kind of goes into it, right?

[00:55:37] Because if the U S is being left out of these conversations, because we can’t get our act together, besides the economic standpoint that we’ll miss out on, God knows how much money, but like it’s also an embarrassment as someone who takes themselves as like the world leader, we need to be at the forefront of this.

[00:55:51] And if we’re sitting back because whoa, we haven’t gotten our act together, it’s going to be embarrassing. So I wonder if the cabinet or the political leaders help push that a little [00:56:00] faster to be like, Hey, like these conversations are happening with, or without us, we need to do something first.

[00:56:05] So we can partake in these conversations because we would like to influence how that arrangement goes. And that might expat the timeline a little differently than I ever thought.

[00:56:14]Nathan Mison: You’re on.

[00:56:15] You’re closer aligned with Russia. and China than you are with Germany, France, Mexico, and Canada.

[00:56:22] Oh my God. Just to throw it out there.

[00:56:25] Oh my

[00:56:26]Bryan Fields: God. If I want to stinks that one hurts, throw it out there. That one hurts. That one really hurts off the clip that, and maybe remove it. Cause that one’s a little too painful for some of our listeners.

[00:56:36]Kellan Finney: Maybe our strategy is just let Mexico legalize it, then they can grow it all. And then we’ll just import

[00:56:41]Nathan Mison: it somewhere.

[00:56:44] Nancy is spinning in her grave. So I’m like, oh my God, it’s terrible. That’s so terrible. That will help our trade deficit. It’s true. I do have to run. I am really sorry. I would really love to carry the conversation that I have to jump to another one. [00:57:00] Thanks so much for your time, Nathan. Appreciate it. No problem. [00:57:02] It was a real pleasure. I look forward to having it again, guys. Absolutely talk soon. Thanks. Be well.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Editors’ Note: This is an excerpt from our Monthly Playbook. If you would like to read the full monthly playbook and join the thousands of others you can sign up below.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Editors’ Note: This is the transcript version of the podcast. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below if you need any clarification. We hope you enjoy!

This week we are joined by Natalie Katz and Wayne Nasby of Ocean Groves Ventures to discuss

  • Israel researched backed medical trials 
  • Big Pharma’s view of Cannabis
  • Challenge of Education/ Marketing Misinformation
  • And so much more

Ocean Grown Ventures mission is to shape the cannabis industry with revolutionary Research & Development through international scientific partnerships and pharmaceutical grade products for the benefit of humankind.

This show is presented to by 8th Revolution:

At Eighth Revolution (8th Rev) we provide services from capital to cannabinoid and everything in between in regard to the hemp & cannabis industry. Our forward-thinking team can diagnose, analyze & optimize every detailed nuance of your company to keep your business safe, smart, and profitable. Our flexibility and experience combined with ongoing research create unique insights into how to best grow your market share. Contact us directly at [email protected]

Bryan Fields: @bryanfields24

Kellan Finney: @Kellan_Finney 


[00:00:00] What’s

[00:00:02]Bryan: up guys. And welcome back to the episode of the dime I’m Brian Fields. And with me as always is Kellen Fiddy. And this week we’ve got a very special guests, Natalie Katz and Wayne NASBE from ocean grown ventures, Wayne and Natalie. Thanks for taking the time. How are you doing today?

[00:00:16]Natalie: Well, thank you.

[00:00:17] Thanks so much for having

[00:00:18]Wayne: us. Great. Thank you very much.

[00:00:21]Bryan: Appreciate you guys joining and I guess for the record, your locations would be.

[00:00:26]Natalie: Los Angeles. We are in LA

[00:00:29]Kellan: it’s a west coast. Bascos here we

[00:00:31]Wayne: go.

[00:00:32]Bryan: Going to have to edit that part out count. So cool. So I’d love for our listeners to get a little background about both of you and how you got into the cannabis space, Natalie.

[00:00:43]Natalie: Absolutely. So I’ll speak on behalf of myself and my father. We kind of got into this together. Um, in 2017, we really wanted to honor my grandfather’s legacy. He passed away from cancer in 2002, and one of the biggest things in his life was being philanthropic and making the world [00:01:00] a better place for people.

[00:01:01] And he had escaped the Holocaust when he was only 13 years old. I’m one of the last boats out to what is now known as Israel. And to honor his legacy, we decided to invest in Israel and kind of. Figure out what they’re doing that are helping people right now. And it turns out they’re actually the leaders in medical cannabis research, which is something we were not aware of.

[00:01:19] Uh, it really all started with Dr. Raphael Meshulum in the sixties, but ever since then, they’ve been the world leaders in medical cannabis research. And we thought that that was the perfect way to honor his legacy is, is providing, um, a product and a solution to help people’s quality of life. And that was our biggest goal.

[00:01:36] So I am the brand manager. Uh, helping kind of create the tone and messaging of the brand, what the packaging looks like and who we are as a company. Um, unfortunately my dad, Jerry is unavailable. He is flying back from Israel as we speak right now, but we do have Wayne RCLO with us. So Wayne, you can give them some background on yourself to.

[00:01:56]Wayne: Yes. Most certainly. Thank you for that. Um, [00:02:00] uh, guys, nice to meet you. Um, my background is a little bit unique. I’ve I’ve been in a pharmaceutical biotech industry for over 30 years and my areas of expertise are really, um, GMP operations, product commercialization, anything related to compliance with the FDA, as well as, um, helping do conceptual designs and build out.

[00:02:25] Of of manufacturing facilities. So really it just encompassing all of GMP operations. And then I started early on in Amgen and then from there, um, I started, uh, co-founded a drug delivery, uh, technology company here in California. Um, and that just took off and we were just doing great stuff there as far as working with molecules and figuring out the best way to deliver them.

[00:02:52] And then, um, it was at that point. That I hooked up with Jerry and Natalie. This was around [00:03:00] 2000 and late 2017, 2018. And they were trying to, um, get me involved in the cannabis industry and taking what I had done in the pharmaceutical world and apply it in the cannabis space. So, uh, needless to say, I wasn’t really interested at the time for various reasons, but, um, at one point.

[00:03:21] I had a very, you know, mind opening event where I was given the opportunity to meet the research scientist at a very well-known university here and there. They’re focusing on, um, pediatric pediatric, excuse me, pediatric cancer. And it was just unbelievable what they were doing. And I realized then that my perception.

[00:03:47] Of cannabis, um, was completely wrong. And I wanted to focus all of my energy and trying to help develop the methodologies and the, and the, and the science behind cannabis from a, from a [00:04:00] commercialization perspective. And I’ve been doing it ever since. So it’s pretty exciting for us.

[00:04:05]Bryan: I appreciate you sharing that.

[00:04:06] And Wayne, I can hear some of that hesitation, so I don’t need to ask you if you hesitated to jump in the space, but Natalie, I want to, I want to start with you. Was there ever any hesitation to kind of come into cannabis? Obviously has Wayne really shared, there was that stigma and there still is the stigma of cannabis.

[00:04:20] So any hesitation for you to kind of attach yourself to.

[00:04:24]Natalie: Funny that you say that because something that my father Jerry always says is, you know, he would never bring me into this business just to create a rec brand for whoever gets some of the most high that is not our goal here. And while we have no issues with recreational cannabis that’s to each his own, this is truly a medical.

[00:04:41] Uh, brand that we’re promoting and that we’re focusing on and it’s really about improving people’s quality of life. So for me, it was an absolute, no brainer. I’m realizing that a natural solution like CBD and also teach, see products can improve people’s quality of life is amazing. So knowing. Whatever you’re doing every day is making someone else’s [00:05:00] life better is very rewarding.

[00:05:01] Um, so although we hadn’t anticipated, when we went to Israel to kind of see what was going on there, that they would be the world leaders in medical cannabis research. It, it almost felt like his man, like I was saying, we wanted to honor my grandfather who passed away from cancer and Israel is conducting clinical trials on cancer research with cannabis.

[00:05:18] So it all seemed to fit. Um, and so, yeah, no, it’s, it was honestly a very easy jump. I came from social media and marketing. And so it kind of just made sense

[00:05:28]Bryan: where the conversations in Israel eyeopening, obviously what they’re doing is pretty impressive. So I’m sure hearing some of the advancements that they have has got to be pretty simple.

[00:05:36] It’s

[00:05:37]Natalie: it’s unlike anything you would ever expect. I mean, they’re around a decade ahead in terms of medical research, just because of the illegal landscape that’s there. Um, you know, our, our partner is actually the first company to be granted a licensed by the Israeli ministry of health to produce pharmaceutical grade CBD and THC products.

[00:05:55] So. our partner, all of their products in [00:06:00] Israel are manufactured, uh, you know, to pharmaceutical standards and then prescribed by doctors and patients get them at a pharmacy. So we’re basically kind of. Taking that same product, but selling it online because of the legal landscape in the United States. So it’s a pharmaceutical grade product, but it’s not going through the same typical channels just because of the current legal landscape and pinata is able to conduct clinical trials and do research and weighs on their product that is just not allowed in the United States.

[00:06:27] And it’s really unfortunate, um, that the U S is so behind in this respect, but we’re really excited to. Bring this technology, this science to the space, we really want to legitimize it. And it’s something we always talk about is we want to bring all the benefits of pharmaceuticals, you know, pharmaceutical manufacturing, the standardization, the quality management, the quality of the raw materials, the consistency, all the things that you like about pharma without any of the negative aspects of it, you know, where it comes to being highly addictive or potentially negative side effects.

[00:06:57] So we have this natural solution of CBD, but [00:07:00] then we’re making it to the same standard that you would take in. I would never question with your Advil that, that, that tablet is going to be different than another one. It’s going to have a different amount of the active ingredient that doesn’t happen in those kinds of products.

[00:07:11] Whereas in CBD, as we know, it’s kind of the wild west in the United States right now, and there’s a lot of mislabeling and there’s a lot of adult traded products. And so we wanted to kind of create a new standard for the CBD industry and match it to that of the pharmaceuticals.

[00:07:29]Bryan: I love it. And it’s quite daunting to hear it because we know some of the challenges that you’re up against and especially with the advancements and where Israel is.

[00:07:36] And especially here in like the east coast, for example, I still have field conversations for people who try CBD products and their first question out of that. Will this get me high it’s concerning because there is an educational gap. And then when you’re talking about marketing a pharmaceutical gate product, there are so many challenges from that sense, because not everybody is handling things, let’s call it quote unquote, the right way.

[00:07:59] So [00:08:00] Natalie, in your opinion, from a marketing standpoint, discuss some of the challenges that go into us and discuss how your team overcome some of those.

[00:08:07]Natalie: Yeah, I would say one of the biggest things is, is misinformation and false claims. So although we know that CBD can help with so many things, legally speaking in the United States, we cannot make those claims.

[00:08:20] So, you know, we cannot say that it helps with pain or anxiety or any disease state. And we’ve actually learned a lot about what we can and cannot say, thanks to Wayne and his. Uh, expertise in this category and with compliance. So what we’ve come to realize is we really need to come from an educational standpoint and explain.

[00:08:39] How CBD actually works in the body and kind of get rid of this whole supersizing culture in America, where they tend to believe that the more CBD the better, oh, this has 5,000 milligrams. Like that’s going to work better than this one that has a hundred. Unfortunately, that’s just really not how medicine works.

[00:08:55] Um, you know, from a pharmaceutical perspective, you always want to start with the lowest dose and increase as [00:09:00] needed. And so one thing we’re trying to convey to consumers is just that is that you need to have. A true pharmaceutical grade product, and it needs to have high bioavailability, which is actually the amount of active ingredient that’s being absorbed into your bloodstream.

[00:09:13] And so it’s able to have an active effect. So it’s not even about the milligram dosing, it’s about the actual absorption of the product, and that has to actually be tied to study. So there’s a lot of companies that also claim that they have high absorption. Where are those claims coming from? They’re anecdotal.

[00:09:30] Right? But because they’re in Israel and able to conduct clinical studies has conducted something called a pharmacokinetic study, which measures the active ingredients flow and metabolism throughout your body and the distribution throughout your body. So unless they have those studies, there’s no backing up the claims that they have high absorption.

[00:09:48] So our products have that pharmacokinetic study testing, and that also helps determine the dosage and the Milgram crowd of our products. So everything behind our products is intensive. And there’s a reason why their dose that way and [00:10:00] why they have that milligram count. So it does take a bit of education to explain that, but we’re trying to partner with doctors and physicians that want a brand they can trust and know is properly dosed and properly manufactured.

[00:10:12] So that is kind of the direction we’re going in. Is the health care practice.

[00:10:16]Kellan: I have a quick question. How challenging has it been knowing that a similar product or identical product from a formulation perspective in Israel can be tied to these claims? Right? And then you are trying then to communicate that same messaging to.

[00:10:31] The is in a different country, but you can’t like how challenging has that been to navigate that world? If you will. I

[00:10:37]Natalie: say it’s frustrating as an under, so a lot of it has to do with semantics as well. Like for example, you said, you know, we can’t mention any disease states that we can’t specifically claim that it helps with something, even though we know.

[00:10:50] That it, it, you know, it does their clinical trials to back it up. Um, but hopefully in the near future, you know, is conducting clinical trials on THC products as [00:11:00] well. And we hope to have clinically proven claims within the next few years, uh, which will be a huge differentiator for us as well. But yes, it’s really difficult.

[00:11:08] We’re also seeing a lot of, um, claims made on packaging, pain, relief, you know, all sorts of things. And if you notice that on a packaging, that should be a little red flag to you. Um, They’re not quite listening to what compliance rules are stating. So that should be a warning sign. Um, obviously every, not every brand is breaking the law, but you do need to be aware of the claims that these brands are making and realize what that actually indicates about how that brand off.

[00:11:38]Bryan: There’s there’s so many, there’s so many challenges here from perspectives too, right? Like, and I want to stay with the supersizing one because in my experience I’ve found most people when they’re purchasing a product more is always better. It doesn’t matter. It’s always, always, always better. And I wonder if that’s just like a cultural stigma, if that’s a global [00:12:00] phenomenon or if it’s trying to get the best of value bang for your buck, but you’re right.

[00:12:03] Like having, having that challenge there. Let’s say all things equal to people who don’t know what they’re doing. Look at the two different products. Sometimes people will, may be more leaning towards the more in just that scenario. I need to make a difference what it is it. So communicating that and educating them, but understanding that from a long-term perspective, the value is so challenging.

[00:12:25] And I give your team a ton of credit for putting up the fight, because it takes individuals like yourself doing it the right way to help set the industry.

[00:12:34]Natalie: Thank you. Yeah. Wayne, do you have anything you want to add to that?

[00:12:37]Wayne: Yeah, I think you’re, you’re absolutely right. And that’s the reason that’s the, you know, the foundation of why we are focused on the healthcare practitioner channel, because we realized early on in the, in the retail channel, the distributor channel, we didn’t have.

[00:12:57] That we’re educating the consumers [00:13:00] and telling the story and having the conversation with the consumers so they could get a better understanding of why they don’t need a super dose and why bioavailability was so important. Right. So when we started to get doctors that were interested in, um, helping their patients with alternative, um, products.

[00:13:25] Uh, not, not synthetic drugs, right? They didn’t have a brand. They could recommend, they didn’t know if a brand was safe. They didn’t know if it worked. They, they were clueless because they didn’t have enough information. So we’re seeing now when we started to approach. Physicians and share with them the information from a compliance perspective, from a pharmaceutical perspective, um, their eyes just opened up and they’re like, where have you been?

[00:13:58] We’ve been waiting for, for [00:14:00] a brand and people in a company like yours. So. W our, our, our goal is it’s the physicians that are going to be our champions. And they’re the ones that are going to be out there helping people when people come, uh, their patients, I should say, you know, and they say, Hey, you know, doc, what do you think about CPD?

[00:14:20] You know, for, for whatever their indication is, you know, that’s when the doctor will say, well, I think you might want to explore this. You know, if, if a doctor recommends something nine times out of 10, You’re probably going to give it a shot. You’re going to give it a try. I know I do. Um, and that goes far for us.

[00:14:38] And I think by going with the HCPs, we’re really going to have a huge impact and do some good. Yeah, I agree.

[00:14:46]Bryan: And I might say your nine out of 10 might be a little low from a real statistical standpoint on people’s purchasing factors recommendations. So staying in that direction, though, when you’re speaking to these physicians, is it more educational focused?

[00:14:58] Are you using the research to let it stand for [00:15:00] itself? How do those conversations go?

[00:15:03]Wayne: Yeah, I would say

[00:15:06]Natalie: I was going to say Wayne. Yeah, it’s a combination, but I’ll let Wayne take this since he has the expertise in this industry. So go ahead, Wayne.

[00:15:14]Wayne: Well, I think the, you know, the pharmaceutical model really, there’s a couple things that are going on here.

[00:15:19] One is that. Doctors strictly focused on science, they focus on results. So that’s the foundation of the discussion. So you have that. We have that from our partner Panex. Yeah. We have the trial data. We have the information and what we’re doing with CPD Or at least our brand is we’re saying, look, we’re going to tie this to a specific indication and that indication will be tied to the dosage of the product.

[00:15:46] And then the dosage and the product will be tied to the delivery method. Is it a tablet? Is it a liquid? Is that a topical and those three things. Is a very common way of looking at a product [00:16:00] in the physician’s world. So they get that and they think, and they’ve always gotten that and that’s how their programs.

[00:16:06] So we’re very excited to have the conversation and the, and the marketing materials, the physician detail aids, all that. Is tied around the pharmaceutical model and that’s what makes us stand out because, you know, we are representing to a certain degree of pharmaceutical company. We’ve got pharmaceutical grade products and we’re having almost like a pharmaceutical grade conversation.

[00:16:28] So the combination of all three really makes a good business sense and it, and it makes sense to the physician. I have a question

[00:16:35]Kellan: about education and how challenging has it been dealing with physicians in the U S where the endocannabinoid system isn’t really even taught in medical

[00:16:43]Wayne: school? It’s a huge challenge and it was even worse a few years ago, but now positions are starting to think otherwise, because now they’re, they’re starting to hear more information.

[00:16:59] Yeah. They’re [00:17:00] starting to read more articles and more of there are more of their patients are starting to approach them and ask them questions about it. And the last thing a physician in my mind wants to do is not have an answer for a patient, right? So they want to have at least some knowledge, some good working knowledge where they can respond to the patient.

[00:17:19] And if we can provide that information to the physicians, then the entire. Um, session with the patient goes so much better. So it’s a win-win for the, for the patient, for the doctrine for us.

[00:17:31]Natalie: And to tag onto that, we also have access to as official physician’s desk reference guide. So anoxia in Israel, in conjunction with Israeli ministry of health actually created.

[00:17:43] You know, a physician’s desk reference to go over how CBD THC works, how it interacts with the body dosing, protocols, indications, everything like that. So they truly have the expertise and knowledge to educate. And we do plan on having continuing medical education courses that [00:18:00] are provided to doctors so that we can educate them in this field.

[00:18:04] And that way they can feel confident actually recommending products to our, to, to their patients. And.

[00:18:10]Bryan: It’s so important to, right, because you’re not just fighting the stigma from a customer standpoint, you’re also fighting the doctors who are, some of them have practiced medicine for God knows how many years trying to put a number to it.

[00:18:22] But life right now, you’re, you’re opening up their eyes to possibly. Endless possibilities. So I can imagine the compliance standpoint is probably a really beneficial aspect when you’re communicating them right. Having a reproducible product, one that’s compliant, and one that follows a similar standard.

[00:18:37] So I’d love to kind of stand on that topic too. Now. So Wayne, in your perspective, what, what compliance aspects now are really differentials for your.

[00:18:47]Wayne: What compliance aspects are unique to us? Is that what you’re asking

[00:18:50]Bryan: me? Yeah. What compliance aspects are important that maybe the most, the industry isn’t following are ones that kind of separates your team from some of the peers.

[00:18:58]Wayne: So this could be a long [00:19:00] call.

[00:19:04] It’s really interesting because. Just about every company that manufacturers are distributes and sells CPD. They all say the same thing to the most part. They all say that, um, their product is third-party tested. They have a certificate of analysis and they claim to be a GMP. So with that being said, if every single product on the shelf, whether you’re in a gas station or a convenience store or wherever you are, if everybody says and claims the same.

[00:19:33] Um, then how are you unique? What makes you different? And, and the reality is as well. Okay. You know, industry metrics tell you that 25 to 30% of everything that’s out there in the industry is adulterated. So there isn’t the amount of CBD in there as they’re claiming, et cetera, even though it’s, third-party tested there’s, there’s ways around that, as we all know.

[00:19:55] So it it’s, it’s, it’s definitely a huge mess from an industry perspective, [00:20:00] but let’s talk about the good guys. So if, if, if you’re a regular decent manufacturer and you are trying to do the right thing, it’s the mindset of the leadership team of these CPD companies. So what I mean by that is when you manufacture a product, even if it’s not.

[00:20:18] If you have a quality assurance department or a QA person, and you say, that’s the person that’s responsible for quality for my product. That’s the person that makes sure we do the testing. We count on this department or group to make that happen. And that’s why you should buy my products. That’s absolutely the worst possible thing you could say.

[00:20:36] Okay. And the reason why. Quality is done by everybody in the company. Everybody that touches that product right from the CEO, making the decisions that the cost of quality isn’t cost. It’s the reality of manufacturing and selling a superior product. So if everybody in the company contributes to [00:21:00] quality, Then your QA persons simply just manages the quality management system of a company.

[00:21:07] They oversee it. So that means the person that’s actually doing. Um, you know, the, the manufacturing or the package. Or the extraction that person is trained. That person is educated. That person has the documents to back it up. They’ve gone through a thorough analysis to make sure that every step of the process has been done to meet the quality management system.

[00:21:33] And at the end of the day, you’re going to have a superior product because your system is going to generate it. And everybody involved is going to be part of that. So that fundamentally is a huge difference between what people do from a testing perspective. When they say, well, we test our product and we, you know, third party tested and it’s good versus truly taking a step back and looking at your entire organization.

[00:21:58] And that’s what we’ve done. [00:22:00] We have a quality management system. With anoxia that allows us to be able to prove to the physicians. This is exactly the type of product that we want to not only manufacturer, but sell to consumers that really need our help. And it seems to work extremely well for us. And I would

[00:22:17]Natalie: say to add on to that, you know, when we talk about quality and everyone talks about the testing at the end, We always care about quality from the way beginning.

[00:22:26] And that includes our raw materials. So our pre determined specifications from Panax CFR, hemp, biomass far exceeded most of the farms, uh, testing specs. So we spent over a year. You can ask Wayne that the, you know, brain damage, he went through to go find a farm that actually passed Maxia specifications.

[00:22:46] But what you’ll find is a lot of companies or, you know, farms left to use marketing terms like organic and all natural. But unfortunately that actually means very little when you look at the FDA and USDA requirements, um, it, it’s kind of just a certain [00:23:00] word that is used in the marketing field, but it actually really means very little when it comes to quality.

[00:23:05] So, you know, our testing. Seeds USDA requirements. So although our products not certified organic, it’s actually a higher quality raw material than an organic biomass. So that is also something to consider as well. So we really take it seriously from the raw material that has to have a predetermined specification.

[00:23:23] Each product has a pre-determined specification. It has to be manufactured in the exact same way. You know, even our packaging is GMP compliance. So we had to source, you know, different bottles from all over the world to make sure that it was in accordance with pharmaceutical studies.

[00:23:38]Kellan: Yeah, so the organic, I mean, I still ended up paying more for my broccoli when it has, you know, but I think it’s, I want to stay on the quality, uh, call the aspect.

[00:23:47] And I think that for our listeners, um, CGMP gets thrown around very actively in the industry. Right. It’s it’s a, it’s a really big buzz word right now, but technically there is two very different [00:24:00] classifications of CGMP, correct? There is, uh, a nutraceutical CGMP. Kind of guideline and then there’s a pharma CGMP guideline.

[00:24:07] And so could you guys kinda, uh, just educate our listeners on some of the differences from a quality perspective when you truly are following that pharma kind of guidelines from a pharma GMP perspective versus the more or less stringent nutraceutical GMP kind of guidelines, could you guys kind of educate our consumers on that aspect as well?

[00:24:31]Wayne: It’s very, um, it’s been a while since someone’s asked me that question. So I’m really excited. And by the way, I am a lot of fun and parties. So.

[00:24:44] So basically, so the code of federal regulations look at it this way. There’s two levels. Um, there’s, there’s the code of federal regulations for pharmaceuticals and there’s the code of federal regulations for dietary supplements. So dietary [00:25:00] supplements that CFR is 1 10, 1 11. You can look it up. And then there’s 2, 10, 2 11 for pharmaceutical, basically the CFR.

[00:25:08] Are the requirements. So the industry, the regulatory agency, the FDA and others, they don’t tell you how to do something. They just tell you what’s required to do something. You have to interpret how to meet that requirement and that requirement and how you do that. Are your GMPs, your current good manufacturing practices.

[00:25:34] So sometimes people get a little bit confused about what GMPs means versus the CFR. So always remember at the end of the day, when you’re being audited, they’re going to come in and they’re going to bring the CFRs and they’re, you know, there’s 35 40. And they’re going to go down the list and they’re going to ask you to demonstrate and show how you’re in compliance with, with each CFR and the CFR can be [00:26:00] anything from how you’re testing the biomass.

[00:26:02] As, as Natalie indicated, how are you designing your packaging components or do your packaging components meet these requirements, et cetera, et cetera. The difference between pharma and dietary supplements is the complexity in how stringent it is. So they are this, they relatively the same, but the depth of what’s required for each CFR is significantly higher for pharmaceuticals than it is for dietary supplements.

[00:26:28] But, um, you also have to take into consideration, you know, the reason why they’re there, where your drug or your product falls into a category, um, how. Uh, is, you know, is it a drug where it’s a scheduled one drug? You know, all of this takes them to play as far as how complicated and how intense the audit could be and, and the regs that you have to meet.

[00:26:51] So there’s a lot of variables to it, but when we’re, you’re making a dietary supplement as a pharmaceutical drug, a lot [00:27:00] of the, um, requirements that you’re doing, like we did, aren’t really that complicated because. At the end of the day, the type of product we have, doesn’t require a significant additional amount of work to make it in compliance.

[00:27:15] Does that make sense?

[00:27:17]Bryan: Yeah. Okay. And I want to kind of piggyback off what you said, kind of prior about the importance of instituting the internal aspects from a culture standpoint and not looking at it as a cost because Kevin and I have had a bunch of conversations where people ask us if we need to do something and the need is.

[00:27:34] Should you do you need to depends on really what you want to accomplish here and the type of game you’re playing from a short-term and long-term perspectives. Right? Because I would argue that a lot of people are taking short-term steps in order to, you know, get through today until tomorrow and not think about it from the long-term perspective.

[00:27:50] So I want to S I want to expand on Wayne, what you said on ask how many, let’s say other CBD providers, competitors of yours are going through the same [00:28:00] rigorous testing from a pharmaceutical standpoint as your.

[00:28:05]Wayne: Um, that’s an excellent question. I haven’t found anyone so far. Maybe Natalie you’ve come across a brand or a product, but I haven’t come across anyone that has taken it to the level we have.

[00:28:18] Um, you know, it took us, um, two and a half years. Two-and-a-half years. We were stealth. We didn’t make a dime for two and a half years because it took that long to develop and commercialize these products to be. Uh, the, the pharmaceutical regulations, even though we knew it was only going to be a dietary supplement, look you at the end of the day, you have to make a decision.

[00:28:42] Are you going to plan for success? When you know, 12, 14, 16 months from now, your product is going to be regulated by potentially the FDA. We already know the California department of public health is already considering rolling CPD, and it’s a dietary supplement. So you either do the [00:29:00] work now. Get your, your product ready.

[00:29:03] And when the, the requirement is acted and they give you 60, 90 days to be in compliance, you’ll be ready to go. Or you’re going to have to fast track everything that you should have done, you know, a year and a half ago, um, without damaging your brand and without losing sales. So it’s really, and it does cost a lot of money to do this.

[00:29:23] No argument there, but it could be more damaging to you later. Um, if you’re not prepared for it because of the disruption. Right. So it’s like, are you going to build a house? Right. And, and with the, with the amount of money that you have, are you going to build it right? Or are you going to try to, you know, To a certain degree where it’s just good enough.

[00:29:43] So it all depends on your philosophy

[00:29:46]Bryan: and just the pig and sorry, just to piggyback off that, what you said when they have 60 or 90 days to get into compliance, what took you two and a half years to try to do? And let’s say three months, what was expensive in two and a half years, I’d imagine would be a little more expensive if [00:30:00] you had any.

[00:30:01] Oh yeah,

[00:30:01]Natalie: that’s it.

[00:30:04]Wayne: Can you imagine having, you know, $300,000 worth of packaging components that you can no longer use? Yeah, just that alone is a sunk cost.

[00:30:16]Natalie: That’s actually, what I was going to add is our packaging components. One of the longest parts of, uh, of our process before launching the brand was having a law firm that specialized in FDA compliance review every last detail of our packaging, even to the boldness of the font in certain.

[00:30:33] So we basically, you know, with Wayne’s expertise for saw that the FDA, or at least state by state would start regulating CBD as a dietary supplement. And as Wayne said, just a moment ago, we’re already seeing that happen in California. So we, we kind of, we positioned our, our packaging and our brand to be a dietary supplement in anticipation of that.

[00:30:51] So everything is fully, fully compliant with dietary supplement guidelines. And you’ll also notice that’s why there are absolutely no claims on our packaging, on our [00:31:00] website.

[00:31:01]Kellan: I think that’s, couldn’t be stated loud enough. Brian and I have a little experience on really understanding the amount of

[00:31:07]Bryan: information that needs to be communicated

[00:31:10]Kellan: on a package label for these

[00:31:12]Bryan: kinds of products.

[00:31:14] It’s it’s wild as a marketer, it was challenging to try to fit everything on it. And it just was like, I don’t know. They’re a smaller,

[00:31:26]Natalie: I sell it with a magnifying

[00:31:27]Bryan: glass

[00:31:29]Natalie: and, uh, certain information has to be visible. It has to convey, you know, at the right time and space. It’s very

[00:31:34]Bryan: complicated. When, in your opinion, why do you think a lot of these other brands and companies are not positioning themselves for a longterm, you think it’s financial base, you think it’s education, do you think it’s more of just like let’s get through today?

[00:31:47] What do you, in your opinion, what do you, what do you think the reason.

[00:31:51]Wayne: I don’t think they’re focused on the medicinal opportunity there, their holes there, their brand, their strategy, everything. I don’t think they’re [00:32:00] focused as a health and wellness product. I think they’re focused as a CBD product and what their interpretation of what that means.

[00:32:07] Yeah. We, we were at a show. We did one show before the pandemic hit and we were approached. As why, why are you here? People kept coming up to us from different booths that the competitors are saying, what is a pharmaceutical company doing it? A CBD show. People continuously looked at us like we don’t belong here.

[00:32:29] You know, it’s just not right. And they weren’t being mean, but we looked like a pharmaceutical company because we. We’re representing a pharmaceutical company. We have a pharma brand. So it’s clear to me that the industry isn’t focused on that. And the reason why is because it’s just not in their business model, they don’t want to do the HCP channel for all of the reasons that makes sense for them.

[00:32:52] Whereas it’s exactly opposite for us. I don’t want to compare. With Joe CPD, gummy bears at, you know, [00:33:00] some seven 11 to me, that’s just not what it, that doesn’t make sense to me. Uh, edibles, aren’t going to work any way to the degree on the bioavailability side. We all know that. So why don’t we just focus on.

[00:33:12] The products and the indications that make really the smartest sense to help people with, you know, what they’re, what they’re going through. And it just it’s clear to me that the industry doesn’t have that same frame of mine. Yeah,

[00:33:27]Natalie: I agree with that. And I would say a lot of companies are just jumping on the kind of CBD bandwagon because it’s an emerging industry and we’re seeing things like CBD candles, right.

[00:33:36] So, I mean, what is that going to do? So I think a lot of the times people are just looking for. You know, a quick buck in the industry, they’re not here longterm, but our whole goal isn’t just to make a lot of money and then disappear when the regs change we’re actually trying to, like I said, create a new standard in, in the CBD industry and as regulations get more stringent, I think we’re going to see a lot of drop-off from [00:34:00] brands that just.

[00:34:01] Meet those regulations. They’re just really not able to perform and create a product that’s safe and consistent in that way.

[00:34:07]Bryan: Yeah. That going to kill a lot of companies that just don’t have the capital investment in order to switch their, their operations. So let’s talk future roadmap, any, any minor cannabinoids on the radar, any up and coming products that you’re excited about, that you can share.

[00:34:23]Natalie: I would say something that we’re really excited about is down the line. When we do have our THC products, because with the CBD industry, we’re not allowed to have certain delivery methods. Thanks to Wayne explaining that to us, they’re considered over the counter delivery methods. So down the line, we’re going to have sublingual tablets that dissolve we’ll have.

[00:34:40] Positories pain patches and other delivery methods like that. And as we mentioned earlier, that can be clinically proven. So is doing, uh, clinical trials on migraines, epilepsy, psoriasis, and other indications.

[00:34:54]Wayne: And then piggy back onto that and to piggyback onto that back to the CBD side, [00:35:00] um, we can’t share with you that we are very focused on doing additional research, um, uh, in the sleep category.

[00:35:07] So we’ve got a very good sleep product, but I’m confident that the cannabinoids that we’re looking at right now at specific levels combined. Um, with, um, with melatonin and other API APIs, um, really could do something really great for us. So I think parallel work. We’re going to continue to look at that and see if we can develop a new form of.

[00:35:28] That’d be

[00:35:29]Kellan: awesome. And so many people in America suffer with sleep deprivation. So if it works, it would literally impact so many, so many people’s lives in a really positive way.

[00:35:38]Natalie: One of the favorite things that we see from our reviews is people saying they’ve gotten off their, their pharmaceutical prescription drugs that often have those potentially negative side effects and are very addicting.

[00:35:49] Um, and they’ve replaced it with our products. So that also, you know, we have that CBD melatonin, which is amazing for sleep. And another product that we’re really proud of is our CBD. Myo-inositol And this once again, I [00:36:00] see your face. You’re like, what is Myo inositol This is why working with a company like Panaxia is just so different than any other CBD brand.

[00:36:06] Uh, myo-inositol is a naturally occurring compound in the brain that affects serotonin and dopamine and other chemical transmitters. And then a clinical trial is proven to be as effective as Prozac at reducing anxiety and panic attacks. So we have this amazing nutraceutical that combines two natural compounds that it’s amazing for stress.

[00:36:24] So we have. Truly unique formulations can act. He has seven patents on their, on their formulations and delivery methods. So when we say it’s proprietary, we actually mean it. We’re not just marketing, um, nano park, you know, nano CBD and all organic and all that kind of stuff, which sounds great. But. Truly pharmaceutical grade manufacturing and formulation development, but it’s using, you know, ingredients and compounds that won’t have those negative aspects of the pharmaceutical industry.

[00:36:54] So that’s what we’re most excited about with

[00:36:56]Bryan: that. And just to kind of expand on the sleep when we met Jerry, I [00:37:00] shared with him the story about my mom and the sleep and how many products that she’s tried and, and Jerry was fortunate and nice enough to share with me. And I gave it to my mom and her response is usually very quickly it didn’t work.

[00:37:10] And this one. I think it worked. And Danny that is such a step forward to think that possibly it could work, right. It was a massive, massive difference maker. And you know, you’re right. Like the sleep aspect is a game changer. If that can go down, it can help so many, so many

[00:37:25]Natalie: people, your whole health and wellness, you know, overall your sleep really impacts all of that.

[00:37:31] So that is, um, probably our best seller I would say is our CBD melatonin.

[00:37:36]Bryan: So what is w one concept or facts. That would shock an everyday consumer about the cannabinoid industry.

[00:37:46]Natalie: Wayne, do you want to take that one?

[00:37:48]Wayne: Hmm. Well, I’m processing. That’s a really good question. What’s one fact that would show.

[00:37:57]Natalie: I mean, I think the one we were talking about before where people [00:38:00] think more is better, I think it’d be really shocking for people to realize that just because something says it as 5,000 milligrams or 500 milligrams, it might not. That is actually the most shocking part is you might think you’re absorbing it and you might think you’re digesting it, but you’re not.

[00:38:14] So even if it says it has that. amount A lower dose product that actually is formulated to have high bioavailability and the pharmacokinetic testing to back up those claims. That is the biggest difference. So I think the biggest misconception about CBD right now is that more is better. Um, besides all the obvious, you know, will it make me high those kinds of questions, but

[00:38:34]Bryan: yeah.

[00:38:36]Wayne: Yeah. Yeah. I think going back to the average consumer does think CBD will continue to make them high. Right. So I think that that has never gone away. The education about CBD is just unbelievable. It’s just, it has to be, um, We have to do a better job of communicating what CBD is and what CBD isn’t. Um, but [00:39:00] again, because people will test positive on a drug test for THC, when they’re taking CBD, they have to be, they have to be educated to understand why.

[00:39:09] You know, so you get yourself into a pickle where you tell them, no, there’s no possible way. You’re going to get high. Trust us, the science, here’s the endocannabinoid system here. Here’s all of the background that you need to know, but don’t take a drug test because you’ll test positive and they look at you, like, what are you talking about?

[00:39:26] So you’ve got to get over that. And it’s very confusing for

[00:39:28]Natalie: people. Yeah. And I would say that actually ties back into a lot of people don’t realize that CBD is just a compound and it’s available at hemp and Marilyn. So, if anyone is telling you that CBD is only from him, that is incorrect information, it is a compound, it is a molecule, right?

[00:39:44] So it can come from marijuana plants as well. It’s just that, that plant overall, the hemp plant has very low amounts of THC, but it’s there they’re cousins. It’s not like an actual distinction there. Um, so I think that’s also very confusing for them. [00:40:00]

[00:40:01]Bryan: Wayne. What’s your opinion? Big pharma has for the cannabinoid industry.

[00:40:05] Are they threatened to, they see it more as an ally, an intersection, a let’s say a new revenue stream, in your opinion, what do you think big pharma thinks of, of the cannabis industry

[00:40:16]Wayne: CPD? And the reason why I say it that way is if the, if the science and the research looks promising, they will pull the trigger in this.

[00:40:28] Absolutely. There’ll be all over it. But until the science and the research justifies them taking a serious look at it, they’re going to keep an eye on it. It’s in the room, it’s over in the corner. But soon as something lands on the desk that shows that this is an opportunity to do some really good things.

[00:40:47] When I say good things, as, as it relates to an indication or health and wellness, then they’re going to go on. They’re going to go after a big time and nobody can be in their way. And it’s just a matter of time because the research [00:41:00] is increasing is getting more solid and like everything that’s happening in Israel, you know, that’s a country, but guess what guys, you know, we have the internet, everybody’s going to know what’s going on.

[00:41:11] So it’s just a matter of time before a farmer just takes. Do you think someone,

[00:41:16]Bryan: a big pharma company will pull the trigger a little early in anticipation of their peers, because if it is an arms race, right to acquire some of these assets and these formulations, you can’t be second to the party. You have to be first.

[00:41:28] So you think some of them will be more willing to let’s say, take a chance and a gamble on some of these acquisitions, or do you think they’ll try to play conservative depending on you know, who is the company?

[00:41:39]Wayne: So they will not be. I think that we’re already,

[00:41:42]Kellan: I think we’re already there though, right? Like Pfizer’s $7 billion entry, um, purchasing or in a pharma, right?

[00:41:48] Like that is as big of a cannabinoid play as you possibly can. It’s from a pharma

[00:41:52]Wayne: perspective, right? Yeah, absolutely. Yeah. You don’t have to, you don’t have to be conservative when you have deep pockets. [00:42:00] Yeah, we have deep pockets. You can do whatever you want. Amen.

[00:42:04]Bryan: And a quick Google search of any of the patents that Pfizer has, would lead you to have over 3000 different patents on cannabinoids.

[00:42:11] So you could see they’re pretty invested in just a matter of time. I’d wonder if, if there’s another acquisition that’s free for, let’s say someone else in order to try to compete with them or Pfizer doubles down and continues to expand in the space.

[00:42:24]Kellan: That’s a good question.

[00:42:24]Wayne: Yeah. Only time

[00:42:25]Bryan: will tell exactly right.

[00:42:28] So Natalie, since you’ve been in the cannabis industry, what has been the biggest misconception?

[00:42:34]Natalie: I guess misconception. That’s a good question. Uh, I think we touched on it a little earlier. I was saying, you know, a lot of people don’t understand the difference between, you know, hemp, marijuana CBD as a molecule.

[00:42:48] And as, as Wayne was touching on, you know, full spectrum versus an isolate, um, I think there’s a lot of misconception about. Y you would take an isolate over a full spectrum product. And in our mind, [00:43:00] the only reason you would ever want to take an isolate or even a broad spectrum is if you’re being, you know, drug tested for your job, it’s in terms of efficacy and the research, and that kind of ties into our pharmacokinetic studies that Connexa conducted.

[00:43:13] The reason that they demanded that we’re full spectrum. We wanted to offer broad spectrum, uh, for people who are drug tested, but they said that will drastically affect the efficacy of the product. So I think. People think there’s a lot of talk about the entourage effect, but they don’t really realize how deeply scientific that, like how rooted that is in science and testing and formulation making, um, and all the trials and studies that these, these people are conducting.

[00:43:37] So. I also think there’s a lot of misconception about how difficult it is to make a product that is made from plant material consistent. Um, Wayne was talking about this earlier, you know, the difference between making a synthetic drug versus making a plant based product. It’s not the same and it’s actually extremely difficult to standardize.

[00:43:58] So I think [00:44:00] people often think that they’re getting the same product every time, but if it’s a new batch, there’s a big chance if they don’t have those standard operating procedures and quality management systems in place that it’s not going to be what you think it is. And so I think that’s the biggest misconception.

[00:44:14] Like not all CBD is created equal and science really does play a part in.

[00:44:20]Bryan: Before we do predictions, we ask all of our guests, you could sum up your experience in a main takeaway or lesson learned to pass onto the next generation. What would it be? Wayne, do you want to go first

[00:44:34]Wayne: lessons learned or as, or from a business perspective or you mean for our consumers? Help me out here. Any

[00:44:41]Bryan: new life it could be live, could be business. Could be.

[00:44:47]Wayne: Um, well, you know, guys, I’ll just say this, the cannabis space right now. It’s probably one of the most difficult [00:45:00] industries to start a company in.

[00:45:02] And the reason why I say that is because you could start an over-the-counter drug manufacturing company, or a lot less. A lot less pain, um, much faster and be in compliance with the FDA in a much shorter time. From a business perspective. When, when, when you know my past history with the companies I’ve worked for, I hadn’t absolutely not near the amount of pain and suffering and living nightmare that I’ve gone through with.

[00:45:37] And the bus is out of control from a regulatory perspective, from an operational perspective. And, you know, I would tell someone that is coming behind me if they wanted to, you know, start and build a manufacturing, uh, cannabis company and sell and distribute. You know. Okay. But you [00:46:00] better really do the research and understand what it’s going to take to make this happen, because there’s not a clear path, you know?

[00:46:08] Um, you know, we talked about the CFRs, the code of federal regulations. There are less, you know, CFRs for an over-the-counter drug company than there are, uh, rules for a cannabis manufacturing company. This is like three times. Uh, regularly regulations for a cannabis company. Then there are an over the counter drug company.

[00:46:29] That’s insane. It’s insane. And, and the margins aren’t there from it because of the taxes. So I would caution someone to really do the research before they pull the trigger on this, because I don’t think they understand how difficult it’s going to be, but if they have the resources and the intelligence and the time to make it happen, it will be rewarding, but it’s going to be a very different.

[00:46:53] Industry to be successful in plain and simple. That’s a marathon. Yeah, it is a marathon. It [00:47:00] isn’t a marathon and you have to have the passion for it. Right? The passion has to be there. If we could take somebody off a synthetic drug, if we can make someone that has, let’s say arthritis and they put a cream on their knee or whatever the case may be, if we can give somebody an alternate.

[00:47:15] To help them feel better. How could you not want to do that? If you want to do that, then it’s the right industry. But if you’re just out there trying to make people feel happy and fun and your product is just recreational. Okay, great. That, that works for you, but that’s not what we’re into. That’s not where our passion is.

[00:47:33] So. Um, it’s an exciting time for us and it’s been, it’s been hard, but, um, at the end of the rainbow, so to speak, I think we’re going to have some really great stories as hell.

[00:47:46]Natalie: And I would say for mine, um, I agree with everything Wayne said, and I also think, you know, we have to realize that not everyone is going to play this game face.

[00:47:55] Um, that in terms of, you know, competing against brands that are [00:48:00] mislabeling making claims, et cetera, and how hard it is to break through that noise. I would say that’s the biggest lesson learned is realizing how we need to communicate effectively and educate not only doctors, but even the people taking these products.

[00:48:13] I mean, they’re really, there’s a lot, we know there’s so much interest, but there really is a lack of, of information and a lot of misinformation. So the amount of times I’ve seen an article talking about. CBD is from hemp and THC is from marijuana and it, it, you know, it makes my day, it just upsets me because they’re trying to explain something, but then they’re actually giving this information and those people are then taking that and spreading that as well.

[00:48:38] So I think the educational aspect of it and getting people on board with the medical side of things is the biggest.

[00:48:46]Bryan: The game is not fair.

[00:48:51]Wayne: Go

[00:48:51]Kellan: ahead. Run. No, you can. You can. I was just gonna say it doesn’t help that we’ve been missing the massive institutes that provide standardization from an [00:49:00] educational perspective for the last eight years.

[00:49:02]Bryan: Right?

[00:49:07]Natalie: And Israel, it’s a totally different world when it comes to cannabis there at like the university level of education. Um, the, the stigma is not there. It’s just not there. And the education for, you know, people in university. You know, there’s, there’s kids that are going to college and actually doing research on cannabis there, which is kind of unheard of in the United States.

[00:49:33] You wouldn’t even think that that’s an opportunity. Right? So, uh, we actually know of people from the U S that went to Israel to study cannabis, because that’s just not an option in the United States.

[00:49:44]Kellan: Ben, who house, who we had on a little while ago and talking to you was doing that exact reason.

[00:49:51]Natalie: I’m just goes to show how far ahead they are.

[00:49:54] And they’re, you know, they’re even doing research, showing that different extraction methods affect the efficacy of [00:50:00] the, of the product on a specific indication. It gets really that, that specific. So it’s pretty cool

[00:50:06]Bryan: prediction time. What medical area do you think long-term cannabinoid therapy will be the most beneficial.

[00:50:16]Natalie: I mean, as we kind of talked about before, I would say sleep, I would say sleep, anxiety and pain are the

[00:50:22]Bryan: three,

[00:50:29]Natalie: all three. So Wayne has nothing to say. I think, I think sleep is probably the biggest category because that impacts your anxiety. Um, and also, you know, physical pain. So I think sleep having and maintaining a restful sleep schedule and good sleep hygiene is one of the most important things you can do for your wellness.

[00:50:47] So that’s probably one of the biggest ones

[00:50:49]Bryan: for sure.

[00:50:51]Wayne: I agree a hundred percent, but I also think that the science and the research in the future is going to focus a lot more [00:51:00] on inflammation. And I think we’re going to find out that inflammation is going to be here. Huge for the cannabis space. And I think there’s going to be opportunities that we don’t, we’re not even aware of right now where the science and the research is going to direct us down paths that are really going to do some great things.

[00:51:18]Kellan: I’m going to go with oncology. I think that, um, there’s some really exciting clinical trials that just got underway in Israel showing, um, how, uh, effective treatment of a specific whole plant extract had on a cancer line. And so I’m really excited to see that kind of research, expand the clinical trials, get more people involved and kind of see what really the benefits cause.

[00:51:43] I mean, I think. Cancer and cannabis have kind of been hand in hand for the last 20 years. I think it’s probably been one of the more, um, Popular use case scenarios for cannabis is individuals that are on chemo, utilizing it for help. And I think that there’s [00:52:00] originally right. It’s, it’s used for appetite to stimulate appetite, but I think that there potentially could be a lot more to the,

[00:52:11]Natalie: you say that because one of our other partners, who’s just a straight up analytical research labs.

[00:52:15] So they’re not making products, but they’re actually doing research on notch. One mutation cells from routine. Without having Whitesell, Dr. Daddy, Mary, um, is one of our partners as well. So he’s one of the lead leading researchers in Israel doing all

[00:52:32]Kellan: the clinical trials.

[00:52:34]Natalie: I had a feeling you were

[00:52:38] we’re partners with him. Um, and he’s doing some of the most amazing work. You know, he really has kind of picked up where Raphael Meshulum left off and is carrying on that legacy. So.

[00:52:51]Bryan: Yeah, that’s a, it’s kind of , I’m going to go with focus, I guess. Right. The list is kind of it’s, it’s [00:53:00] kind of small at this point.

[00:53:00] I think if you think about all the people, especially in college that use, let’s say Adderall in order to kind of keep themselves. Attentive or for other purposes, I think if they could find a more natural solution to help them and feel that same sort of attentiveness that they’re looking for. I think that can be beneficial.

[00:53:17] And especially if it’s an all natural one, I know there’s already a bunch of other products out there that try to be a replacement for Adderall. I would hope that there’s a variety of different medical benefits. And I think with some advancements, and I think with some individuals like yourselves, doing things the right way and cutting through some of the noise, it’ll help change the stigma and help the advancement of the industry pretty aggressively and really commend you guys for taking those steps and doing it the hard route, but the right way, which is what this industry really needs so far listeners, they want to get in touch.

[00:53:47] They want to learn more and they want to see some of the products. Where can they find.

[00:53:51]Natalie: Yeah, so they can find us at the health. T I K B a H E a L T h.com. And all of our social media is also take the health. So we’re [00:54:00] on Facebook, Instagram. That’s where you can find us. We’re also, you know, um, in some pharmacies across the country, but I would say e-commerce is the easiest way to access us.

[00:54:09] So yes,

[00:54:10]Bryan: we’ll link it all up in the show notes. Thanks so much for your time guys.

[00:54:13]Natalie: Thank you. It was great speaking with you guys. Yeah.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Editors’ Note: This is the transcript version of the podcast. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below if you need any clarification. We hope you enjoy!

This week we are joined by Nate Lipton  to discuss : 

  • We debate Indica vs Sativa
  • Canna Cribs Viral Sucess 
  • Jungle Boys, and the next growers to know 
  • and so much more 

Growers House is Your #1 Online Hydroponics Store.

Canna Cribs is The MTV Cribs of Cannabis. 

https://www.youtube.com/c/GrowersNetwork

https://growershouse.com/

https://www.instagram.com/cannacribs/?hl=en

At Eighth Revolution (8th Rev) we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain 

The Dime is a top 50 Cannabis Podcast 

 Contact us directly at [email protected] Bryan Fields: @bryanfields24 Kellan Finney: @Kellan_Finney


[00:00:00]Bryan Fields: What’s up guys. Welcome back to our episode of the dime I’m Brian Fields. And with me as always is ke Finney. And this week we’ve got a very special GA guest, Nate Linton co-founder of Canna cribs, grow house and grow network. Nate, thanks for taking the

[00:00:14]Nate Lipton: time. How you doing today? Doing well, doing well. I’m uh, had my coffee, have my tea now.

[00:00:20] Cause I’m a caffeine freak. I like to have a whole different variance but yeah, feeling good. Thanks for having me on the podcast.

[00:00:26]Bryan Fields: Excited to dive in. Ke how are you doing?

[00:00:28]Kellan Finney: I’m doing well back home finally, after a lot of travel and I’m super excited to talk to, to Nate and big fan of what he does out there.

[00:00:35] Brian, how are you? I’m

[00:00:36]Bryan Fields: doing well. And I appreciate you asking co and not giving us a weather update for what we’re doing.

[00:00:41]Kellan Finney: I’m working on getting better. Nate, for

[00:00:42] the,

[00:00:43]Bryan Fields: the record, Nate, I will ask Nate your location

[00:00:46]Nate Lipton: for the record. For the record I am in, uh, Tucson, Arizona near the Swan and river area for those who know Tucson kind of near the base of the mountains.

[00:00:56] That’s the check off the west west

[00:00:58]Bryan Fields: coast, the west coast. Yes. Another one [00:01:00] for the west coast. So I, I’m excited to kind of dive in Nate for our listeners. Can you give a little background about you and how you kind of got into the cannabis

[00:01:06]Nate Lipton: space? Yeah, for sure. So I’ve been in the cannabis space. Um, since I graduated college in 2010, working, you know, in dispensaries cultivation, um, equipment used for cultivation and, uh, you know, in 2011, um, after working for a few other companies, I started growers house in Tucson, Arizona equipment supply company for like, um, hobbyists and commercial growers.

[00:01:31] And then, um, you know, in the years that followed, we launched, uh, other companies associated and affiliated companies like growers network, um, that’s growers network.org, it’s a forum and a website to learn, um, cultivation knowledge, as well as communicate with other growers. And then we launched the cancri YouTube series, which is kind of like what we call a docu-series.

[00:01:51] We call it edutainment, um, with educational and entertaining, uh, where we do kind of like a walkthrough of commercial growing [00:02:00] operations, uh, that you know, are growing some of the best cannabis in the country. And we try and show how they do it. Like, what are their processes and methodologies? What products are they using?

[00:02:10] Uh, so that we can kind of make it that knowledge a little more democratized and people can learn because like, you know, right now I don’t think people know this, but there’s like over 10,000 commercial, like licensed businesses growing cannabis. So a lot of them are like new, never done this before on a legitimate level.

[00:02:28] Um, some of them are like families who are like, oh yeah, I used to have a convenience store now, screw it. I’m gonna go try my hand at cannabis. And you know, there’s a lot of information that people wanna absorb. And I think we’re providing kind of like what I think of as discovery channels, how it’s made episode.

[00:02:44] But on how to grow cannabis, um, as a profession, as a business, you know,

[00:02:50]Bryan Fields: I’m really glad you shared that. I’m excited to kind of dive into that because I think what your team’s doing there is really not recognized for how much value it’s doing because across the, the series, [00:03:00] it’s just, just jampacked with the information.

[00:03:01] So I wanna stay back when you first got started in the space, did you always think you wanted to be in the cannabis industry? Were there hesitations to kind of dive in, take us back to that origin days when you first wanted to get into the space?

[00:03:12]Nate Lipton: Yeah, you know, I think when I was like in college, I was like, Uh, the best way I can put it is I was very drug friendly.

[00:03:18] Um, maybe is a good way to put it. that’s a good way to put it. and, um, I don’t know those things. I, I didn’t think of it as career though. I just thought of it as like a lifestyle. Right. And, uh, I was like, oh yeah, I’m gonna get into one of those careers that like, everyone tells you about when you’re a 13, you’re a lawyer doctor, you know, or something.

[00:03:37] I was like, you know, I kind of took a lean towards like doing math things and I love spreadsheets and, you know, I love calculations and figuring things out. So I ended up like kind of going the economic slash finance direction and, um, did an internship at Morgan Stanley. And I was like, P bro, I hate this.

[00:03:54] Like, I absolutely hate it. And then I was like, okay. I, uh, obviously don’t like this [00:04:00] kind of like bureaucratic hierarchical structure. I want it to be a lot more free flowing. I probably need to like work in an industry that’s like, not as mature. And, um, maybe I even have to work for myself eventually. So what’s that process gonna look like?

[00:04:13] Obviously I should work for other people and, you know, get kind of bust my chops a little bit. So that’s what I did. And I was like, the cannabis industry is probably the most interesting one because, you know, I think I’ve heard a lot of people tell me whether it was professors or mentors or family members that I respected.

[00:04:30] They’re like, you know, yeah, it’s important. You know, like maybe how much effort you put into things and maybe how lucky you are and how smart you are, all these things. But you know, what really kind of matters too, is making sure that you’re riding a wave that’s cresting. And I was like, cannabis seems like a wave that’s cresting.

[00:04:49] So why don’t I, you know, kind and see what I can do there. And that’s lit literally the rest is history, you know, got into it, never came out of it. And for me, I wake up some days [00:05:00] and I’m like, You know, I do like we even see comments on the can cruises of YouTube, where people are just like, man, I would love to go walk through this facility.

[00:05:09] Like you just did. And then I wake up in the morning. I’m like, dude, like these guys wish they could have just spent, you know, I just spent two days, 12 hours a day running through this facility, filming all this stuff. But at the end of it, I’m like, man, this is really cool. Like, yeah, it was kind of tiring and kind of grueling and maybe, you know, it was more of like making the sausage rather than consuming it, you know, which is a lot tastier.

[00:05:32] But man, there was like, I wake up sometimes and it’s like, I can’t, I almost don’t even know what it would be like to work in another industry. and I don’t think I care to find out too much right now I’m in too deep and I’m staying here. You know, that’s kind of how I feel what the cannabis is. So

[00:05:51]Kellan Finney: when, when you were first walking through these facilities and getting going, what was the biggest thing that kind of, um, shocked you from like a, an old school [00:06:00] kind of closet grow, where you’re just supporting you and your friends versus, uh, a commercial operation that’s licensed, that’s trying to support an entire state’s market.

[00:06:09]Nate Lipton: Yeah. There’s, you know, it’s funny. I, um, I thought about, I was talking to someone, I was trying to give them a metaphor of like old school growers versus new school growers. And, um, the metaphor I came up with, which I kind of liked. And maybe this’ll kind of get to the question a little bit. Maybe it’ll be a little bit deviant, but, um, So old school growers are like, yeah, they, they started in their closet.

[00:06:34] Then they started blowing out the garage. Then they did multiple rooms, you know, then they might take over a whole house and they’re like super crafty DIYs. They’re usually super into like being on forms online or Instagram and like looking up what they can learn from other growers trying to perfect their craft, doing a little bit of their own research and development.

[00:06:55] You know, I would say some growers are a little bit better at doing controlled studies versus [00:07:00] others. , you know, you know, it’s like change one variable, keep everything else the same, grow, see how it turns out. Some are like change 10 variables at once and then pick the one that you like most that, you know, , uh, that’s not the way to go.

[00:07:12] Um, but then you have the other side, which I would say is like, let’s just call it traditional ag. Think in your head, like the guy who has been growing row crops of corn. For three generations or something like that. And the weird thing that’s happening right now is like, we’re seeing this convergence of the two where like you have the old school growers growing in a really big setting and learning some of the commercial ag techniques, but then you have the commercial ag people coming in and you know, saying like, oh yeah, it’s just a plant’s plant.

[00:07:44] You know, I can grow this plant and we’re gonna grow it the same way I always have. And it turns out they both have a lot to learn from each other, but they both came in, not really respecting one another. Okay. But what I’m seeing now [00:08:00] is they are a little more receptive to learning from each other.

[00:08:04] Whereas at first I felt like it was like, you know, them really bashing heads. And it reminded me of like old school days. I’m a big snowboarder. And I didn’t see this as much, but I grew up watching like snowboarding and skiing documentaries. And I remember seeing those old movies, like those eighties, like party, you know, mogul skiing movies, where the snowboarder would go up on the mountain.

[00:08:26] He’s like that new school cat kind of weird. And the skier would be like, dude, get off my hill, you know, and things like that. And it’s like the traditional skiing method. And then they used to like separate the mountains. You have like the skiers and the snowboarders. And that’s kind of like the, do two different styles of growers.

[00:08:43] But now it’s like, they’re starting to play well in the sand together. And like, you go to the mountain and you see the skiers, the snowboarders, they’re all interacting well. And it’s like, you go to a cannabis conference now. And it’s like, the, the lines are becoming very blurry between someone who like is a professional cannabis grower and [00:09:00] someone who.

[00:09:01] Um, well, who has a background? I would say in growing cannabis, in the legacy market versus someone who’s, uh, came from traditional ag and now is growing cannabis. And what they’re doing is they’re realizing like shit cannabis actually is a little bit of a different plant. And there are these like small things that I really have to tweak when you’re coming from the commercial ag side.

[00:09:20] And from the cannabis side, they’re like, man, you know, these commercial ag guys, they have actually learned some processes that are really efficient that we, I don’t know why we haven’t thought of it until now. We really should apply these. Um, so it’s really cool to see. And I think people should, um, you know, not try and have that division of like, am I a legacy go my commercial ag.

[00:09:42] As long as they don’t shit on the other side. Right. Um, just say like, cool. I learned a lot. I have a lot of skills coming with me, but I’m gonna be a lifelong learner. Always try and learn from everything that I can to apply myself to grow the best cannabis possible. I think

[00:09:58]Bryan Fields: that’s so really well said.

[00:09:59] And as the [00:10:00] industry kind of matures, the trust factor is so critical, right? Mm-hmm because what you’re able to do in small scale, when you expand out, you need extra hands and you’re not able to have that same artistic touch because it’s, it’s not as easy to touch all the plants as, as some can do as they kind of scale out.

[00:10:14] So I’m curious to know, from a trust standpoint, Nate cannabis has always kind of been a little more hush, hush and a little under the radar. How are you able to cultivate those relationships with these growers to allow you to kind of come in with a camera and start filming some of these process.

[00:10:28]Nate Lipton: Yeah, it’s when we started can cribs.

[00:10:31] Um, so the first episode we ever filmed was at glass house farms with Graham Ferra and Kelly and Ash, a few other people, um, that were out there that were business partners of his, and we, we got in the first episode because we were just like, Hey, it’s a concept Graham. And we knew Graham from, you know, just doing business and, um, on the equipment side.

[00:10:56] And he was like, yeah, you know, seems like cool [00:11:00] project. That’s the kind of guy that Graham is. He’s like down for anything. He’s like, yeah, come on, bring, bring a bunch of cameras. Yeah. I’ll let you in the facility, we’ll run around. Cool. Did that, you know, um, we were not efficient at all. There was like a 10 person team, which is still around 10 people.

[00:11:15] And then it took us like literally like six to eight months to edit that episode. And then we launched it on YouTube and we had no idea whether it was gonna like do well or not. And. Did pretty well, like picked up a lot of steam, got a lot of views. And we were like, cool. Like people started to take notice.

[00:11:31] People would be like messaging me in the industry and be like, yo, I saw that like thing that you did, that was pretty rad. And we were like, Hey, you know, we like lost our ass financially on this first one, but we might be able to like monetize this thing in a way we can keep it going. You know, we could do it more often.

[00:11:48] And um, I ended up calling another one of our customers, which was, um, fat panned up in Washington, golden pineapple. Yeah. Yeah. So they, you know, they have awesome branding. [00:12:00] Rob is their CEO. Yeah. I walked

[00:12:01]Kellan Finney: around the facility. I spent a lot of time with Rob. I’ve worked with them closely. Nice. Uh, when I was in Washington, I mean, so impressive.

[00:12:07] They’re they, they took, they turned that Pepsi co facility into super, super impressed with their

[00:12:12]Nate Lipton: facility up in SPO. Yeah. It’s and yeah, F Panda great brand, Rob crazy guy. He’s just like fan, you know? Totally. Um, but yeah, we went up and I was like, Hey, can we do this? And he, he has a little bit of a marketing mind.

[00:12:27] I would say, you know, actually not a little bit. He has a lot of a marketing mind and he was like, yeah, this would be great. You know, like I’m trying to build a brand, the, you know, the Washington market’s pretty busy. So we film that episode and we, we, what we do is we, how we monetize the thing. Like, it’s not a secret and I’m not trying to hide this from anyone, but like, Basically, we go to a facility and, you know, we ask them for just like, okay, what’s all the kind of equipment that you’re using.

[00:12:55] Cool. Then we touch base with those, those, uh, equipment providers. And we say like, [00:13:00] Hey, we’re gonna go film an episode here. Um, if you help us fund the episode and pay for production, we’ll, you know, give you a little bit more time on camera. We’d love to like, help get a testimonial from the farm of how they like using your product.

[00:13:12] And that’s how it works. And that’s what helps pay for production. So, um, we did it and then that episode we didn’t lose money. We’re like, holy shit. Okay. We can keep this thing going, you know? And I think now we’re at like episode 40 or something like that. I don’t even know how many episodes we’ve done, but we had to get a second host cuz like I don’t actually have the bandwidth to host all the episodes and we have autumn, um, from col Tevo, she’s a really awesome host and a really great cannabis grower.

[00:13:41] But, uh, you know, my day job is like running this business. You know, we got like 70 plus people, mainly we help equip facilities and consult. So that’s kind of the day job doing the candy Crips thing is more like the, on the weekends, every three months, fly out, film a few episodes, then come back to life [00:14:00] and reality, you know, how

[00:14:02]Bryan Fields: long are the reportings?

[00:14:03] Because you cut up a 45, well put together documentary. So my assumption there has to be a ton of extra footage that has to get sliced down in there. So how long is the total recording and how long does it take from when you let’s say you show up on a Wednesday, do you record three straight days?

[00:14:18]Nate Lipton: How does that work?

[00:14:19] Yeah, so dude, it’s like, I mean, we have so many terabytes of footage. It’s like wild, how much we film. Um, each like each episode can be over a terabyte, um, worth of just like photos and video. So there’s quite a bit, but. You know, we have to plan it with the farm, orchestrate it. They have to be ready. Our team has to be ready, all everyone to fly out converge.

[00:14:41] Um, so it’s like three months planning ahead of time. Sometimes even more in four months before we even get there, then we fly out there. It’s usually, you know, we have a, maybe like a dinner with the, uh, farm the night before just like, Hey, let’s break bread, meet you, meet everyone. Let me hear about your story a [00:15:00] little bit.

[00:15:00] So we can kind of think about what direction the episode will go. And then it’s usually two full days, like 12 hour days of filming. Um, and then we fly out. Um, and then, uh, it probably takes another 30 days to edit the episode ish. Now it used to take a lot longer, but we’ve gotten a little bit of a process.

[00:15:21] And then, uh, yeah, you’ll see it go live.

[00:15:24]Bryan Fields: I mean, I saw one of your episodes with jungle bloods and I was just fascinated with the type of questions you’re asking about like how many people have been in this room and he looked at you and he was like, maybe five, including you. And it’s just like, I know.

[00:15:35] Yeah. Wild to think that they like opened up their doors to allow you to come in and ask the type of questions you did, which were exceptional because. I mean, you can’t find that information elsewhere on the internet. So was that experience different than the others? I mean, that had to have blown you away when he only said five people.

[00:15:50]Nate Lipton: Yeah, it is. And it’s, you know, the, both of the jungle boys facility and a few other facilities they’ve said like, yeah, you’re the first crew that we’ve ever allowed in here. [00:16:00] And we try and, you know, respect that quite a bit. Cause when you go into a cannabis operation, look, there’s a risk of letting a camera crew in because you know, what you’re scared of is will these people mess up, you know, our workflow or our processes or even worst case, are they not gonna respect our SOPs of cleanliness and bring something in that could damage our crop?

[00:16:22] And you know, we never, um, want that to happen. Um, because it would, you know, really tarnish our reputation. I mean, it’d be bad for the farm. It would be a lose, lose, lose, you know, like no one would be happy. So our crew. You know, uh, the people on the crew they’re a lot of ’em are cannabis growers themselves.

[00:16:41] We are very, very adamant that when we go in, you know, we’re like twice as clean as everyone else in the facility, you know, we’ve even people don’t see this, but we have like ISO isoprol alcohol, like our equipment, you know, before going in and, you know, wear lab coats. And we just try [00:17:00] and make sure that we’re really, um, kind of responsible and respectful of the facility when we go into it.

[00:17:05] But it is cool that they let us in and do that. And, you know, as some farms have said is, uh, which we didn’t intend, but it makes a lot of sense. They’re like, you know, we have to give tours all the time, whether it’s investors or you gotta bring a bank through, or I don’t know, you have to, there’s all these people that want to come through.

[00:17:20] And they’re like, after we filmed an episode, we don’t let them come through. We just send them the episode. And so by letting us come in once with 10 people, for two days, they can prevent like hundreds of people touring me up, touring their facility. And I was like, oh shit, that’s right. So now I tell farms that, and then they’re like, oh yeah, that does make sense.

[00:17:40] Yeah. Come on down. you know, so there’s these little like unintended consequences or cool outcomes that have come from it. Um, obviously just making friends and networking in the industry and learning some of the best practices, seeing what people are up to. I mean, that’s, that’s rad. So yeah, I think, I

[00:17:58]Bryan Fields: think it’s massive for [00:18:00] the industry.

[00:18:00] I think it’s great for consumers who can get to see behind the scenes look, and for some of those operators who maybe used to not be comfortable being on camera, that’s a big step forward for them to be associate. Right. You’re asking someone how long they’ve worked for some of these companies and 10, 15, 20 years.

[00:18:14] That’s a, that’s a substantial career in a space that for a while, wasn’t so comfortable with being on camera, published on social media.

[00:18:23]Nate Lipton: Yeah, exactly. And, uh, it’s cool hearing their stories too. Like almost everyone we go to it’s like. You, you know, you’re talking to, uh, companies that are doing seven, eight, even nine figures in business.

[00:18:35] And the guy was like, oh yeah, I was started dealing when I was 13. And then I started blowing out houses and, uh, yeah, next thing you know, went legal and I started to get legit and you’re like, cool. You know, like, those are, those are rad stories to hear RA than the guy who’s like, yeah, I own, uh, 37 other companies.

[00:18:53] And I, uh, allocated some, uh, equity over here and I acquired my 38th and yeah, I hope the macroeconomic [00:19:00] environment really supports it. You know? ,

[00:19:03]Bryan Fields: I feel like that’s a new Yorker you had in mind from like a big

[00:19:06]Nate Lipton: suited person when you were given that canvas statement.

[00:19:09]Kellan Finney: So which one of your guests,

[00:19:11]Bryan Fields: or which one of the facilities on can cribs, did you think one thing going in, but absolutely shocked you when you were leaving.

[00:19:17] You’re like, wow. I, I completely MIS misrepresent or MIS thought about that, that guess prior to going in.

[00:19:24]Nate Lipton: Um, wow dude. So many of them I met, what, what I might do is speak to some of the most recent ones we just filmed. Perfect. Um, I just got back from filming can antibiotics in Los Angeles and then Glasshouse brands, um, in which is like carpenter slash Santa Barbara area.

[00:19:45] And for those of you who don’t know the Glasshouse brands, they were also our first episode ever. So us going back and filming them now, um, they’re the first episode we’ve ever filmed where it’s like a follow up. Like five years later [00:20:00] and it’s like, cool. They had like a 150 or 300,000 square feet. Their facility now is insane.

[00:20:06] Yeah. Since then, like, you know, this like 5.5 million square foot tomato greenhouse became available on the market. And he was like, grandma’s like, and Kelly were like, yeah, well, we can’t afford it, but I guess if we go public, we could raise enough money and buy it, you know? And that’s what they did. Like, that’s the kind of craziness these guys are.

[00:20:26] But the cool thing is Graham is also like one of those guys that I told you who was like, grew up in Santa Barbara, surfing guy, you know, growing in like property that he shouldn’t have thinking, well, maybe it’s some water that you shouldn’t have or something like that. And now he’s running like one of the biggest cannabis companies in the us and.

[00:20:45] I think there are a lot of people who like, look at that and they’re like, oh, public cannabis company, dude, you know, screw that. That’s against like the ethos of what’s happening. And I think to myself, I’m like, cool, well, you can either have like Philip Morris running that facility, or you could have someone like Graham, [00:21:00] so pick your poison and I’d way rather have someone like Graham, like that guy is cool as shit.

[00:21:05] Like, um, so, you know, as, as things happen in the industry, you can’t please, everyone, you know, there’s gonna be a lot of haters. I would just say think twice before, you know, you just immediately blurt out that like people doing cannabis on a large scale is a bad thing. A hundred percent of the time. It can be bad thing.

[00:21:24] Not gonna say it’s not, but not a hundred percent of the time. So let me, oh yeah, sorry. I was circling around. I’m gonna answer part of that question though. Really fast. Cause I realize, dude, I just start speaking and I just go off, right? Like I go into first gear? I’m like in six, you know? Uh, but on the antibiotic side, what I didn’t know is that they have like the number one selling flower strain in all of California called cereal milk.

[00:21:51] I believe it was. And I was like, dude, these guys came outta nowhere and they do all their own research and development at their facility. Um, cross breeding, strains, [00:22:00] pollination, like pheno typing tissue culture. Tons of cool shit. I had no idea about that going into it. I think those guys are create, like I was speaking to the owner and he was.

[00:22:10] I was like, you ever sell like your genetics? And he is like, no, I’ve had people out for me, like 50 gram for like one clone before. And he is, turned it down. I was like, damn mad respect, you know? And then when it, you know, it came to Glasshouse brands and, and gram for, and things like that. I guess one of the weird things is like, I heard that.

[00:22:28] Um, yeah, I’m trying to think about it probably. Well, let’s think of the antibiotics one when it comes to the Glasshouse one, I kind of knew what I was jumping into. Cause I’ve known Graham for some, some time and I knew he what he was up to. So that one, I think I understood what was going on. But if I think of some other cool ones throughout this episode, I’ll interject and stuff.

[00:22:50] So you, I mean, you went to Glasshouse

[00:22:52]Kellan Finney: five years ago and now you, you went back for a follow up episode. Was there any. Has there been any like specific technology, especially cuz you’re on the [00:23:00] supply side as well. Is there any specific technology now that like Glasshouse integrated into their, um, operation that wasn’t there five years ago that’s been kind of a game changer for them?

[00:23:12] Um, or is it just kind of getting more commercial ag stuff in

[00:23:15]Nate Lipton: these facilities? Yeah, I would say, um, yeah, there are things that have changed over the last five years. And the weird thing about cannabis is like the, the, uh, technological innovation for cultivating on the cannabis side is just, it’s crazy.

[00:23:32] It’s going at such a fast rate. It’s so much faster than like any other. Agricultural sector. Like there’s not enough money in lettuce for someone to invest, you know, half a billion dollars into R and D . Right. It’s just, we peaked, we peaked on the lettuce train , but uh, you know, there’s so much cool stuff like it it’s just that that crop is so valuable.

[00:23:57] People will spend money to optimize it, right. [00:24:00] Once the price per pound of cannabis is a hundred dollars, there’s probably gonna be less innovation. But until then, um, you know, a lot of people will be funneling their, um, we’ll call it their, you know, profits into R and D and optimization. One of the biggest ones is definitely LEDs.

[00:24:17] Five years ago, everyone was shitting on LEDs. They’re like, it is, are crap. You know, never use L E D and now it’s like, you’re not, you know, you, you you’re basically, if you’re not using LEDs, it’s probably cuz of a cash constraint, um, cash flow purposes. But other than that, every it’s like almost, um, unilaterally understood that it’s just like, yeah, you use LEDs for production.

[00:24:40] They’re gonna be more efficient, give you a better product. So Glasshouse is using LEDs, um, where they really weren’t before it was more of just growing with the sun. Um, and maybe some HPS or IDs. Um, I will also say like, You know, there’s people have gotten a lot better on [00:25:00] the cannabis side of using less pesticides and herbicides and insecticides and trying to optimize basically like root zone health, use beneficial insects.

[00:25:12] Some of the things that more of that I think is adopted from the commercial ag side. Whereas back in the day with cannabis, they were just like, see a bug nuke, the room, you know,

[00:25:23]Kellan Finney: everything in Eagle 20. Yeah. Every, every clone

[00:25:26]Nate Lipton: gets dipped. having forbid, you know, everything like that. And it’s like, no, we’re testing stuff now.

[00:25:32] Like let’s find a more elegant and healthy way to treat the plants. So, you know, that’s a. A big shift. And then I would say controls like now these days, like if you don’t have a controller that like pings you with a text message and email, when like any parameters out of whack, then you’re doing it wrong.

[00:25:50] Like you’re living in the stone age. So those are some of the things that I’m seeing. But, um, other than that, I mean like, yeah, still grown in cocoa, still using, you know, [00:26:00] uh, what I would call elemental salts and nutrient side and yeah. Still, still growing plants.

[00:26:06]Bryan Fields: Do you think they’re leaning on technology for, because of margin compression to optimize?

[00:26:11] Is it a, is it a mixture of both perspectives? Like what do you think is leading bigger brands to make the move for advancements in

[00:26:17]Nate Lipton: technology and automation? Yeah, I think it’s always a question of return on investment. So, you know, someone comes to you and says like, look, man, you spend a hundred bucks and you’re gonna get 300 back by implementing this in your facility.

[00:26:30] Most people are gonna say yes. So, um, They’re getting 300 back because, and you know, it’s a direct function of the price of cannabis though. Price of cannabis drops. Now that three to one ROI could go to two to one, or if it’s a one to one. Now shit, we’re not spending money, we’re not investing in research, you know, those types of things, but, um, yeah, all turns out to be more ROI based, which is, uh, kind [00:27:00] of interesting.

[00:27:00] Yeah. I mean, we’re, we’re doing a lot of studies with that. Um, like I said, we have a consulting group, can groups consulting. We have, you know, an awesome team, two PhDs along with a few other guys that are wicked smart, you know, director of science, Aurora, um, first, um, first PhD in cannabis cultivation, north America, Darren on our team.

[00:27:21] Awesome. Dude, they’ve run a whole bunch of like side by side testing Canada. They actually. Have a, uh, Canadian government licensed cannabis research facility, which you can’t even have in the us where, you know, the Canadian government gives these different licenses out. Some are like production licenses, like Aurora and canopy have, and all that, the research ones you can grow cannabis, send it to testing labs, do a whole bunch of side by sides, write academic papers on it.

[00:27:49] But then at the end you have to take the cannabis and destroy it. So you can’t sell it. Um, so we have one of those up there and, um, yeah, we’re testing like nutrients doing [00:28:00] side by sides. There’s just one that we tested the flavor, nutrient additive, where like increased the yield by 14% versus the control, um, in a statistically significant, you know, well done white paper that we’re publishing online, uh, here on the Ventana plant science website.

[00:28:20] And so that’s a good product. They’re also running tests for a lot of other nutrient companies who are just like there’s nutrient companies who come out and they’re like, Cool. We, um, work in, you know, maybe a different like ornamental flowers, but they have something that works really well for flowers.

[00:28:35] They’ll send it to these guys who will do a side by side on cannabis and then give them the results. And if it does have like, you know, uh, let’s just call it desired effects on the cannabis plant, then maybe that nutrient company will then bring a product into the cannabis industry. So our team does those kind of side by side tests for companies.

[00:28:56] And it’s cool. Cause we clean information on what’s working what [00:29:00] isn’t, but look, there’s a lot of stuff they test that literally like doesn’t do anything. You know, they tell me the majority of stuff they test just like actually is just like marketing hype doesn’t really do anything. So the cool thing is we can take some of this knowledge and obviously their academic knowledge, everything they’ve done and we can implement it on the consulting side so that we make like our customers have what we think is all the best, um, knowledge available on growing cannabis.

[00:29:24] You know, do you guys, uh,

[00:29:26]Kellan Finney: screen some of those ornamental nutrients as well for like other ingredients? Because I know within the ornamental market, they’re not required to disclose, um, all the other ingredients besides the active ingredients. So is that kind of some of the services that you provide? Um, the cultivators up there as well?

[00:29:43] Um, I, I just know from experience that like some PIRE can get in that aren’t the major product and then you get a, a random fail if you’re in California for that kind of stuff. So are those, uh, kinda like safety measures and those kind of, um, research projects that you guys conduct as well up in Canada?[00:30:00]

[00:30:00]Nate Lipton: You know, that’s interesting. You brought that up. I, um, all the studies that are done on the nutrients are really efficacy trials. Yep. Um, rather than us operating more, like, let’s say, I’ll call it the California department of, you know, um, what is it? Co department CD F a of farm and agriculture. I think it is.

[00:30:18] Yeah. That’s exactly what it’s. Yeah. Um, where they would be like, cool. You wanna sell your product in this state? Give us your MSDS. And then, you know, they might have the product tested themselves before they green light it to be used. But no, we don’t do something like what the California department, um, the pharma culture.

[00:30:35] But I think we could, I just don’t think anyone’s asked us for, they’re just looking usually for more efficacy trials. Yeah. That makes sense. That makes sense. Yeah.

[00:30:42]Bryan Fields: See if it works, can you expand on the differences of the two for those who might be unfamiliar with the differences in the.

[00:30:48]Nate Lipton: Yeah. The differences between like testing for efficacy versus testing for like, whether there’s something harmful on the nutrient that shouldn’t be like used on something that’s ingested.

[00:30:58] Yeah. Yeah. So like [00:31:00] really, you know, the efficacy trials, usually they’re focused on three things, so they’re focused on. Does it increase yield, or does it increase quality, which is measured usually by cannabinoids or terpenes or, you know, things of that nature. And then, um, you know, on the other side, you know, let’s say it’s a nutrient, you’re just trying to figure out if it’s safe, you’re really looking for, you know, um, yeah.

[00:31:23] Are there any heavy metals, you know, in the nutrient, are there any things that are on a list of things that are in concentrations where they would not be healthy? If someone ingested either by eating a product or smoking a product that it was grown with. Um, and even going back to those pesticides, like Abid and forbid that we were chatting about earlier, like Eagle 20, like those are for ornamentals.

[00:31:44] Those are not for crops that you’re meant to like eat or smoke. Like , they’re not fat stuff. So like they work well, though. They, they do work extremely well likes. Yeah. But you know, it’ll kill you if you eat it too. [00:32:00] So like, there it is. There’s the, there’s the big butt. Yeah. There’s the big butt. So don’t use that stuff.

[00:32:07] But the good thing is most states right now they do testing prior to products going on market. Yeah. So like, if it someone’s using that stuff in your cannabis, in like any legal state, you’re not buying like black market weed, you can be pretty rest assured that it doesn’t have that stuff in. It agreed.

[00:32:22] Um, but it’d be good as a grower to like, you know, not obviously use a product, go through a whole harvest, send it to a lap, find out it failed, then you just lose probably millions of dollars. So, um, yeah. I, I think any product that would be used that way would. you know, uh, have a pretty bad reputation pretty quickly.

[00:32:42] Yeah, I agree. Yeah. Yep. Nate, what is

[00:32:45]Bryan Fields: one factor statistic about growing cannabis that would shock 90% of the cannabis industry?

[00:32:55]Nate Lipton: Oh, shit.[00:33:00]

[00:33:01] That,

[00:33:04] you know, I don’t know if this would shock them, but I mean, here’s two things that maybe this is more market dynamic based, but you know, I think the cost of production for cannabis, like it’s gonna be commoditized and it’s gonna be like a hundred bucks a pound in like probably 10 years, something like that.

[00:33:29] Like it’s, it’s gonna be a commodity, just like any other thing that you. Grow, you know, just like you’re thinking about grain or strawberries, people buying futures on cannabis and you know, things like that. Um, and you know, another thing that I think in the market, like I don’t see in the next 10 years, there’s gonna be any interstate commerce of cannabis.

[00:33:47] Even if it goes federally legal, none, you don’t see any, I, I don’t think that’s gonna happen. I think there might be like three states that would allow exportation, um, maybe importation, but the other like [00:34:00] 47 states will be like, nah, we’re not allowing that because they’ve already built cannabis commissions who regulate the industry within their state.

[00:34:09] and they get a lot of tax revenue and jobs from it. And as soon as you allow things to cross state borders, um, at least in a wholesale way, I don’t mean like, oh yeah, you buy a joint in Cali and you drive to Arizona. And it’s like, all of a sudden, you know, you have the DEA rating or something. But what I mean is like, I don’t think there’s gonna be like a dispensary in Cali who wholesales a hundred pounds to a dispensary in Arizona.

[00:34:35] That for example, is what I don’t think is gonna happen because, you know, Cali would have a pretty big advantage on growing cannabis over Arizona and Arizona would see their cannabis market dry up pretty quickly, which would be a big hit to their tax revenue. So every rapid Senator who wants to protect, you know, their budget would vote against.

[00:34:56]Bryan Fields: What about states like New York that maybe don’t have optimal growing [00:35:00] conditions that have a big appetite for cannabis. What do you think will happen there from, let’s say a price standpoint. If California can grow it at a really low level, New York is, is, I

[00:35:08]Nate Lipton: mean, nobody wants to, yeah, it’ll be a little bit more in New York and you know, it’ll take a little bit more to grow.

[00:35:13] You’ll have to grow in greenhouses, um, to grow year round versus some other places where you can, so price will be a little bit higher and you’ll employ more people.

[00:35:22]Bryan Fields: Yeah. Good old money. Right. Influences a

[00:35:24]Nate Lipton: lot of decisions. It does. Yeah. But, um, maybe going down to like, I’m trying to think most of the stuff, like I don’t, when it actually comes to like the biology of the plant and growing cannabis.

[00:35:38] I would say this actually. So two things that I think one THC and any cannabinoid testing is pretty imperfect. So like, if you’re like buying something that’s 25%, like you could test parts of that same plant that would register like probably 30% and some that would register like 18%. Yeah. [00:36:00] And, you know, I don’t think people understand the variability of THC testing.

[00:36:04] And, uh, also when you do blind smoking, when you basically remove the THC, you just have people smoke. It usually the intensity, the high does not correlate with the percentage of THC actually on the bud Uh, so I think, you know, people need something to like figure out what the quality is. And like THC is kinda like the only objective indicator out there.

[00:36:26] So people gotta use it. So like, I don’t blame people for using it, but I would say. don’t think that it’s like, you know, the G you know, the, the north star that’s gonna guide you , you know, to where you want to go necessarily. So relax a little bit on that. Say just smoke something, see how it works with your body, you know, try to remember that strain, if it does.

[00:36:45] What’s your

[00:36:45]Bryan Fields: thoughts on the indica versus sativa conversation that’s currently happening? Is that good for the industry? Is that bad for the industry? Is it good for consumers? What do you feel about

[00:36:54]Nate Lipton: that? You know, I think humans naturally just love to categorize and organize things. [00:37:00] It’s just so much, yeah.

[00:37:03] So much cleaner for your head. I love to organize things and categorize ’em put ’em in buckets, but yeah, it seems like those buckets are a little bit more artificial, um, right now than maybe useful, um, is what I would say. So it just comes back to like, your mileage may vary, you know, like. It’s even funny, like people, you know, I have a fiance.

[00:37:25] Right. And when I was growing up, I could be like, yeah, you know, and this is not true, but just hypothetically I’m into blondes. And then you like meet a brunette and she’s awesome. You’re like, oh, well, shit, guess I’m into brunettes. You know, like you like women.

[00:37:41]Bryan Fields: Right? Right. Like, yeah. You

[00:37:43]Nate Lipton: like women. That is the category.

[00:37:44] Yeah. But it’s like, so, you know, you like weed, you like smoke this blue dream. That was like 30%. You’re like, you know, I’m gonna love that shit, you know? And then you smoke it and it’s high, but then you smoke this granddaddy purp. I was like 14%. You’re like, shit, dude. I love granddaddy purpose 14%. And I really [00:38:00] thought I was gonna love this banger over here, but that’s not the case.

[00:38:03] You know, it’s like, you kind of have to just like experience it. And since everybody’s biology is so different, it’s like, man, just take those categories, throw ’em out the window and realize we don’t fucking know anything, you know? Yeah. Yeah. I agree. What is your favorite strain? Ooh, dream Walker. So that’s the best one that I just had the most pleasant and it’s, it’s like so hard to find these days are so many strains.

[00:38:29] It’s like, if you smoke something once, like even just finding it again could be a mission, you know? Yeah. Um, but I had this in Cali, like yeah, probably brown five years ago. And it was just like, literally I smacked it. And I just like, felt like I was like meditating for like three hours, you know? Like, but that, that, like, if you meditate in that like part where you get where you’re like, okay, I’m in it, you know, like I’m in the zone right now.

[00:38:52] Like I just felt like that for like three hours. And I was like, this is dope, you know? So I like that one, but I also more of like, , [00:39:00] you know, I’m more of like a nighttime smoker. Uh, so I’m more smoke, you know, kind of like when the seven to 8:00 PM kind of rolls around and that’s usually when I do it, I’m usually not too good at being like productive and smoking or like daytime going out with the friends and smoking as much.

[00:39:16] Yeah. I mean, I go out, but I just don’t talk,

[00:39:17]Kellan Finney: you know?

[00:39:18]Nate Lipton: Yeah. No, and I, obviously you can tell, I talk a fair amount when I smoke. I kind of slow down a little bit. People what’s wrong with you. Yeah. You know, people who know me, I’m like, dude, just super high in the corner. Like smile. Like I’m totally fine. You go get some food food too.

[00:39:37] So who ISN’

[00:39:38]Bryan Fields: under the radar grower brand or strain that you think will explode over the next

[00:39:42]Nate Lipton: two? Hmm, dude grower my man miles. Sadowski I gotta give that guy a shout out. I love that guy to death. He’s uh, a grower out here in Tucson. Arizona grows for Earth’s healing. [00:40:00] Um, I don’t know. His Instagram handle is like miles for grow or something.

[00:40:05] I’m gonna give him a good shout out. I’ll find him while we’re chatting. But that guy literally, you know, he started legacy dude, like, you know, blown out shit. Next thing, you know, get thrown into the fire, you know, just like running a small facility out here in Arizona. Self-taught like everything wicked smart.

[00:40:23] Um, and now he just built out like 140,000 square foot, like, uh, greenhouse on top of the indoor they’re growing out here and he just like everything he reads, he just absorbs and you just have a conversation with him. He is so casual. He’s like my age. We both DJ and like hang out together, um, just casually.

[00:40:42] But that guy is like, he’s a, he’s one of those guys that like, is so humble and then you have a conversation with him and he just like, blows your mind you. Right. Um, so I love miles. I think he should, he he’ll be doing big things in the future. He just had two kids though. So he was probably pretty busy.

[00:40:59][00:41:00] Um, and then cannabis brand that I think is gonna blow up who who’s doing something well, you know, this isn’t a brand in particular, but this is more of a trend I’m gonna put out there. And some brands are jumping on this trend, but, uh, like for example, have you guys ever tried any of like the, uh, kind of water soluble, nano emulsified edibles?

[00:41:24] Yes. Yeah. I,

[00:41:27]Bryan Fields: so many of them at this point now, I don’t, I know maybe like I just wanna pop em in as soon as I get them.

[00:41:33]Nate Lipton: So those are becoming more and more popular and. What I do see in the future. I think, you know, if I were to like guess is like, I’ve seen some sodas come out where they’re like trying to be like the alternative to white claw where it’s like, you know, it comes on in 15 minutes and it’s done in like an hour or an hour and a half.

[00:41:51] So it’s like, you can take an edible and you’re not high for like eight hours, you know? And like they have those on the edible side. I think they’re gonna have them in like nasal [00:42:00] sprays. They’ll have ’em in drinks and it’s gonna change the game on edibles and edibles are so much more discreet than smoking that I think that is gonna be a huge trend.

[00:42:10] And I see some brands jumping on getting those products kind of first to market in some states. How, how would you

[00:42:16]Bryan Fields: know that those are, that, are they labeled on the, on the product or are they just described

[00:42:20]Nate Lipton: a different way? Yeah, they usually are labeled that way. Yeah. But if you like go into, if you’re like in a recreational or medical market and you walk in the dispensary or you just call them, be like, Hey, do you have any like fast acting or nano emulsified product?

[00:42:33] They’ll tell you, or if they have no idea what you’re talking about, they probably don’t. So probably I know like, yeah, like usually it says like nano emulsified or fast acting or something like that. Like I think one gummies. Yeah. W quick, I think they called them. Yeah. Yeah. So they came out with some, um, planet 13 had their high, high drink.

[00:42:52] That was kinda like the Whitelaw type thing. Yeah. Can the, yeah, so there’s, you know, there’s a company called [00:43:00] source O R S E. That makes that product. It’s like the, the input that a lot of people would be licensing to put in that stuff. So if you’re a canvas brand, you wanna do it hit up source, shout out, Joe.

[00:43:11] I do not get paid for this. I don’t even know who runs the company. Like , we’re gonna, we’re gonna send

[00:43:15]Bryan Fields: Joe at source an invoice after this

[00:43:16]Nate Lipton: first. Yeah. Got a love, Joe. Cool. Cool. Sounds good. Yeah. Give me five bucks too, for a drink, right?

[00:43:26]Bryan Fields: what is one takeaway you found through your experience that most growers, our facilities are overlook.

[00:43:35]Nate Lipton: Well that are overlooking. Hmm. I think there’s a, in California, not so much, but I think in a lot of other states, they’re not doing testing in their plans for certain viruses, um, hop late and Throid is probably the most well known and popular one. And, um, What happens when you have plants and plants can have [00:44:00] like varying degrees of H L V.

[00:44:03] Uh, so it’s not like, you know, it’s not binary. It’s not like you have it, or you don’t, it’s like your plant can be kind of infected medium infected or super infected. But what can happen is if this is barely infected, you’re just like, man, you know, my yields are going down a little bit and my testing results on the cannabinoid side are going down.

[00:44:22] And like, that’s one of the indicators that you could have HIV along with a few other. Kind of morphological things in the plant, but I think there’s a lot more people who are growing, who have HLV in their gardens, who don’t know they have it and are having like issues where like, you know, their yield is just slowly going down over time and they’re like, oh, I gotta switch my moms out.

[00:44:44] Oh, I gotta switch the lighting. You gotta switch the nutrients, my light, you know, there’s some weird happening and it’s just like, HLV you gotta get your plants tested, take some plant tissue, get it tested to figure out if you have it. And you know, the problem is that like the good thing is plants don’t really [00:45:00] pass it from like, just hanging out in the same room.

[00:45:03] It’s kind of like aids. You have to like pass it via like, you know, uh, tissue or like blood, things like that. But usually how people get it is like, um, cutting clones. You’ll cut one from one mother and it’s on your blade. And then you cut another one from another mother, and now you just transferred it to that club from one mother to another.

[00:45:22] Okay. Um, they even found out that it can transfer like through seeds, so you can have a seed that has HLV right out of the gate. So you should still be testing things like that. But, um, that’s one thing you should definitely watch out for. I’d say

[00:45:37]Bryan Fields: that’s a good one. Mm-hmm , since you’ve been in the Canna industry, what has been the biggest misconception?

[00:45:45]Nate Lipton: Mm. Maybe that everyone’s just killing it, like rolling in money every night. Like , you know, I think a lot of people assume that I think it was like a study that came out that was like, you know, two thirds of like cannabis [00:46:00] businesses that have within the last five years are still not profitable. Yeah. Um, yeah.

[00:46:05] And you know, just because it’s got the allure, like this black market appeal where you’re just like, you know, PABs of our. Your money. It’s like, it’s not like that. It’s just another business. And honestly, there’s not a lot of great guidelines on how to run the business. Well, that’s why there are a lot of consulting groups, uh, like ours are trying to take some best practices and apply them to different people.

[00:46:26] Um, help them out, become successful faster, like learn from other people’s mistakes, not your own. Um, but yeah, man, it’s, uh, it’s a new industry. People are still trying to pave the way I would say the road to success right now is still like, uh, a muddy trench. Yeah. It’s not like a well paved road, you know?

[00:46:45] So, uh, that’s a big one, you know, mm-hmm , before

[00:46:50]Bryan Fields: we do predictions, we ask all of our guests, if you could sum up your experience in a main takeaway or lesson learned to pass onto the next generation, what would it be?[00:47:00]

[00:47:03]Nate Lipton: Um,

[00:47:08] yeah, I would say. It probably has to do a little bit with just a little bit of putting yourself outside of your comfort zone and just trying to start, start at the bottom if you really want to be somewhere, but make it known that you want to learn and you want to grow. Don’t assume that other people are gonna know that and that they’re just gonna like throw you on the back of their coattails and take you with them.

[00:47:38] Like, say like look down and put in the work, but I want to be constantly progressing and getting better. And I’m willing to put myself outside of my comfort zone to do that. And look for, you know, I think the most learning I’ve done in this industry, or just in my professional life have been the days that have been really hard and really shitty.[00:48:00]

[00:48:00] Um, those are definitely the ones that provided the most growth for me. The days that go really well are nice to have, but if you just have those days, you’re gonna have a full sense that you’re actually good at something. Um, cuz you’re probably not you’re just like misattributing the fact that everything is going well to it being something that you brought about.

[00:48:24] I mean, humans just fucking, I’m telling you, man, I don’t even know if I can swear here, but I’ll just yeah, yeah. Just I’ll start it over. Cause humans, you know, um, have a natural inclination to just, uh, have, uh, good days and bad days and just find your own way to weather the bad days because um, then the good ones will come and.

[00:48:51] You’re gonna be a stronger person for it. Probably something related to that. That’s really well said. Thanks.

[00:48:57]Bryan Fields: All right. Prediction time, Nate. Okay. It’s [00:49:00] 2028. When you walk into dispensary to buy flour, what characteristics will help consumers select the product of their choice?

[00:49:10]Nate Lipton: Hmm. Interesting. I like this question, man.

[00:49:14] This is good. You guys have found some good questions. Hmm. Okay. Um, I think what would be really cool is to figure out some type of like cannabis, genetics, you know, if we can really attribute them to like where in. The world. We think that we first had a record of that product being grown. It’d be really cool to like look at the genetic material.

[00:49:46] Like I’m assuming genetic testing is gonna become way cheaper six years from now, but, um, you know, you’d be able to tell like, oh man, this is like, from the middle east, this is some like Afghani stuff. And, [00:50:00] you know, maybe there’s we come up with a better way to like isolate more cannabinoids and the artificial intelligence ends up figuring out the interaction of some of these cannabinoids terpenes a little bit better.

[00:50:11] And, you know, by figuring out those interactions are, maybe it’s funny, we might come up with new buckets to put things in, you know, and I almost think of it like the Myers Briggs test, you know, there’s like I N TJ and all of those kind of things. There’s all these like 16 buckets that. You know, you can put things in like with cannabis.

[00:50:32] I think you, we might end up coming up with our own buckets that we make based off of kind of, uh, AI figuring out what the actually, so let me see, you have a background in biology, so let’s see. How would someone, what would we call that? The interplay between multiple variables, polyp pharma. Okay.

[00:50:57]Kellan Finney: Yes.

[00:50:57] Right. So currently it’s only single [00:51:00] APIs is how the pharmaceutical industry treats diseases. Mm-hmm and that’s why like Marinol and syntax, which is just THC molecule. That’s why they never really took off with like chemotherapy as a treatment because there’s that missing variable besides just THC. So like, if you ever eat Marinol, you feel really weird.

[00:51:16] If you eat in edible that you just distillate, it’s not the same as smoking flour at all, which is why wild gummies have just exploded across the entire nation is because they’re capturing the full spectrum. So they’re including all of these other. Um, final chemicals are in the plant into their gummies.

[00:51:33] Right, exactly. Um, so that’s exactly

[00:51:35]Nate Lipton: it. Yeah. And so it’d be cool if we could like find these like categorizations of buckets that we find like certain interactions work certain ways, and these are buckets that we like. Don’t even know what they are right now. Yeah, totally. Let’s and then we put ’em in there.

[00:51:47] That’s what I think the future might look like. No,

[00:51:51]Kellan Finney: and I think you’re completely right. And there’s an organization called the C E S C the clinical endo cannabinoids, uh, science consortium. And what they’re [00:52:00] doing is going through and trying to tie specific terpenes and cannabinoids, right? So like type one type two type three type one being THC, heavy type two being THC and CBD, then type three, just being CBD dominant.

[00:52:13] They’re trying to tie those three types with specific terpenes, to like a cause and effect situation. Mm-hmm um, and they’re on the brink of publishing all this data. So I don’t really want to kind of like do a spoiler alert and take their thunder from, um, but there’s come up with some really, really.

[00:52:29] Astounding, um, results and some really, really cool correlations. Um, they ran a massive dosing project is what it’s called out in California, where they had all of these consumers it’s called, um, um, an objective study. It’s not a clinical trial, right. Because everyone is willingly participating in willingly giving the information.

[00:52:48] Right. Uh, and so they took all this data from the dosing analysis as like, Hey, I tried this strain and they know that this strain has these terpenes and. Cannabinoids. And then they tried to do like a cause and effect situation, and they took these [00:53:00] massive data sets for the whole entire like California consumer market.

[00:53:03] And then they tried to correlate it to like cause and effect and they came up with some really cool correlations. Yeah. But I think they’re kind of in the last stages of publishing that information. So I don’t want to kind of like, uh, disclose anything that is about to be published by them. So, but they’re, they’re really working on it and you literally hit the nail right on the head.

[00:53:22] And I believe that that’s exactly how consumers will make those decisions in six years. And I think that the indica sativa hybrid thing is great, but I think that what this will do is kind of come in on the backside. And provide that robust scientific foundation. Cause right now it’s just really tough to know.

[00:53:41] Okay. Yeah. Blue dream should be an indica, but was that blue dream

[00:53:46]Nate Lipton: lineage?

[00:53:48]Kellan Finney: Perfect. Right. Is it the true lineage that everyone says or was one grower somewhere in the middle there being like, you know, a blue dream crushing it this year, I’m just gonna call this blue dream. No, one’s gonna know. Right. Yeah.

[00:53:58] And so there, it’s like tough [00:54:00] to say if that’s truly like a, a concrete foundation within the strain naming protocol. And I think that as the industry matures more and more science gets involved, this kind of foundation, we will actually help us sort out those kind of categories that we’ve grouped

[00:54:14]Nate Lipton: them in Zach Damo.

[00:54:15] I mean, that study sounds super interesting. I gotta get my hands on that.

[00:54:19]Kellan Finney: So I think, yeah, I’ll connect you too. Dr. John Abrams and John Tran, they’re running it’s, uh, an MD and a PhD immunologist, and they have a whole group of people. Um, love to connect to you. You can chat with them and meet super, super smart people doing.

[00:54:31] Really really robust scientific research on this stuff. So

[00:54:34]Bryan Fields: they’re also gonna publish some studies in our cannabinoid playbook. So you can definitely sit back cuz it’ll be in the playbook for the next six months. So we’ll definitely have some of that research coming out. Kevin didn’t tease it correctly.

[00:54:44] He teased it, but he didn’t give all the

[00:54:45]Nate Lipton: information on where find the information,

[00:54:47]Kellan Finney: but that’s why you’re here. I wouldn’t wanna take you

[00:54:49]Nate Lipton: under Brian, right? An playbook. Yeah, little playbook.

[00:54:55]Bryan Fields: Um, so I agree. I think the effects is definitely where we’re gonna go and we definitely need the science [00:55:00] background to kind of validate that because if you’re looking to take a creative product, let’s say during the day to spark, you know, some, some breakthroughs and some of the challenges you’re having and then you have like one of those heavy products that put you to sleep.

[00:55:10] It’s not gonna work. Right. And even more so if you, if you give it to a, a more inexperienced consumer, who’s more hesitant to try and say, Hey, like this is a more uplifting feeling. And then they experience it and it, and it puts them into the couch and they don’t like it. They might be perturbed to not try again.

[00:55:25] And I think we really need to find that that balance between side scientific information to kind of validate some of these claims and also communicating to consumers when they walk into dispensary for the first time. So they’re not overwhelmed because like, for me, I’ve only been into a large handful of dispensary since I’m, I’m locked into New York here.

[00:55:42] And when you go into these, some of these calories, these Washington dispensaries, there’s hundreds of products. And it’s like, this is almost overwhelming. I wanna buy all of these, but I also want to try new products and I’m unsure where even to start. So I would imagine some other people who have that inexperience might have that same feeling when they walk into these dispensaries for the first

[00:55:59]Nate Lipton: time.[00:56:00]

[00:56:00] Yeah. And you know, one of the interesting, the interesting things that just kind of occurred in my head, but it’s like. We have such a, um, like right now, like, I would say a little bit of like a curiosity in really figuring out like what cannabis does, what, and like what types of cannabis do you know, have certain, uh, I don’t know, effects or things like that.

[00:56:23] But then I was thinking about like beer and I’m like, man, I, I drink like a Pilsner or I drink like an IPA and I actually have like a pretty different effect from those two. And I don’t think it’s. The alcohol content. I think there’s actually more going on ES

[00:56:38]Kellan Finney: it’s like wine drunk, right? Like you get wine drunk versus beer drunk versus like, I was actually being a grad school and I was sitting with my professor and he was like, you go to a party where there’s a keg, the vibe is way different.

[00:56:50] Everyone’s like smiling, giggling, whatever. You go to a party where everyone’s just taking vodka shots, completely different thought. And like he’s saying that he was distributing it to the [00:57:00] terpenes and this was like way before cannabis was legal or anything like that. And he’s a big brew beer brewer.

[00:57:06] And I think that that also is why you saw this huge, um, influx of micro brews in the last like 15 years, because they’re increasing those Tering content and. Brewing beer has truly become a really intense, like scientific process for these micro breweries. You go to like Odells or some of these big breweries here in Colorado in Fort Collins.

[00:57:27] And they literally have like organic molecules drawn all over the entire whiteboards. And they’re all like trying to figure out what hops have, what chemicals in them to try to get the beer and the flavor. So, yeah, I think, I mean, it’s exactly it, right. I think it’s the terpenes because I mean, wine drunk is very different than,

[00:57:42]Nate Lipton: than beer drunk and beer or vodka drunk.

[00:57:44] Yeah. There’s, there’s definitely some cultural things. I think there’s, you know, Cultural things with like the, the people who take the vodka shots versus the people that drink the beer versus the people who drink the wine. , you know, there’s probably some, you know, multi-variate analysis needs to be done.

[00:57:59] That. [00:58:00] Exactly. I think the thing is like, we’re going after understanding cannabis, like so much more intensely than understanding beer. Like even though the beer people are super into it, they’re just like, oh yeah, make a beer taste. Great. And they’re more about taste and then, right. But it’s like, they kind of stop.

[00:58:17] They’re just like, now we’re just going after different flavor profiles, but they’re not saying like, oh yeah, this beer is gonna make you, you know, uh, it’s Arod easy act for you or something, or this one is gonna make you, I don’t know, give more energy or something like that. They’re not like categorizing or marketing beers that way.

[00:58:38] Which is interesting. It’s just more of like a, a little bit of a realization, but I don’t think there’s much to it. Yeah.

[00:58:45]Bryan Fields: It’s also challenging for consumers too. Right? We’re asking them to make decisions based on like form factors and then the indica, Sativa’s a common one. Then we’re asking ’em to decide on like strain names.

[00:58:54] Then we’re asking ’em to decide on, on cannabinoid content. And now we’re introducing terpenes to them. And plus, as we [00:59:00] talked forward, the combination of those variables influences outcomes completely different. So we’re kind of ch making it a little more challenging for the consumer than we should, but there’s also this balance of like the science needs to catch up.

[00:59:11] We also app the consumer needs to catch up. So we got a lot of variables. So we gotta work through in the

[00:59:15]Nate Lipton: next five to six years. Plus, you know, once you start doing something, this is maybe it goes into the cultural practice too, but there’s like, there’s a little bit of, um, Stickiness to it. That’s hard for you to like change everyone over to a new mode of thought, like every dispensary in California, you can’t just like, say, oh yeah, we’re getting rid of indica and sativa today.

[00:59:33] And then, um, yeah, we’re done with it, cuz it doesn’t really mean anything. Like people still want to shop that way. Even if they know that it’s probably wrong. Yes. Like you can’t like just take it away. It’s like, it’s gonna take years of trying to come up with some alternative to give these people before they can move off of it.

[00:59:52] So like this stuff is gonna, you know, the change there’s cool things that are happening, but. The societal change will be a little bit like [01:00:00] yeah. It’s not a light switch. No,

[01:00:01]Bryan Fields: your consumers are always right. So if they walk in, they’re asking, I’m looking for indica sativa, you know, how can you be that establishment?

[01:00:08] It’s like, you know what? We don’t have that here. We don’t abide by those

[01:00:10]Nate Lipton: principles. Those are the wrong buckets. Sorry. Yeah. Sorry. We don’t call things indica anymore. They’re gonna be like, am I in the right store? Yeah, cool. So Nate,

[01:00:20]Bryan Fields: for our listeners, they wanna get in touch. They wanna learn more and they wanna watch can cribs.

[01:00:24] Where can they find you?

[01:00:25]Nate Lipton: Yeah, so the YouTube channel is actually called growers network. The series is, can cribs on the YouTube channel growers network, uh, growers house.com is the eCommerce site where we sell everything. You need to grow cannabis, nutrients, lighting, you know, like 16,000 products, whether you’re a hobbyist or commercial grower growers, network.org.

[01:00:45] Is the forum, stuff like that. And they all have their social media channels and stuff like that. And then I have my own Instagram, Nate, DOJ, Lipton. If you want to hit me up, I respond to DMS like 90% of the time. I’d say not perfect, but I try [01:01:00] cool. We’ll link all those up in the show notes. Thanks for taking the time.

[01:01:03] Yeah. Appreciate it guys. Cool.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Editors’ Note: This is the transcript version of the podcast. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below if you need any clarification. We hope you enjoy!

This week we are joined by Leslie Bocskor   to discuss :

  • Paper, Plastic & Fiber will be disrupted
  • Making sense of Cannabis policy
  • Why the Cannabis industry has not self-regulated

About Leslie Bocskor

Bocskor’s insights, expertise, and global stature make him the man who policy makers, investors, and entrepreneurs seek out for future planning and immediate fixing. He is the undisputed choice as the voice on cannabis issues and business, from state-of-the-art technology and best practices to policy, industry financing and expansion. Committed to a culture of compassion at Electrum Partners and throughout the industry, he takes pride in ushering in changes that rewrite history, whether it’s the empathic opening of patient access, or the invention of a national innovation funding reset button.

His far-reaching banking and entrepreneurial experience and inimitable style are bolstered with his knowledge of any cannabis vertical — from domestic and international policy to finding your niche investing opportunity, from supercritical extraction to ERP solutions, from seed-to-sale to the entourage effect of strategic business integration. Bocskor has become one of the most influential people in the cannabis space, guiding policy and reform.

https://www.linkedin.com/in/lesliebocskor/

#Cannabis #hemp #INQD

At Eighth Revolution (8th Rev) we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain

The Dime is a top 50 Cannabis Podcast 

Contact us directly at [email protected] Bryan Fields: @bryanfields24 Kellan Finney: @Kellan_Finney


[00:00:00]Bryan Fields: What’s up guys. Welcome back to the episode of the dime I’m Brian Fields. And with me as always is ke Finney. And this week we’ve got a very special guest, Leslie Butch core. Leslie, thanks for taking the time how you doing today? I’m

[00:00:11]Leslie Bocskor: doing fantastic. It’s really great to be here. It feel really great to be here on camera with you.

[00:00:15] You know, I’ve been reading, uh, what you’ve been doing and watching what you’ve been doing. And it’s just such an honor, and I, I love what you’ve been doing. Your, your fans are enormous. The, the following is great and the content

[00:00:25]Bryan Fields: is excellent. I really appreciate you seeing that.

[00:00:27]Kellan Finney: And Kelly, how are you doing?

[00:00:28] I’m doing well, just enjoying Colorado and really excited to talk to Leslie. Yeah. Leslie,

[00:00:32] for

[00:00:32]Bryan Fields: the record, where were you born? Leslie? I was

[00:00:35]Leslie Bocskor: born. I was born in New York city. That’s an east coast of France. I located now though. Um, I’m out in Las Vegas. The west coast. Yeah. Well, you know, right. Yeah. Yeah.

[00:00:45] Pacific time zone. I was born at a hospital that no longer exists. Flower fifth avenue grew up in, in and around New York city and moved out here to Vegas in 2010. Awesome.

[00:00:57]Bryan Fields: Awesome. So let’s, let’s kind of dive in a little bit [00:01:00] for our listeners that aren’t free about you. Can you give a little background about you?

[00:01:03]Leslie Bocskor: Sure. Uh, so, you know, personally, like I said, I’m from New York city. I actually spent some time growing up in Northwest, in New Jersey as well. Uh, so you know, very much an east coaster. Um, I, uh, as I said, you know, before you can take the. The boy out of the city, but you can’t take the city out of the boy.

[00:01:20] I’m always gonna be very fond of New York. I try to get back as often as I can. Um, you know, on a personal note, I’m very oriented towards, uh, a cultural endeavors and sort of, uh, values oriented projects. I’ve been the chairman and founder of a couple of arts and Phil philanthropic organizations. Uh, personally, I’m an avid attendee and have been, although not recently of burning man, my wife and I have been going since 19 together since 1998.

[00:01:47] My son went for the first time, uh, when he was just two months old, he’s also the youngest ever, um, recipient of a burning man, honorarium art grant for a project called the Jedi dog temple for kids that [00:02:00] ended up being in a burning man, uh, art show that was in the Smithsonian. Uh, I’ve been as a professionally.

[00:02:06] I started out in investment banking and finance. Uh, a number of years ago, I was one of the first investment bankers to focus on the internet. And new media as a new sector back in the mid to late nineties. Um, I have been, uh, a cannabis enthusiast. My original due diligence on cannabis goes back to when I was 15 years old.

[00:02:27] And I started smoking pot for the first time at my school bus stop prior to going to high school. And, um, so, you know, anyway, personally, I ended up coming out here to Vegas for quality of life reasons. It, it, it turns out that when I came here and I didn’t realize how awesome warm. Dry and sunny was, but it’s been fantastic.

[00:02:49] And then also I got really lucky in that. Nevada is one of the jurisdictions and probably the jurisdiction with the best regulatory framework for legalized cannabis [00:03:00] and, um, adult for medical and adult use cannabis. And then when I got out here, I just sort of switched my focus originally coming out to the, to Las Vegas, to do research on the casino and gaming industry.

[00:03:11] And when I got here, I saw that hemp and cannabis presented an opportunity that when I did my research was unlike anything I’d ever encountered in all of my previous years in finance and banking. And so I focused on it exclusively. And so here we

[00:03:25]Bryan Fields: are, I’m excited to kind of dive into some of those specifics.

[00:03:28] So when you were making that transition or thinking about making that transition from that pivot from investment banking to cannabis, was there any hesitation take us through what those early days were like and what you were feeling when you were making that

[00:03:38]Leslie Bocskor: move? Okay. So, um, 2010, I come out to Vegas and I’ve been a cannabis, you know, aficianado on and off for many years, since I was 15, I stopped when I was working in finance, I stopped having anything to do with it.

[00:03:54] Not because I thought there was anything wrong with it, but just, I went through a period where I wasn’t drinking. I wasn’t smoking. I wasn’t, you know, I [00:04:00] was just not drinking coffee. I was just being super straight and narrow and focused on my career. Uh, and so when I came out here, although I wasn’t an active, consistent cannabis user, uh, I had always been very much a, you know, had an affinity for it.

[00:04:20] And so I came out here and I saw there was a medical marijuana market. Although, not a market. There was a medical marijuana law in Nevada. I went and visited some friends in San Francisco. You know, they, they showed me what was going on with dispensaries in the medical marijuana market in, in California.

[00:04:36] And I started to do some research on it, cuz I knew that if there was gonna be legal, legal adult use cannabis, it was gonna be a massive opportunity. So I started reading some research in 2010 and 11. One of a couple of reports I read were the Rand Corp and the United nation studies that were done about the illegal market, the black market for marijuana cannabis in the [00:05:00] United States.

[00:05:00] And in 2010, according to ran Corp in the UN the market for black market, uh, cannabis in the United States was between 42 and 50 billion a year. Now to give you an idea, the total value of the all professional sports, essentially the same year, major league baseball. The NFL, the NHL and the NBA was under 35 billion.

[00:05:26] So weed was bigger than sports in America. And that got me to really sort of think, and I was really digging into it. And then Colorado and Washington. Past adult use a friend of mine. Who’s a political operative, Joe BSK, who is just without him. I don’t think we would have the weed industry in the United States, the cannabis industry in the United States that we do.

[00:05:49] Uh, he said, you know, watch what happens. It’s gonna, they’re gonna pass these ballot initiatives. And I said, Joe, you’re just a hopeful stoner. It’s never gonna happen in our life lifetimes. Sure enough. They passed them exactly the way they said. [00:06:00] He said they would, I sat down with him. I said, okay, you’re right.

[00:06:03] I was wrong. Explained to me how you knew that and what’s going on. And he showed me the data and I said, oh, this is the moment. And so I UNW all of my previous projects that I was involved in and I began to focus exclusively on hemp and cannabis and what those industries would represent in the United States and beyond, and how that was going to, to roll out and how that phenomena was going to.

[00:06:28] Move throughout the world. And, uh, as a result, I got very fortunate. I got involved very deeply in the policy side, advising policy makers here in Nevada, in California, Pennsylvania, Florida, uh, Costa Rica now, Mexico and other places. And, um, I haven’t looked back. It’s been a spectacular shift. It’s uh, candidly, it’s one of the, the five best decisions of my life.

[00:06:53]Kellan Finney: Did you ever consider moving to Colorado or Oregon after they, they passed those ballot?

[00:06:58]Leslie Bocskor: So I’ve considered [00:07:00] moving to Colorado prior to my moving to Vegas, actually. So one of the, um, places that my wife and I had on our decision matrix to consider moving to was Glenwood Springs, Colorado love Glenwood.

[00:07:15] It is one of the, like talk about quality of life. One of the best places in the world

[00:07:20]Kellan Finney: I’m originally from crest Butte. So it’s just right over the

[00:07:22]Leslie Bocskor: pass. Oh, no way. Oh, dude. That is totally. Let me tell you that Colorado. Listen, I love, I love my life here in Vegas, but I gotta tell you if, uh, the, uh, you know, the opportunity presents itself.

[00:07:36] I would not be surprised if I were to start, you know, spending some time every year, uh, out at Glenwood Springs. I’ve been looking at it very seriously. Ever since we moved to Vegas. Beautiful hots Springs there. Oh my God. One of the, one of the only naturally occurring vapor waves in the world, I know, gave with a hot spring emanating in, into it in like, and as a matter of fact, it’s a famous, it was famous for, uh, doc holiday [00:08:00] that’s right.

[00:08:00] Nine days because of his being, uh, tub Cullo and it’s such an incredible place. And the energy there is amazing and the food and the environment and the, you know, activities. It’s just such a great, a great location. One of the most, one of my favorite places in the entire country

[00:08:16]Kellan Finney: and now the

[00:08:17]Leslie Bocskor: cannabis too.

[00:08:18] Oh yeah. Oh yeah. Oh yeah, yeah, yeah. Yeah. As a matter of fact, I’m hoping to go back and visit there if not this summer, early fall of this year.

[00:08:28]Bryan Fields: So I wanna ask your hands are tied all across the industry with multiple companies. Take me through what a day to day is like for Leslie. What type of topics is, is he going through?

[00:08:38] What type of conversations are you having? And talk to us about what goes on.

[00:08:42]Leslie Bocskor: Okay. Uh, great question. So, um, the days can be very different on a day to day basis, but overall on a week to week and month to month basis, it’s pretty consistent. Our focus right now, my focus right now is one. We are [00:09:00] very interested in the moment in time that we’re in, as it regards the beginnings of the establishment of brands, that will be the brands that last for years to come in cannabis in hemp, in consumer products that cross, uh, around the entire.

[00:09:20] The spectrum. So one area is we’re very focused on brand development and where that’s going, understanding what the, who the consumers are of the various different pro product categories. Making sure we understand those discrete product categories, understanding the consumer and their need states in those product categories, understanding what they’re spending patterns will be, and then understanding what brands will, what brand type of presence will likely be able to establish a relationship with the consumers and last for time to come.

[00:09:54] So there’s a big portion of my time that’s spent on that. A another portion of my time is [00:10:00] spent on policy. What is, how is I, how will policy evolve as regards. Cannabis domestically and internationally. So meaning for example, some of the issues we look at, even though hemp is legal, there are still so many gray areas, Delta eight, Delta 10, um, there’s even someone out there that said that believes that as long as the gummies, they produce are less than 0.3% THC by weight, that they can produce THC gummies that are legal to ship across borders.

[00:10:40] Cuz technically speaking, if it’s less than 0.3% THC by weight, it’s considered hemp, it’s not considered marijuana on a federal basis. Then there is also, we’re trying to understand how does the work in process hemp extract and the fact that when people are making these different products, how does the fact that the [00:11:00] extract goes above 0.3% THC in the manufacturing process, thereby breaking.

[00:11:06] Federal law. And then that extract is now considered marijuana. So does that mean that the products that are made from that now are illegal, legal, again, gray area. How’s that going involved? What’s going to happen on the federal basis with the safe, the safe act what’s going to happen with descheduling what’s the department of justice going to do.

[00:11:27] And when and why? Um, then we’re looking at Mexico, Mexico, or, you know, three years ago, their Supreme court declared. Prohibition of cannabis on individual use and possession, and even having a market for it was illegal. And so they, for three years now have been trying to implement a regulatory framework to create a legal market there.

[00:11:49] Uh, how is that going to evolve? How will Europe evolve? Greece, Germany, Spain, Italy, um, uh, Portugal, France. How will those markets [00:12:00] evolve over time then looking at Asia, India, uh, Thailand and others, how will those markets evolve over time? So there’s a lot of time that we spend on analyzing that, um, speaking to the stakeholders in those areas and trying to really not just understand what’s going on, but where we can, how can we help on a pro bono basis?

[00:12:21] How can we write white papers? How can we provide access to real data so that in every one of these conversations, it can be a conversation of fact based. Data between sensible people. So we can start to see the beginning of real, uh, rationality in how cannabis and hemp are dealt with moving forward.

[00:12:44] Then another part of my day is spent on the enterprises that navigate these areas. And what is it that we’re going to do? What are we, you know, so again, Mexico, I’m extremely interested, not just in the Mexican market. I think [00:13:00] that the entire, um, Spanish and Portuguese speaking Mar market, the Latin X market is over 750 million people worldwide.

[00:13:09] The United States and Canada is Canada is just 360 million. So essentially. Double the size of that market is the Latin X market. And so we see that as an area that people have not been as focused on. And we’re very interested in, in what that is. And then, you know, there’s a, I’m a father. I have a, my, my son is, uh, you know, is 10 years old and I am, uh, I’m, I’m hopefully gonna be trying to make it to burning man this year with him and my wife.

[00:13:37] So when I get some free time, we talk about doing things like that. But as regards, you know, professionally. We are focused on what the changes are going to be and how they’re gonna manifest what’s going on from a policy perspective and how can we help with that? And then also, you know, I have been extremely interested in the public markets.

[00:13:55] What’s gonna happen with the public markets because we see that when we do ultimately see the United [00:14:00] States change its federal policy, that the, uh, corresponding shifts as regards to the flows of capital, the velocity of capital, the establishment of businesses, the creation of value, the creation of jobs, et cetera, is going to have a significant change as well.

[00:14:14] And so we spend a lot of time trying to understand that, prepare for it and, and be in a position to make the most of it as a, as it changes.

[00:14:21]Kellan Finney: That’s a, a ton of items that you’re kind of juggling back and forth. uh, do you, is it like scheduled out where you’re like, okay, from eight to nine, I think about policy from nine to 10, I deal with brands or is it a lot more fluid throughout the day or is it kind of like each day is kind of devoted to one of those

[00:14:37]Leslie Bocskor: topics?

[00:14:38] So it’s really fluid because this is a very entrepreneurial time, you know? And so, um, in, in the beginning of any industry, when I was there at the beginning of the, the, uh, internet and new media industry, when I’ve watched the beginning of the cryptocurrency and FinTech revolution, that’s come out of blockchain and hash draft when I’ve looked at the [00:15:00] cybersecurity industry and where we are with that, which is also another industry that is very, you know, sort of it’s, it’s big, but it’s gonna become a lot bigger PR pretty quickly.

[00:15:11] When we look at the early stages of those industries, agility and, um, flexibility. Are really the rules of the day because things move so quickly changes happen so fast that if I establish a more rigid structure for myself, I’ll miss a lot of the opportunities and I’ll find myself at odds with the environment I’m trying to navigate.

[00:15:37] So at this point, the, in, in what we’re doing, we’re very entrepreneurial. We’re very, we focus on agility. We focus on flexibility moving forward so that we can navigate this rapidly changing, super dynamic and very challenging, um, [00:16:00] environment from a. Perspective of how we can contribute as corporate citizens and as citizens in general, because we’re very value based.

[00:16:09] We wanna make sure that what we’re doing is the right thing to do, and then how we can also navigate it from an economic basis to make sure we’re making the right decisions for ourselves and our partners.

[00:16:18]Bryan Fields: They also place so nicely together, right? When you’re talking about like domestic challenges and what, what could potentially happen from a scenario standpoint that’s critical for your current day to day, but then forward looking from an international standpoint where you wanna expand even more.

[00:16:31] So for, let’s say with the future opportunity holds and then communicating with policy makers about the importance of, Hey, we need to get our stuff together because if not, we’re gonna be left out of important conversations in the us will be literally locked into the United States without having access to that global market.

[00:16:46] So while, while it is probably challenging to juggle all those, it’s probably also super critical to have a perspective on the different variables so that you can make accurate recommendations when you’re leading up your team for success in the future.

[00:16:57]Leslie Bocskor: Brian, you couldn’t be more, [00:17:00] right. Let me just make a couple of observations.

[00:17:02] I’m not gonna name any names, cuz I don’t want to throw anybody under the bus. We have seen billions of dollars just lit on fire and burned just to create warmth. There’s been no effect from so much money that’s been spent on people trying to come in and, and navigate this and make money in the cannabis and hemp industry.

[00:17:24] Why? Because this is a unique moment in business history. We have never seen anything like this before, where there’s been a prohibition of something for 80 years. That’s the size of these industries. Let’s talk for a minute about hemp. So hemp as a result of the marijuana tax act of 1937 and then the single convention treaty of narcotic drugs at the United nations in I guess what was the 63?

[00:17:54] Um, Essentially hemp was made illegal on an international basis because [00:18:00] of policy changes that the United States made internally. And so, um, those, those shifts making hemp illegal, kept it out of these three very important industries where it’s extremely important. You know, hold on a minute, let me just turn off.

[00:18:18] There’s something that keeps sending me, uh, notifications. There we go. So the three industries that hemp was left out out of that it’s now starting to come into as a disruptor are plastics, paper and fiber. So hemp was made legal during world war II, cuz it’s a great source of, of parachute material cord, all sorts of reasons.

[00:18:48] It’s such an incredibly useful plant for so many things, but in the last 80 years, a hundred years nearly. There’s been so much innovation in hydrocarbon based plastics. It’s a [00:19:00] 1.1 trillion industry. Five years ago, the global fiber industry, cotton and other fibers, 700 billion. The global paper industry, the average us consumer uses 700 pounds of paper per year, 700 pounds of paper per year.

[00:19:21] The average consumer, the global paper industry, just the top 300 companies is something like 600 billion a year. And as a regard now, Pulp paper made from trees is horribly inefficient. I mean, a lot it’s sort of generally known, uh, uh, a paper mill in a town is so toxic or so unpleasant that people that live there end up getting an odor in their bodies that emanates from their bodies, just because they’re proximity to the plant and all of the affluent and what comes out of it, the plastics industry, I mean, you [00:20:00] know, who doesn’t know about the.

[00:20:02] The garbage patch in the Pacific ocean. How many times a day do we hear stories about microplastics in our body, microplastics in our food microplastics in, in, in our, in the water where we’re finding out about plastic and not just the plastic itself and the difficulty it has in biodegrading into other components, but the things that get released like toluene and benzene and other toxins that are endocrine disruptors, carcinogens, and, and more that go into our, our, um, environment on a consistent basis from our use of plastics.

[00:20:34] How many things do we have that are made of plastic? Our phones, headphones, water bottles, everywhere. Everything is made of plastic. And these plastics are highly. Toxic to our environment, hemp based plastic, and bioplastics even Henry Ford in the forties recognize the value of it when he built a car, largely outta bioplastics that were, that was [00:21:00] that hemp was a huge component of which is why.

[00:21:03] Now automobile manufacturers are starting to do the same thing. They’re making many of their components out of hemp based plastic. Well, why is that so significant? It’s significant because when hemp biodegrades, it doesn’t create the type of problems that plastic does. Not only, it ends up becoming one of the largest carbon negative industries in the world.

[00:21:19] As we pull the carbon dioxide out of air, into the hemp plant we make plastics out of that. Carbon that’s in the plant. And then when it’s, it goes into landfill is waste. It’s essentially carbon sequestration taking the carbon oxide out of the atmosphere and putting it back in the earth in a positive way.

[00:21:35] Now, what, what does this have to do with your original question? It has to do with the fact that what we are trying to understand is how these changes will manifest in these industries. Where will those opportunities be? How do we need to understand how regulation will affect it? And how do we position ourselves first and foremost, to make the best contribution to the world around us, to add value, to do things that are [00:22:00] values based and to, in some way to reduce harm in our actions, by making the world a better place, then we, we, we, of course we wouldn’t even be looking at it.

[00:22:09] If we didn’t see that there was a way to do this, that made a lot of sense economically. And then we look at the various businesses that are going to be able to come out of that then. That’s one big part of it. HAMP and industrial uses. Then we look at consumer products that are based upon it and what we’re gonna be able to do in that area and how the regulatory market will be important to navigate and influence not to for regulatory capture for ourselves.

[00:22:32] How to make good regulation for the citizens of the jurisdictions, where the regulation exists, because when you have good regulation, you then have good business environments that have good outcomes for everyone, for the business people, for the citizens and for the policy makers that that are in the jurisdiction.

[00:22:53] So we’re super involved in that as well. And every day, our focus is on trying to, to, to [00:23:00] hone our know. To, to sharpen our knowledge, to get more data research more, and then to do what we can to one, you know, contribute to the world around us and two, to do it in a way that is going to be economically sound for us and our partners.

[00:23:17]Kellan Finney: Yeah. And I think policy is gonna be a huge, uh, factor in all of those kind of concepts, if you will. I mean, if you just look at kind of your standard cannabis operator, who’s making an extract, right? There’s a ton of waste products that could be chemical feed stocks for all of those products that you just mentioned, but there’s regulations and policies in place that prevent the sale of chemicals derived from cannabis to these major markets.

[00:23:42] And then if you look at the hemp industry, who’s able to actually. Play on an industrial scale, cuz they have federal backing or at least kind of more institutional funding, if you will. Mm-hmm, , it’s really, really challenging for those, those, uh, startup companies. If you will, to enter into one of these established a hundred year old sectors, cuz [00:24:00] in order to produce the volumes, cuz it’s gonna be high volume, low margin kind of plays there.

[00:24:04] The, the upfront capital needed and the runway required for say a hemp bioplastic plant to come online and actually become competitive isn’t it’s it’s astronomical. Right? And so I think the only way that any of those entities truly have a, a fighting chance is through

[00:24:22]Leslie Bocskor: policy. So the other thing is it, I would agree with you and I would add this knowledge of policy and influencing policy, creating good policy critical, and it will allow you to understand how to position yourself from a business perspective.

[00:24:37] And I’ll also add this, the cause of this extraordinary opportunity of these products of this plant. This feed stock being off of the market for so long, the opportunity to create innovation in technologies, how to create the plastics, how to breed the best plant [00:25:00] for plastic production, how to breed the best plant for paper, and then understanding how to create the best system and, and the best methodology there’s been for creating paper.

[00:25:13] There’s been 80 years of investment in how to create pulp paper from trees. I mean, we have invested trillions of dollars over the time, over time in how to. Get that industry efficient trillions of dollars into how to make plastics work and different types of plastics, trillions of dollars into fiber on a global basis.

[00:25:34] And now there’s an opportunity to start focusing on how to create opportunities to compete with those industries based upon access to the hemp plant. And so you can play in that even while avoiding the enormous capital outlays necessary to build plants by focusing on the IP and by focusing [00:26:00] on the innovation, that’s the place where the individual investor, the smaller, tighter, more focused team.

[00:26:08] Be involved without having to be as capitally, have as much capital behind them. What they need to do is make sure that their knowledge, their research, their due diligence is extraordinary. And the more they, more time they spend focused on that, the better they are with that, the better they’ll be positioned for being able to navigate a space where there’s gonna be much more players with a lot more money.

[00:26:36] And I’ll go back ke to my comment about billions of dollars being lit on fire and just burned. There’s been, I don’t need to say who they are. There’s been a bunch of big companies who put huge amounts of capital into the cannabis and hemp industry and all they have is writedowns. So having the money doesn’t actually necessarily mean you’re gonna have the [00:27:00] success.

[00:27:00] This is a great time in history where being smart, we’re being diligent. We’re being. Um, effective in how you navigate the environment. It’s like the age of the dinosaur on a corporate basis is coming to an end and the smaller, more agile, more nimble, more adaptable animals, corporate animals like, like into the mamals of when the age of the dinosaurs ended, being able to navigate it, end up becoming more significant.

[00:27:30] And I think that that’s the point in time that we’re at. And again, and then when you add things like crowdfunding and the sort of solo entrepreneurship that’s going on now, it really does give a path where yes, if you’re not careful, you’ll get crushed by the dinosaurs as they just stomp on you with their billions of dollars of capital and, and you know, legal teams, et cetera.

[00:27:54] If you’re smart and you focus on good, good information and innovation, [00:28:00] you can out, you can outwit and outplay them.

[00:28:02]Bryan Fields: You also need a real strong sense of, uh, resiliency because operating in this industry is far from hard, right? I would say it, it hard would be on the easier side on how to describe it. And you need to be ready to navigate, because like, as you were saying, when you first got started your, your scenario planning for variable challenges domestically and internationally, and for someone who’s new or from outside industry, that’s kind of unknown space, right?

[00:28:24] Because when you come from a CPG world, you come from a Clorox, you’re used to having the path established the rules and regulations are written for you. You know how to navigate, you know, who the players are here. You’re not really sure. And things are changing on a day to day basis. So kind of being able to navigate and be nimble is really, really critical.

[00:28:39] But I wanna challenge you one point, Leslie, I wanna ask how do we get in wide industry adoption? Right. It makes sense. I understand from a scientific standpoint, all the benefits, but how do we go from where we are today to get wider adoption for everyday consumers to wanting to make that choice to go to more of the hemp plastic versus the, the conventional current method.

[00:28:59]Leslie Bocskor: So. [00:29:00] You know, a dear friend, Joe BSK, who I mentioned brilliant, brilliant political cooperative. He has one of my favorite nuggets of wisdom as regards policy. He always says, you can count on a politician to do the right thing after you’ve removed every other choice. And so the same thing is true to a certain extent with consumers, we, as consumers tend to navigate to what’s easy.

[00:29:33] What is fast? What is a habit we aren’t even aware of the marketing and information that influences our decisions on a day to day basis. And as a result, it’s hard for consumers. To actually make those choices with their money to vote. What they, for what they think is right when there’s economic forces at play, you know, it’s [00:30:00] economically things are tough.

[00:30:01] We’re going into a recession. There’s been this divergence in, in wealth, in the United States in particular between wealthy and the not wealthy. And, and that’s all very real. So the answer to your question is it has to be driven by the entrepreneurs. The entrepreneurs have to be smart. They have to be resilient.

[00:30:22] They have to be diligent. This is a time where the opportunity is unlike anything we’ve ever seen. And if you are not incredibly diligent and spend your time really doing your homework to make sure you understand how to navigate it, if you’re not incredibly focused on the partners you work with and their quality, and the fact that you’re aligned from a cultural and values basis.

[00:30:48] It will become a problem. So the answer is how do, how to, to the question of how do we get the consumers to be able to make those right choices? It has to be driven by [00:31:00] economics. Yes, you have to do the right thing and it has to be economically feasible. So we have to get to the point where it’s cheaper to produce plastic straws with hemp plastic, where it’s cheaper to produce paper products with hemp paper, where it’s cheaper, which already it is.

[00:31:20] It’s more effective to produce fabrics based upon hemp done on cotton, less water, less affluent, easier to process it in some ways, easier to process. And so we need to make it efficient. One of my great examples of this is we all have heard of he pre. Yep. Right. So, um, I’m in Vegas. And one of the great things about being in Vegas is trade shows.

[00:31:42] There’s a trade show for everything. There’s a trade show for the yarn industry. There’s a, a trade show for the concrete and cement industry,

[00:31:49]Kellan Finney: Vegas trade show in the world, Vegas one. Yeah. Vegas one in the world is the concrete one, 135,000 at attendants or something else. Like that’s what,

[00:31:55]Leslie Bocskor: so I send, I, I can’t believe you know, that that’s incredible long story, long story.

[00:31:59] You’re like one [00:32:00] of the only people that, oh, like you guys knowing this data point as extraordinary. I mean, I’ll never forget that though. Shout

[00:32:06]Kellan Finney: Uber

[00:32:06]Bryan Fields: driver shout out to the Uber driver,

[00:32:07]Leslie Bocskor: thought it said. Oh, my God. That’s amazing. But let me tell you what’s I sent my team to go to that trade show. I’m here in Vegas so I can get into, I, I can find ways for my team to go into almost any show to help to do something.

[00:32:19] They go there and they go around and they ask all, they were ch tasked with, go speak to every single company, go find scientists, go find engineers and, and then go find executives and ask them, what’s the story with hemp pre, are you doing anything with hemp pre what do you know about hemp pre and most people didn’t know anything.

[00:32:41] There were a half a dozen or so that did. And what they said was really fascinating. Hemp creates strength is its biggest drawback, because what makes cement and concrete so usable is there were solvents and tools [00:33:00] developed to be able to get rid of excess material flash. So when somebody. Is using their equipment and there’s all sorts of dried concrete on it.

[00:33:11] You can’t let that make the machine unusable. You have to have something to get rid of it. Well, they have solvents that have been developed to specifically address that. So you can remove it without having to harm the equipment you can, you know, when you’re making something, you can make sure that it looks the way you want without excess material on it.

[00:33:27] You don’t go looking around at buildings or seeing big pieces of, of some of, of hardened materials sticking out on the side. That was wasn’t part of the original mold that just, you know, no, they have ways to get rid of it, but hemp is so durable and so tough and it hasn’t had, again, this gets back to what I said about innovation, the invention of the solvents, the, the materials to render the excess hemp Creek that is unnecessary or even.

[00:33:56] In the way to be able to get rid of it doesn’t exist yet. [00:34:00] So as soon as we have that, then hemp Creek becomes really competitive. But until that time it’s only gonna be a cottage industry. Pardon the pun, because it’s going to be focused only on people that can deal with that in a small basis. Not at, not at scale.

[00:34:16] Yeah.

[00:34:16]Kellan Finney: And I’ll actually add one point to that. There’s a really cool company. I was a big fan of called JDF. Uh, just bio fiber. They’re based up in Canada, they’re making like Lego block mold, injection Lego block, like cinder blocks. Right. But they’re made from hemp heard and, and, uh, water and, and lime, I think, but they’re doing this plastic mold injection, right.

[00:34:35] From an automated factory perspective. And what they mentioned was one of the biggest obstacles that they were trying to overcome was they have this big VA that they mix it all up. And then the, a super cool, like modern mold injection goes down and injects it into the, the Lego block. Kind of situation, but unless the factory’s running 24 7, and then they stop it, all the machinery breaks because of that exact point you just made, which was wild.

[00:34:58] They were trying to get, get over it [00:35:00] economically. And like, um, trying to find solvents that didn’t bankrupt, the, the company trying to get, get that stuff out of the, the system. So that’s,

[00:35:06]Leslie Bocskor: that’s pretty cool. It’s spot on. And you know, again, there are so many things about this plant and so many things about this as a, a phenomenon that are just unbelievably disruptive, uh, construction, um, uh, you know, just look at the, one of the largest industries in the world of consumer products is nutraceuticals and supplements.

[00:35:28] It’s gotta be approaching 400 billion a year. At this point, when I was looking at it six years ago, it was 320 billion, 360 billion a year. And again, what’s the single most disruptive aspect to it, to he implant right now, pharmaceuticals the narrative around drug discovery. Now. It’s no longer just cannabis and hemp.

[00:35:46] Now it’s gotten into psychedelics and things like that, but the entire conversation narrative around drug discovery has changed again, as a result of the disruption from this. So everything in the, in the industrial sector, fiber, [00:36:00] plastic paper, consumer products are being influenced. There’s so much that’s happening and so much changing.

[00:36:06] Again, going back to what we said, agility and adaptability and flexibility are the key to being able to navigate this and also policy,

[00:36:15]Kellan Finney: because like with the hemp construction material, you can’t go get like a, as an everyday home buyer. You can’t go buy, get a loan a first time home loan. If it’s not a, a stick.

[00:36:26] And I can’t a stick in a stick and frame structure, meaning it’s built out of lumber. Like I can’t go get a loan from the bank to build a hemp house, which then goes right back to policy in terms of that’s where it’s all starts for these kind of innovative technologies to be have wide

[00:36:41]Leslie Bocskor: adoption. It’s a great point, gets me back to one of the things that’s most interesting about, you know, there’s some really interesting, um, counties in the United States with very low populations.

[00:36:51] It’d be great to see policy in those counties, uh, lead the way because at a county level you can actually make a difference and you could [00:37:00] create new zoning regulations in those counties that would allow things to be done that way that could then be adopted by larger counties. I think that we’re gonna see that happen at some point than not, not to distant future.

[00:37:11] It just makes, again, it makes as you remove every other choice and leave only this, because it makes economic sense that’s gonna start

[00:37:20]Bryan Fields: to happen. Does it also help the environment from a, an environmental protection standpoint?

[00:37:25]Leslie Bocskor: Absolutely. I mean, the, it it’s again, can you, could you make, could you be involved in the hemp industry and have it be toxic?

[00:37:35] Absolutely. I mean, just look at the packaging problem that the legal cannabis industry has. It’s really, it’s a problem. I mean, go order a delivery and a plastic bag that’s not made out of hand. Plastic has packages that are wrapped in plastic that have plastic packages inside. It it’s like three layers of plastic packaging for [00:38:00] something that doesn’t really need it and should really be in again, hemp, plastic, and hemp paper.

[00:38:06] And even if it’s not hemp, it should just be packaged more, more intelligently. But I, you know, so the answer is, uh, yes, it can be, it is. Potentially, and really much easier to do things that are environmentally feasible and positive in these industries. It’s it still requires the intention, the diligence and the follow through to do it the right way.

[00:38:34]Kellan Finney: Yeah. Cause in like a perfect world, you would take the, the plant, right. You would process it. Any leftovers would then be used to create the packaging in, you know, so the whole plant was used to package it and deliver it in the perfect world.

[00:38:46]Leslie Bocskor: Right. exactly. Let’s you know, let’s talk about, and again, there’s so much one of the amazing things about being alive right now is as a global culture, we are entrepreneurial.

[00:38:59] We’re [00:39:00] still figuring it out around the world. Let’s take a look at the like. Day, doesn’t go by here in Vegas. When the conversation of water doesn’t come up, lake meat is at historic low levels. That’s not just water for farming in California, which is a huge part of it in Arizona. It’s not just water for Vegas, although not much for the water for Vegas comes from lake meat.

[00:39:22] Some of it does. It’s also the water for the Hoover dam for the hydroelectric plan. If that water goes below a certain level where it’s not going to the intakes for the turbines, a very large number of people are gonna lose electricity. So the conversations about drought and water are rampant. There are major cities around the world that have been facing real water shortages like, oh, uh, Chenai, India, Mexico, Mexico city.

[00:39:53] Right. And so now, and yet go look at how our bathrooms work. [00:40:00] People are using for waste. Perfectly good clean water is being flushed down the toilet. Literally when, instead of using the waste water from sinks that gets recycled into the, into the, uh, to the other waste in the home. It’s just all just getting flushed down the drain.

[00:40:21] And so we need to be more efficient in how we utilize all of our resources. And this is a great way. One of the things I’ve said, and so many other people like Emily had said, this is not just a new industry. It’s an opportunity to conduct industry in a new way so that it sets examples that other industries can follow.

[00:40:46] And we still, I, I believe that and we’re still doing it. And I think it’s, you’re going to see more and more of that.

[00:40:52]Bryan Fields: Leslie, what is a lesser known fact about hemp that would shock or surprise? 90% of the people [00:41:00] in the cannabis industry?

[00:41:02]Leslie Bocskor: Okay. Uh, so I’ll, it’s not just hemp, but I’ll, I’ll talk about it. The, the only truly legal consumer product in the United States is hemp cigarettes.

[00:41:12] Why? Because what I said earlier about wimpy working past hemp extract, when you are under the farm bill of 2018, where it’s hemp, if it’s less than 0.3% THC, everybody that’s taking that hand plant processing it through all of the different methods that are out there to process it and concentrating it down to an extract that then gets turned into C B, D C BG, CBN, C B D V.

[00:41:38] And the list goes on in that extraction process. The percentage of THC by weight goes way above 0.3%. At that point, it’s federally illegal. You and every, and, and every derivative product you’ve made from it is technically illegal. Not only like, are there issues with shipping and prostate lines because of the gray area around [00:42:00] CBD and, and other cannabinoids.

[00:42:01] But there is, I mean, clearly it’s, it’s according to attorneys that represent the FDA and other government agencies, once that happens, it’s not, it it’s in a gray area, whereas hemp cigarettes, you’re just taking a hemp flower processing and put it into a hemp cigarette and then selling it. You never get above 0.3%.

[00:42:25] So technically speaking as a consumer product that is based upon that for, for use, it’s essentially the only legal product out there. Nobody really thinks about that. Let’s do a

[00:42:36]Bryan Fields: quick rapid fire. Yeah. True or false Las Vegas will eventually become the Disneyland of cannabis.

[00:42:44]Leslie Bocskor: It already is true.

[00:42:47]Bryan Fields: Outside us country, you think will be a major disruptor for the hemp or cannabis industry,

[00:42:53]Leslie Bocskor: Mexico

[00:42:55]Bryan Fields: single favorite aspect of burning man.

[00:42:57] And are you still

[00:42:58]Leslie Bocskor: involved? [00:43:00] Uh, single favorite? Uh, the community aspect aspect, the culture and community, and I absolutely am still involved

[00:43:07]Bryan Fields: psychedelics as a medicine. Yay or nay. Absolutely.

[00:43:11]Leslie Bocskor: Yay.

[00:43:14]Bryan Fields: Do you think the media influences culture yay or. Ha

[00:43:19]Leslie Bocskor: I am a big fan of yay. I’m a big fan of Marshall McCluen and, um, uh, Doug Robertson and others.

[00:43:25] I mean, our world is we live in media. Now. Media is the world we live in. Uh, McCluen said in the book, understanding media, the media is the message and that’s the world we live in today. It is the matrix. The matrix we need to get unplugged from is the world that surrounds us, which is the media that surrounds us.

[00:43:46] And it’s all individualized to every person. What each person gets is their own specific feed of information. That’s different from the person right next to them. We are surrounded by media and it’s com and we have no [00:44:00] idea. It’s every aspect of our lives is influenced by it. Yeah. Yay. In a big way, how do we unplug, ah, go to burning man.

[00:44:10] That’s a good answer. Blue,

[00:44:11]Bryan Fields: the red, right. 15 years from now, most homes will be built using hemp.

[00:44:18]Leslie Bocskor: No. NA sadly

[00:44:21]Bryan Fields: true or false. You met your wife through cannabis sales.

[00:44:25]Leslie Bocskor: It’s true. I met her because when she was I sold her pot when that’s, how we first met. When, when we were both kids, the statues or limitations are long past.

[00:44:35] That’s why I asked,

[00:44:36]Bryan Fields: I knew the statue limitations

[00:44:37]Leslie Bocskor: past. Good. And, and, and it was due diligence.

[00:44:40]Kellan Finney: Really. I was just doing recently due, due diligence. Always. I

[00:44:42]Bryan Fields: appreciate the due diligence, true or false. We will see a collaboration with Cypress hill in the future.

[00:44:49]Leslie Bocskor: Well, I have every intention and desire to do it.

[00:44:53] And if it serves, be real, if it serves Cyprus, I am there to do to work with them. He’s a dear friend and he’s a [00:45:00] great guy. And, and, and he is the O they are the OG man. Like they got banned from Saturday night, live in the nineties for lighting up a joint before anybody was ever realistically thinking about a legal market.

[00:45:13] They were there. And so if I can do something to continue to work with them on the, and what they’ve done, I would absolutely do it in a heartbeat. He knows that they know it, the team knows it, and I’m here to do it. And I hope that we have the chance. And I think we will.

[00:45:28]Bryan Fields: What draws you into early stage disruptive trends in technology?

[00:45:32]Leslie Bocskor: Great question. I’ve asked myself that for a while and I think the answer is it’s just the way I’m wired. I, for whatever reason, I was re I got involved in computers back in 1980, you know, which was pretty early. I was just a kid and I was just fascinated by them. I got super involved in the inter inter in the internet and new media in the mid to [00:46:00] late nineties.

[00:46:00] I was involved in online games in the nineties. I was, I got, I got attracted to burning man in 19 97, 98. I went for the first time I got super interested in, um, I was writing about virtual currencies and studying money banking and gold from 2004 on, I was studying virtual currencies before there was even such a thing as a crypto currency.

[00:46:26] So when I first encountered cryptocurrencies, I was floored. That was around 2010, 2011, and I’d been speaking and writing about it. So the answer is I’m just wired that way. I’m attracted to things that are new and that represent massive change in how we’re gonna live and do business on a global scale.

[00:46:44] Uh, it’s nothing that I ever tried to, to develop. I just, it’s just how I, you know, how I came out

[00:46:51]Bryan Fields: since you’ve been in the cannabis industry, what did you get? Right. And most importantly, what did you get wrong?

[00:46:56]Leslie Bocskor: Wow, great, great, great [00:47:00] question. And one that most people don’t ask, cuz you learn more from your mistakes than you do your successes.

[00:47:06] So let’s talk about what I got wrong. First. What I got wrong.

[00:47:21] Some of my, okay, I got wrong in self-regulation. I was sure that by this time the cannabis industry and the hemp industry would’ve followed the alcohol industry after the drop of prohibition. And they would’ve realized how important self-regulation was like alcohol did within a year of the drop of prohibition.

[00:47:44] The alcohol industry had been investing a ton of money into self-regulation cuz they realized if the industry doesn’t self regulate government is gonna come in and regulate and they’re not gonna be nearly as good at it as if they self regulate won’t be as good for business. Won’t be as good for the [00:48:00] consumers.

[00:48:00] Won’t be good for anybody. Well, the, I was sure I was speaking about this in 2000. 14. I started talking about, oh, self-regulation is imminent and it’s critical. And we still haven’t been able to see it happen. And I was way off. I was certain we would have have self-regulatory bodies that would be making it easier for, for government regulators.

[00:48:23] Would’ve made a bunch of things easier and it just hasn’t happened. And I don’t know why. And there’s all sorts of, um, there’s all sorts of consequences of this. Why do you

[00:48:31]Bryan Fields: think it hasn’t happened?

[00:48:35]Leslie Bocskor: I think it has to do with, and this is another thing I, I think it has to do with the flows of capital and the, that, you know, historically capital free market, where, where there was a, a ton of loose money out there. There was like, look historically low interest rates, a lot of capital out there for many years now, [00:49:00] the cannabis industry, legal cannabis industry, and even the he legal hemp industry.

[00:49:04] Even federally legal in a federally legal industry has had a challenge as it regards getting traditional lending and access to capital because of the stigmas and because of the artifacts of prohibition. And so that’s my friend, Rick ick, the former, uh, associate editor of high times. And he always said, the artifacts of prohibition are gonna follow us for years to come.

[00:49:25] And he was right. And so the answer is it’s those artifacts of prohibition following us that have limited capital capital’s limit has then affected so much decision making, particularly around having the free capital to invest in, in the, in a self-regulatory body. So you have to have enough money in your enterprise to donate a quarter million dollars a year for a period for the bigger businesses, 10, 20, $30,000 a year for smaller [00:50:00] businesses to these.

[00:50:02] Uh, uh, self-regulatory um, ideas and nobody really wanted to write the check. And it’s not that the entrepreneurs are greedy it’s that they don’t have access to capital the way other industries do. And it affects so much of your decision making and that’s one of the things. And so I definitely got that wrong.

[00:50:21] Um, and then some of the things that I got right. Well, I, what I also got wrong. I expected that by this year we would see the descheduling of cannabis. Now I’ll claim force mature for that. I never anticipated, you know, governmental, uh, gridlock on the scale that we’ve seen, um, in the last, you know, six years.

[00:50:43] And I also didn’t anticipate a global pandemic, which greatly influenced the policy. If you could have forecasted

[00:50:50]Bryan Fields: that, my God, you could have really ,

[00:50:52]Leslie Bocskor: could’ve really changed some lives. I know would’ve been, it would’ve saved some lives and it would’ve just been made the world easier to navigate the [00:51:00] last few years it’s been challenging.

[00:51:01] So I got that wrong. What did I, you know, some of the things that I got, right, I got right. The need for self-regulation. I got right. I got right. The, um, a couple of the trends in the industry that were going to start to see the importance of brands that were going to start to see. I, I had been saying for years that, um, We need to get to micro dosing rather than macro dosing.

[00:51:25] I was saying, you know, there’s 75 milligram edibles. Yeah. There are some people out there that are gonna use those, but it’s gonna be the three milligram edibles and the five milligram edibles that are gonna be the ones that really end up being where the market is. And I’ve been predicting back, going back to 2014, I’ve predicted a couple of other things that we still haven’t seen happen, but we will see happen.

[00:51:44] So I, I think I’ll be right on blends. We’re gonna start to see in the legal cans industry, we’re gonna start to see blends hemp cigarettes. That’s something I’ve also been saying is gonna become something for a while and we’re starting to see happen now. And I think is gonna become massive for so many [00:52:00] reasons, uh, harm reduction, um, a, a natural place for people to use as an exit from the use of tobacco, uh, to eliminate addiction, to nicotine, and as a way to get some of the terpenes and cannabinoids into your body.

[00:52:12] Um, the, some of the things that I got right were, um, How policy was going to manifest on a state to state basis. And that each state was essentially creating a ring fence where it was going to be its own market. And that, that was going to favor small operators and that large operators were going to have challenges around that, which they still do.

[00:52:31] So you start to, you can still see small regional operators get very big, even while the MSOs are out there. They’re not able to really come in and shut down. The small operators, small operators can compete effectively against an MSO because they have a better understanding of how to navigate their own local, uh, regulatory framework and influence it.

[00:52:52] And so the MSOs trying to manage the regulatory framework of California and Nevada and Oregon and Washington and [00:53:00] Illinois and New Jersey and New York. I mean, that’s a, that is a catastrophic burden to try to, to, to manage at this point. And we haven’t gotten to the point where they can achieve the economies and scale.

[00:53:10] So it still is, is, uh, um, really favoring the smaller state based operator. And there’s, I mean, there’s probably a couple of other things I’ve gotten wrong and right. But those are some of the ones that I like. I appreciate

[00:53:23]Bryan Fields: you sharing that. What is one tiny nugget about you, Leslie? That the Leslie hive wouldn’t know.

[00:53:32]Leslie Bocskor: Um,

[00:53:37] great question again. Uh, probably

[00:53:44] that I played dig do I played, Thery do as a musical instrument. I started playing decades ago and I still do to this day. Amazing. I have one, I have one here in the office. There’s one over in the corner. I have one there.

[00:53:59]Bryan Fields: It’s not the, [00:54:00] since you’ve been in the Candi industry, what has been the biggest misconception about what, since you’ve been in the industry, what has been a misconception where you thought one thing and it was completely different.

[00:54:15]Leslie Bocskor: Hmm.

[00:54:19] Oh, it was my, not my learning about policy. Uh, I thought that politicians speak English and they don’t, it is English actually. I’m sorry. I thought they spoke the same language as me. Yeah, it’s English. But what the words mean from a policy perspective, the way that they make their decisions? I, I completely misunderstood it.

[00:54:42] And again, my, my Joe SME mentor and friend, it was his and, and a number of other people, Congressman BAU and others that I’ve had the, the, you know, good fortune to work with the treasurer of Nevada, Zach Kona, and the governor of Nevada, and so many other people along the way, [00:55:00] uh, that have gotten me to understand that the political environment in the United States makes the navigation of policy.

[00:55:09] Uh, So completely different from the navigation of business decisions that you would not be able to think that the same language describes both. And yet it does. So people who speak about policy will use English words, but they don’t have the same meanings in the context when they talk about them, that, that it does for business and things.

[00:55:30] A normal question,

[00:55:32]Bryan Fields: before we do predictions, we ask all of our guests, if you could sum up your experience in a main takeaway or lesson, learn to pass onto the next generation, what would it be

[00:55:45]Leslie Bocskor: slow is smooth. Smooth is fast, slow down, take your time and be diligent. And the major lesson that I’ve learned is the importance of taking your time to [00:56:00] know who you’re working with. And when they tell you who they are, believe them and, and be, and don’t and, and be completely comfortable saying. We can, we’ll be friends it’s best for us to, to look into, uh, working, working separately

[00:56:17]Bryan Fields: well said, all right, prediction time, Leslie it’s 2032, what sector or part of the world does hem impact the most

[00:56:29]Leslie Bocskor: 2032 plastics plastics.

[00:56:31] That’s gonna be like, so we’re talking about nine years from now. Yeah, it’s gonna begin. It’s gonna, so I, I say it’s gonna be paper first paper fiber, then plastics is sort of in that order or fiber paper, and then plastics, plastics will take the longest, but we’ll have the biggest impact.

[00:56:50]Kellan Finney: I think the chemical feed stock industry, right?

[00:56:53] The commodity chemical feed stock industry that, I mean, terpenes, there’s a ton of potential for terpenes to be used in [00:57:00] novel plastics. Right? I mean the amount of chemicals that come off of the. In cannabis extracts, right? There’s over 400 different chemical components in an extract. And we’re typically only selling one or two.

[00:57:12] Right? I think that the, the opportunity for the commodity chemical industry is

[00:57:18]Leslie Bocskor: massive, great call the ingredients industry. Yeah. The ingredient, massive industry for food. And for so many things, I, I think that that’s a great comment.

[00:57:29]Bryan Fields: Ellen’s done some pretty cool research. There. It is a eye opening when you see some of the numbers mm-hmm um, for me, I, I wanted plastic and, and paper also is good, but you took those off the board.

[00:57:39] So I’m gonna have to go with the housing market cuz uh, I still feel like they can make a big disruption if we can start building some houses and, and kind of get away from cutting down the trees. I think we can make a big difference. And I think the climate aspect and everyone’s screaming, climate can like, we need to help the climate.

[00:57:55] Well, what are we really doing? So if we can start by doing step ones, which seems like a, [00:58:00] an easy way to get started, you know, that would be the route that I would hope that, that we would.

[00:58:05]Leslie Bocskor: I love. I love that. And I’m still thinking about Kell’s comment about the ingredients industry. You’re the, that’s the first time I’ve heard anybody.

[00:58:12] I mean, I’ve been looking at the ingredients industry. There’s a huge ingredients company. They say that they influence a billion lives every day. Um, it’s a company out of, I think Kansas or maybe Iowa. I’m sorry, what McCormicks maybe? Uh, no, it’s a, it’s a family name and I don’t remember it’s a private business.

[00:58:30] And, uh, I remember talking to them and they were interested in, in the hem plant and the cannabis plant to start adding it to their ingredients business. And, um, That really got me thinking, because it’s such a sleeper that people would normally just go by and it’s such a huge part of how commerce exists in the world today.

[00:58:54] PE there are businesses that do nothing but make different ingredients for industry. Yeah. And that is a, [00:59:00] that’s a massive

[00:59:00]Kellan Finney: one. Yeah. That’s a, I mean like the cosmetics industry, right. That’s just, it’s insane. How big, like those,

[00:59:06]Leslie Bocskor: those feature are, who, who knew the fracking industry uses hemp, hemp, uh, uh, uh, hemp based, uh, components as an ingredient.

[00:59:14] Yep.

[00:59:16]Bryan Fields: So Leslie, for our listeners, they wanna get touched. They wanna learn more. Where can they find you?

[00:59:22]Leslie Bocskor: Uh, they can go to, um, my Twitter account, Leslie box score on Twitter. They can find, um, there is a, uh, page on. Facebook Leslie box score. They can find me Leslie box score on LinkedIn. They can go to the electron partners website and they can go obviously to the indoor harvest website, indoor harvest.com, electric partners.com.

[00:59:45] So really those places, electron partners.com, indoor harvest.com, Twitter, LinkedIn, and Facebook are the places to find me. I’m pretty easy to find.

[00:59:54]Bryan Fields: We’ll link those all up on the show notes. Thanks so much for taking the time.

[00:59:57]Leslie Bocskor: It’s this has been a great conversation. [01:00:00] I hope I have a reason to come back.

[01:00:01] Yeah, we’ll have to have you back. Sure. I really enjoyed it. This has been fantastic.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Editors’ Note: This is the transcript version of the podcast. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below if you need any clarification. We hope you enjoy!

This week we are joined by Chris Piazza Co-Founder of Cannadevices  to discuss : 

  • How to identify quality glass
  • How they are helping artists
  • Dispelling the myth of the double blown glass
  • and so much more 

About Canna Devices 

CannaDevices was founded by Robert Bank and Chris Piazza to service the fast growing cannabis industry in the United States.  Both local glassblowers of the Chicago suburbs they have had a working partnership for over two decades supporting the local industry of glass blowing and their communities.Experience of over thirty years in glass blowing, retail and the cannabis industry allows us to understand and meet your needs with precision. Moving into today, CannaDevices has become the premier Glass Service Provider in Illinois Dispensaries and growing throughout the country.

At Eighth Revolution (8th Rev) we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain 

The Dime is a top 50 Cannabis Podcast 

 Contact us directly at [email protected] Bryan Fields: @bryanfields24 Kellan Finney: @Kellan_Finney 


[00:00:00]Bryan Fields: What’s up guys. Welcome back to the episode of the dime I’m Brian Fields. And with me as always is Kellen Finney. And this week we’ve got a very special guest, Chris Piazza co-founder of Canada devices. Chris, thanks for taking the time. How are you doing today?

[00:00:14]Chris Piazza: Oh, not too bad, Brian. Thanks for having me

[00:00:16]Bryan Fields: excited to dive in Kaelin.

[00:00:17]Kellan Finney: How are you? I’m doing really well, you know, looking forward to holding down the west coast and especially looking forward to chatting about the ancillary equipment needed to consume cannabis. You know,

[00:00:27]Bryan Fields: I’m doing well and justice for the record state. Chris is an east coaster. So the record is state-funded on that.

[00:00:34] So Chris, for our listeners that aren’t familiar about, you, can you share a little background about you and how you got into the Canada?

[00:00:40]Chris Piazza: No problem. No problem. So, uh, you know, I started out in, uh, 2008 as a glass floor. I, um, actually learned the trade myself and, uh, you know, did a little bit of traveling around.

[00:00:52] Living in my car. Uh, I’ve just lived in that free life, you know, uh, as a, as a starving artist, pretty much. And, um, moved [00:01:00] back to the east coast, I guess, in Chicago, um, you know, Midwest, east coast, whatever. I just gotta throw it out there. So, uh, moved back to Chicago where my family was and, um, got situated a little bit more, uh, you know, sort of planted some roots.

[00:01:16] Started blowing glass. Uh, with my business partner, he had a, a chain of, um, head shops in the area. We had like a little school going, I got into the scientific glass world. So I did some work with like the DOD and things like that went back off on my own. Um, and then my, uh, My partner, uh, Bob bank, he came to me with an idea, um, to start to build a distribution company for dispensary’s.

[00:01:43] Um, I’d been working in the head shop, smoke shop space for most of my career. And then, uh, we saw this opportunity that there was so much import, uh, Not super high quality glass and dispensary’s, and I have, uh, a [00:02:00] pretty strong network of glassblowers. So we built this company, Canada vices, and the, it started out with a mission to, for one, provide quality products to dispensary’s, but also take care of artists and have they have true full-time opportunity and work.

[00:02:19] Because up until this point, there hadn’t been anybody. And able to provide solid, consistent work as a distributor, it’s sort of intermixed, some distributors did better than others, but, uh, for the most part, as an artist, I never was able to find a distributor that could keep me, keep me working. Um, and so that was our, our main thing artists before.

[00:02:40] Um, now we’re getting into some other products as well, but yeah, so I’ve been in the cannabis space since 2008, um, in other industries that I guess isn’t that long, but in this industry, it’s crazy how many people are like, oh three months. It’s like, wow, cool. Like, I’m glad you’re here. And I know it’s more than three months cause you probably were partaking before you got into it.

[00:02:58] But, um, you know, [00:03:00] uh, yeah, that’s sort of my journey. I’m

[00:03:03]Bryan Fields: fascinated by how you got into glass blowing. Was it something that you did as a child, the ranger interested, certain artists. Qualities and the kind of led you on the path, like take us how one finds that

[00:03:12]Chris Piazza: journey. Well, so, uh, like I just said, a lot of people partake before they get into the industry.

[00:03:19] So I was like 14 and this kid came back from a fish show and, uh, it was, uh, I don’t know, trench coats means something different today than they used to, uh, this get out of trenchcoat though. And he had a whole bunch of pipes and he just started showing all these things off and I was. What is this? So I bought a pipe and, you know, we ditched first period and we went, um, out in the woods and we were just smoking.

[00:03:44] And, uh, I remember it, you know, I obviously, you know, got it. First. I, I passed around and it came back to me and like the light hit it. And I’m just looking at this, I’m getting tingles, just thinking about it. I was like, you know, there’s like four of us sitting around. I saw this piece, it lit up in the sun.[00:04:00]

[00:04:00] I looked around and said, I’m going to fucking make these, excuse me. I don’t know if that’s all right. That’s cool. But I want to make these, this is what I want to do. Everybody’s are all yeah, yeah, yeah, yeah, whatever. Um, then, you know, yeah, it was like a 22 or so. 21 out in Colorado. And before Facebook there were forums and I found a glass forum.

[00:04:24] I put up a post, I said, Hey, I’m, I’m finishing up doing seasonal work at copper mountain, looking for an apprenticeship and, uh, got down. And within 24 hours, I found an apprenticeship and Rowan glass. I always like to throw out some love to him. It’s at R O N E glass, uh, on Instagram. He’s amazing artists.

[00:04:44] He took me under his wing and, um, Yeah, that’s how I got started,

[00:04:48]Kellan Finney: but I mean, with glassblowing, there’s a ton of different items that you can make. Right. Um, but you kind of ended up settling on, on smoking devices. So was it [00:05:00] just kind of that pairing the passion of cannabis and the glass blowing together?

[00:05:04] And it just created that that opportunity is that kind of the, the whole story associated with Y uh, spoken devices where your, your specialty

[00:05:12] okay.

[00:05:13]Chris Piazza: Pretty much, you know, I I’d, I’d been involved, um, in the cannabis industry and different ways, um, you know, sourcing, supplying type of situations. And then, uh, so it was just sort of like a, like a nice transition from there, you know?

[00:05:30] Um, it, it, it was where I, yeah, the industry has always been. I kind of felt my place was what’s the

[00:05:38]Kellan Finney: biggest difference from a glass for like perspective in terms of glowing blowing glass for like spoken devices. Versus you mentioned earlier, you kind of dabbled in the scientific glassblowing sector as well.

[00:05:48] So what are the, some of the differences associated with those two methods?

[00:05:53]Chris Piazza: So actually there’s not as much as you would think. So in, from pipes to, uh, [00:06:00] scientific, those are generally speaking of a bore of silicate blend of some sort, which is a hard glass. Um, the glass. Most pipes came from the scientific glass, uh, raw material.

[00:06:15] Now, when you’re talking about vases and all sorts of other things, like things you’ll, I’m in Vegas right now at the G4 conference. And I’m seeing like the truly exhibits and stuff like that, that’s all what’s called soft glass. And so that’s a totally different animal. That’s like, uh, how I describe it as like oil painting versus like painting with a pencil or, you know, drawing with a pencil.

[00:06:34] Um, but as far as scientific glass, it’s actually very.

[00:06:40]Bryan Fields: I want to stay on like the learning curve associated with that. Right? So your first day of blowing glass, is that something where like it’s a week learning curve, it takes a month or something like you’ve got skills just based on your artistic and you can kind of hit the ground running day one, take us through what the.

[00:06:55]Chris Piazza: Um, so I really went through like the Miyagi school of glass [00:07:00] and that’s how I’ve always taught to like, um, definitely there’s, there’s a level, like I can see someone on their first day if they are going to have an easier time or a harder time to learn it. Right. I think anybody can do anything, you know, and you might not be able to shoot a basketball, like, like Kobe Bryant, Coby, or something like that.

[00:07:21] But like at least. you could Don’t play a pick-up game. Right. So like, I don’t think that, um, there’s like a, you can or can’t, but there’s definitely some level that you can see naturally, um, from the beginning. But yeah, I went through the Miyagi school, man. I, I, I had to put like two rods together. And just put them together.

[00:07:42] And then I had to make marbles and I had to make a jar of marbles and my teacher would pull them out. And if they didn’t roll nice, then they’d throw those out. He’d say, Hey, your jar is not filled because these aren’t marbles, they don’t roll. And then, you know, it was that type of thing. And so back when I started, there was no YouTube.

[00:07:58] You know, training and all this [00:08:00] other stuff. I mean, these kids, these days, it’s crazy. They’re making rigs after six months and that school, some of them are actually nice, but most of them have no fundamental understanding of how glass works and, you know, um, it, it, I don’t know now I just sound like an old, old guy, but, uh, this.

[00:08:20]Bryan Fields: I mean, most people haven’t had their marbles rolled out and said, do it again. Right. Or tune of watching YouTube over and over again. So I’m sure the learning curve, while it probably is steep, but it’s probably super helpful to have, you know, like an established teacher, like you’re saying. So is it, is it easy when you’re looking at glass now to tell the differences between one, let’s say that’s high end versus low end, is it like a noticeable for your eye?

[00:08:41] And can you kind of share some of those, those, those tricks that you had noticed.

[00:08:46]Chris Piazza: Uh, it’s uh, I can, I can try. Um, I can definitely see, you know, I, I can see an important piece from a mile away. Um, they always look basically the same. They, they just, they just look off like, there’s [00:09:00] something just off about it.

[00:09:03] Um, colors are melted in a lack of much color, things like that. Um, as far as a quality piece, like a nice. If you’re looking at like the weld. So the attachment of the mouthpiece and the can, if there’s like extra thickness or if you look at it in the light and there’s any sort of weirdness there, it’s a bad description.

[00:09:27] But if you just, if you pick up a bunch, you’ll see like certain ones have like. Look, it’s glass show should be melted and blended together perfectly. And a quality, a quality weld. There’s no thicknesses. There’s no anything else it’s just clear and you can look right through it. So stuff like that is what I look for.

[00:09:47] And so

[00:09:47]Kellan Finney: you guys, you have a ton of different artists, artists that you work with. Um, you mentioned that, is there a certain vetting process that you have to kind of, that they go through so that they can actually be part of your network? And, and can you walk us through it that, that he processed. [00:10:00]

[00:10:00]Chris Piazza: Oh, no, that’s a great question.

[00:10:01] Um, yeah, so currently we have 65 artists that work for us. Full-time, um, they’re all over the country and, um, we’re shooting to be at a hundred by the end of the year and 300 by 2025. Um, these are full-timers. They literally, we asked them how much do you want. And they tell us a number and we just buy it from them.

[00:10:22] Um, so it’s a pretty cool little setup. They get to pick their own, uh, their own income and everything, as far as the vetting process goes, you know, we, so we have, we have everybody send us samples and then we look at the samples and we compare them to what we have. And if they’re good, Um, I, if they’re not in, they need a little bit of work, then I can step in and help make suggestions and things like that.

[00:10:46] We’re actually building out a full, um, the, the, the bigger we get, the more busy I am, and I’m not at the warehouse or at the studio very often anymore. But what we’re trying to [00:11:00] do is to build out an actual education sort of platform for guys, that guys and gals that, uh, ended up joining the. And so then they’re going to be able to have a whole education platform that, uh, I can present to them, uh, as they get on.

[00:11:15] But yeah, we, we make sure that everything’s to the spec that we need it to be. We have them send in samples. We always pay for the samples. I used to hate it as an artist. Oh, send me some samples, blah, blah, blah. It’s like, dude, I can’t eat. Like I can’t send you a hundred dollars worth of. Like, you know, um, I just can’t do that.

[00:11:33] So we make sure to pay our artists, even for the samples. Um, and we get them onboarded from there. Do they

[00:11:39]Bryan Fields: have creative freedom, freedom to do the designs that they think are best or they get input from you? Because I would assume someone like you who’s established has probably a keen eye for what’s probably going to sell and what’s going to work.

[00:11:49] So how does that process work?

[00:11:51]Chris Piazza: Well, I, I appreciate that little spin you put on that. You know, uh, visit. So essentially this is my product line that I’ve had [00:12:00] for whatever 10 years or so. Um, so what we say is we need that. We need our artists to make our products, um, and then that awards them time to be creative on.

[00:12:16] Right. So when we ask them, how much do you want, how much do you want to make? If they’re like, oh, you know, I’d like to make some creative stuff too. It’s like, okay. So just tell us what you can make in four days. And then you got three days to do whatever you want. Um, and if you are having, if you’re hard up and you need a seven days worth of work for the next few, few weeks or whatever, that’s fine too.

[00:12:37] Um, so yeah, our, our product line is, is, uh, is pretty much everything between my partner. It’s our catalog products. Um, and they need to stay within that range. Did they ever

[00:12:49]Bryan Fields: submit like designs and say, Hey Chris, I think this is really awesome. I think this will sell. And then you have to take a look. Is that part of the creative process at all?

[00:12:57]Chris Piazza: So as of right now, it’s not, uh, the [00:13:00] reason for it is, uh, you know, over here on the east coast. I’m just kidding, but we’re, we’re. We’re really targeted and all these dispensaries, which are a lot larger. Um, we don’t really work with many mom and pop dispensary’s at this point. Most of them are, you know, 3, 5, 10, a hundred locations or, you know, in that range.

[00:13:21] So what’s hard for us is if John Smith has this awesome piece, how many can he actually make? And when I get an order, if it hits. 10 or 20, you know what I mean? Um, so that’s why we have to be real strict as far as how we’re, uh, what, why we’re not, while we’re not able to be super open to these other products, it’s sort of where we’ve, we’ve needed to as a business.

[00:13:50] Expand our product offering. And so that’s where we’ve started to add non glass products, to be able to have something new, um, you know, [00:14:00] grinders, we can source in a very large volume, which is no problem to serve a hundred locations. Right. Um, bringing on a new style of glass from a unique glass boards, uh, a very tricky thing.

[00:14:11] We are in 2023, going to be launching. Like a heady line, essentially, we’re going to call it something different because corporate doesn’t understand, honey. Um, but it’s going to be something where it’s like $500 and up, and then in that case, we will have very limited supply when they’re gone. They’re gone that type of thing.

[00:14:32] Um, but not in the production side.

[00:14:35]Kellan Finney: Do you, I want to stay on the artist aspect. Do you guys have certain artists that like a, these 10 are really, really good at making this specific type of rig and that’s what they focus on and these 10 make this type of rig. And what is that process in terms of like categorizing the artists into those specific categories?

[00:14:51]Chris Piazza: Oh, dude, that was a very intuitive, uh, question right there. Yeah. We like our, like our Fritz spoon, for instance, for our Fred hand pipe, we have [00:15:00] 20. People about 18 to 20 people that make it, um, really it’s sort of a two part thing. One is, Hey, is the quality there? And then we turn it back to the artists and we say, okay, so you can do these byproducts.

[00:15:15] Which ones do you make the most amount of money doing? And if they say it’s going to be product one, two, and three, then they’re going to be put into the first tier of that product. So we really want to make it so the artist gets to decide. As long as their quality is there, then it’s whatever you want to make.

[00:15:31] And so sometimes they’re like, you know what? I’m getting burnt out on that. Can I make this one, even though they don’t make much money on it, they’ll still want to change it up. Totally cool. Um, but mainly it’s, it’s about the artists and certain tour, like certain people that have certain porches, which they’re faster at making certain things, things like that.

[00:15:51] And so, um, we really wanna make sure. Tailored to them.

[00:15:55]Bryan Fields: How did you get in front of the big Ms. Sows? And then what’s that pitch like with the glass [00:16:00] in order to kind of have them stock?

[00:16:03]Chris Piazza: Oh, man. It is, uh, the game is definitely who, you know, um, it’s, it’s a, it’s a good old boys network for sure. Um, so my partner, he was a director of wholesale for one of the large RSOs.

[00:16:19] And so he was. Basically, uh, illegal, uh, legal weed dealer, um, wholesaling to other other dispensary’s. And it just was a pretty natural fit. And his boss at the time was cool with him selling glass on the side. So he was just totally connected to all the right people. And it was just a here’s your weed?

[00:16:42] Would you like glass and. Got us plugged in. We really, we get introduced to purchasers from like the executive level down, rather than having to go into a store and try to talk a bud tender, to talk to a manager, to talk to whatever. Um, so we’ve been very fortunate [00:17:00] in that. And then sort of once we got in, uh, Because it’s such a small network work.

[00:17:06] Everybody knew, you know, those big companies. I mean, in Chicago, we have, I believe it’s four MSOE that all have offices on one block in the city. And so all of them go to lunch together. They’re all friends like, yeah, it’s competition, but like their employees they’re their friends. They don’t care that we always, um, so it, it was a pretty unique there as far as the pitch goes, it’s like, If you want, if you have quality cannabis on your body glass, simple as that.

[00:17:37]Bryan Fields: Wow. When you’re stocking those products, right. Is the dispensary or the bud tender kind of influencing the purchasing manager? Like how does the relationship between all the different dynamics? Right? Because if the bud tender is speaking to the customers, but the purchasing managers kind of like one step removed, it’s kind of interesting dynamic of like each person likes something slightly different.

[00:17:56] So how does the conversation go from selecting the inventory? [00:18:00]

[00:18:01]Chris Piazza: You know, we definitely look a lot more at price point than style. Um, just, you know, the, the corporate side, you know, this is the, you know, the big guy taboo thing to talk about in when it comes to cannabis is the corporate cannabis. But a lot of times we’re looking at price points and then from price point, we can then, okay, Hey, the $15 price points doing strong, let’s try another skew in the $15 price point.

[00:18:28] That sort of thing. Um, budtenders are. Yeah, like you said, they’re the gateway I’m here at the G4 conferences, the budtender awards. Um, you know, I want to be here supporting them and, uh, they’re, they’re, they’re the most important piece of the whole puzzle. Right. And, uh, purchasing managers, they are removed, but they do a lot of communication with their budtenders and, uh, yeah, it’s, uh, there’s just a lot of community.

[00:18:56]Kellan Finney: Is it a one size fits all kind of situation where [00:19:00] the St. Juan MSO has Spencer’s across the country. And they’re just like, all right, every dispensary has this same, same skew, or is it almost like customized based on like geographical region at all?

[00:19:11]Chris Piazza: I, it depends on the company. Some companies, um, we have one company that, uh, They’re going after like the McDonald’s model where, how, how long will it help?

[00:19:22] Can we shave 10 seconds off of a customer to get them through, to, um, you know, through the line or whatever, through the drive-through they’re doing stuff that’s similar to that. So they had 15 skews then they’ve said, no, let’s go down to eight, but double the volume. And so, and then. There their customers or patients aren’t looking around at different pipes.

[00:19:45] Right. Smart. So you have that, right? Exactly. Um, there’s that going on? It’s honestly, all of the above is the answer. Some places like to have the same thing everywhere. Some places like at, based off of how the layout in the dispensary [00:20:00] is. Um, and then some of the state regulations, Florida, um, if you have.

[00:20:06] Two pipes. One is blue and one is clear. They both need to be approved separately. The, the department of health, they’re the same damn thing. They’re both glass, they’re both the same shape. There’s nothing different except for the color, but they need to be separately approved. So Florida dispensary’s, don’t want to be messing around with a whole bunch of different approval stuff.

[00:20:30] Right. So, um, very, very different on, on the legal side, for sure.

[00:20:36]Bryan Fields: Is that on your team to know the differences in all those rules and rags, or is it. Spencer to help that, because I can imagine with all the different states, you have all different challenges, which makes you know, your role a little harder in that.

[00:20:49]Chris Piazza: Yes, both. Perfect. It’s all across the board. Um, yeah, we’re we [00:21:00] need to do our own internal so that we can, um, choose to where we, where we market and where we put our attention. Um, we are very fortunate to be with these large RSOs where, when Florida, uh, about six months ago, they, uh, it was actually September of last year.

[00:21:16] That’s when they opened. Allowing glass to be sold in dispensary’s and our partners told us on Friday, the news came out on Saturday. Right. So a lot of it is relying on, on the big episodes. I mean, they have legal teams that are yeah, probably same amount of as. Mike, my company,

[00:21:38]Bryan Fields: the football team, football teams, long of

[00:21:40]Chris Piazza: players.

[00:21:44] building

[00:21:45]Bryan Fields: what’s the lead time from, let’s say inception idea to finish product for some of those products.

[00:21:51]Chris Piazza: We do our best to warehouse, uh, ahead of time. So we’re trying to forecast, um, forecast manufacturing to [00:22:00] have as close as just-in-time inventory for our customers as we can. Um, it’s definitely. I think there’s certain products that, uh, are in such high demand and very tricky to make.

[00:22:12] So that creates bottlenecks for us. But, um, we’re at about a three to five day ship period for general orders. We also, um, actually have one over there. We also do like custom branded class, so private label, and we can make like hitters, spoons, uh, nectar straws, theme, rollers, chillums all with like the company’s logo on them.

[00:22:38] Initial order of those take about six weeks. And then afterwards it’s about a two week lead time. Cause we bring in all the decals in house, but, uh, that’s, that’s been a big one for us there. Um, for actually. These hitters that have a ceramic decal that’s baked into the glass. So it’s not like a vinyl sticker or anything like that.

[00:22:57] And they’re durable. They’re. [00:23:00] Because even with a lighter, the ceramic doesn’t melt, I mean, a lighter is not that hot. So, uh, it’s a, it’s a great promotional item, but yeah, the lead time starts out a little bit longer, so it depends on what product. Um, yeah,

[00:23:15]Kellan Finney: so it does kind of, uh, those kind of products and say you have artists across all country and they have dispensaries across all countries.

[00:23:22] You already saw, I’ll make it ship it to a central location. And then you guys distributed. Is that kind of the business model associated with it?

[00:23:28]Chris Piazza: Yeah. Yeah. All it comes to Chicago and it goes back out from there. You know, we, you should be you, you, uh, we can have our artists ship direct. Um, it,

[00:23:40]Kellan Finney: I can only imagine

[00:23:44] good stories and

[00:23:45]Bryan Fields: you’re like, Charlie, what is this Charlie?

[00:23:50]Chris Piazza: We had Christmas paper in July in the box, in the bottom of the box, like where did this come from?

[00:23:58]Bryan Fields: I respected, right. He’s a big fan of the [00:24:00] season. Just didn’t want it to end.

[00:24:04]Chris Piazza: Love it.

[00:24:05]Bryan Fields: So, Chris, I heard you on another podcast and you shared a tidbit about what you look for in a bowl between the carb hole and the actual size of the bowl to kind of tell the difference if it’s made well, can you kinda expand on that? And maybe some backstory. Cool.

[00:24:19]Chris Piazza: Yeah, no problem. Um, this goes back to the, the Miyagi school of glass that I went through.

[00:24:24] Um, you know, a pipe is a pipe is a pipe, but you can have one that’s nicer than another. Right. And so, um, really what I, what I was referencing there is his bowl hole. So the part that’s in here to the carb on the side, the bowl hole needs to be smaller than the card. If you’ve ever used a pipe that never seemed to Clear It just, it always was Chalked like, and it just, it just won’t, it would never, it would never clear it’s because your bowl hole was bigger than your carb hole. And if, if you think about the logic, it just makes [00:25:00] sense. That means that the point of least resistance is coming through the bowl. So more air is traveling through there where there’s a burn plant.

[00:25:07] That’s, that’s continuing to, you know, um, continuing to burn. You need that carb hole to be bigger than. Brings in the fresh air and then clears it up.

[00:25:17]Bryan Fields: I’m glad you shared that because I didn’t know that. I’m curious to know if Kellan knows that and then I take it one step further. Like when you go to these smoke shops, I wonder how many of these bowls have it incorrectly?

[00:25:27] Do you have any sort of guests.

[00:25:30]Kellan Finney: A lot, cause I just went spin shopping, and I didn’t know that exact like ratio thing, but I’ve always been a person who doesn’t like a large bowl, just cause like you get Scooby snacks and stuff. Right. But it’s, it’s wild because that is, there is a ton of glass out there when I was just looking at it like a head shop last week, actually.

[00:25:48] And literally there’s a ton of glass out there with just massive bowls. I was looking at it and I was like, No, that’s too big of a hole in there. You know what I mean? Like I’m literally going to have to have like a plug or something in there to stop her up the hole so I can actually [00:26:00] load a bowl. I

[00:26:01]Bryan Fields: can only imagine how many people are going to hear this and immediately go grab their bowl and start looking me.

[00:26:06] This is why it doesn’t work. Right? Like uncle David, you finally figured out what the problem was. The sizing is completely off. So what is one fact or concept about glass blowing that would shock a cannabis.

[00:26:22]Chris Piazza: Well, I’m going to pause for pause for intenseness. You ready? There’s no such thing as double blown.

[00:26:30] You guys ever heard that phrase before? Yes, no such thing. No, such thing. Is it just good mark? It was okay. Brian’s a little uncomfortable. I just

[00:26:41]Bryan Fields: think like I’m thinking now, like, was I sold the hat? What was I sold?

[00:26:48]Chris Piazza: So there was a, as the story goes, it was some head shop out in California that just started saying this I’ve double blown, triple blown card, do a full blown blah, blah, blah, all this stuff.

[00:26:58] So. [00:27:00] What, how, when you start with a pipe, you start with broad material, the thickness of the raw material gauges, how thick the pipes going to be later on now you can take a thin wall then a long piece and condense it down so that it becomes thick. Or you can start with a really thick. And shape a pipe from it.

[00:27:26] The closest thing to double blown is if you see pipes that are there, they’re full colored. There’s a bunch of lines in them. How that’s done is there’s a clear tube on the inside and then color rods, glass rods that are color on the outside, and then an outside layer of clear and that’s all melted together, but it’s still.

[00:27:50] Wall of glass. So yeah, that phrase is just not true. There is no such thing. And then I asked, what is double block? Like, what is double [00:28:00] block? What would it even mean? Like I blow it out once and then I blow it out again. Like it does. So when you think about it, it doesn’t make sense to, but yeah, so that’s the, hopefully nobody’s that uncomfortable.

[00:28:13] It’s a

[00:28:13]Bryan Fields: good, it’s a good marketing phrase, right? There’s probably a few people are removing items from their shelves.

[00:28:19]Chris Piazza: It’s not going to work

[00:28:20]Bryan Fields: anymore. What is, what is scientific glass?

[00:28:25]Chris Piazza: So I was doing, uh, x-ray tubes for, um, for GE and then I did some work for the DOD. Um, essentially it is. The, I was making the tubes that go, when you go to the dentist and you get like the, uh, the x-rays on your teeth, there’s a ball that does that.

[00:28:47] And I had to make those because they’re made on a lathe of bite human, who I by a person. And so, um, I could get super technical, but basically, uh, extremely [00:29:00] fine, detailed spacing, all this stuff. Angles need to be perfectly right. That was the stuff that I was doing in the scientific world. Yeah. Um, I was

[00:29:11]Bryan Fields: unfamiliar with that.

[00:29:12] Kevin, were you aware of those?

[00:29:13]Kellan Finney: Yeah. Besides that side to the class. It’s like, well, a lot of glass wearing came from like the science world and like most chemists when they were trained to be a chemist 50 years ago, they were trained blow glass. And so like being a chemist or a scientist, you would learn to blow glass because in order to do all these crazy scientific experiments, the number one media, it’s all done in his class because it’s inert.

[00:29:36] And so like blowing glass and doing science has been hand in hand. So. At the beginning of time. And I mean, it’s one of the most, uh, it still is probably the most, um, hands-on, um, trait, right? Because you can’t automate class boy from a scientific perspective, at least, uh, at least to my knowledge still to this day, it’s all like every, like if everyone in the industry that’s an operator right now.[00:30:00]

[00:30:00] Round bottom flask, that’s on a white, still a white distillation system, like a Pope or a VTS or whatever. All of those are. Hand-blown all of the glass columns that do the distillation are all. Hand-blown the amount of scientific glass that permeate like glass and cannabis, especially nowadays with how much standard, uh, science is going on.

[00:30:19] And all of that is they just go hand in hand. It permeates the industry

[00:30:23]Chris Piazza: so much. You’re spot on. That was an, that was an I w I want to change my answer to what he said

[00:30:33]Bryan Fields: was the chemist and him writing.

[00:30:39]Chris Piazza: We could have talked a little bit more about the electrons and everything else.

[00:30:44]Kellan Finney: We can still do that nerd out hall if you want.

[00:30:49]Chris Piazza: It was pretty cool. Yeah. That was what we were doing. So we were shooting. Like it was an electrical charge that would show. From one side and then it would reflect off of a titanium disk [00:31:00] and it would knock off one of the electrons.

[00:31:01] And that’s how you create the, uh, um, the x-ray from like, yeah, I don’t know. It’s been a long time since I’ve gone down this rabbit hole,

[00:31:11]Kellan Finney: the how, like how the temperature of the glass and all that stuff affects like how the light travels through it. It’s insane. How, like the amount of attention to detail assigned to the class requires is phenomenal.

[00:31:21] Right? Mad respect for anyone that can do it.

[00:31:25]Chris Piazza: In my opinion, I’ll shoot you a picture of, uh, of one. When I get back into town, I would love that.

[00:31:31]Kellan Finney: Thank you,

[00:31:33]Bryan Fields: Chris. Since you’ve been in the cabinet industry, what has been the biggest misconduct?

[00:31:39]Chris Piazza: Huh that it’s bad for you.

[00:31:46] Um, yeah. You know that, uh, I think that’s, I mean, I don’t know what else to say. That would be the one that my dad he’s a he’s 76 and for the longest time he was so against it. But when I start to [00:32:00] hear it, Changed his mind. It’s, that’s pretty cool. You know? Um, and, uh, I don’t know, just thinking a lot about that.

[00:32:08]Bryan Fields: Yeah. That’s really well said for, we do predictions. We ask all of our guests, if you could sum up your experience in a main takeaway or lesson learned to pass on to the next generation, what would it be?

[00:32:20]Chris Piazza: Hmm, we have a, if you have a good idea, sometimes timing is more important than the idea. So don’t let.

[00:32:30]Bryan Fields: Nice. We haven’t had that one. That’s a, that’s a really good, yeah. All right. Prediction time, Chris. It’s 2030. What percentage of cannabis? Flower consumers will own the glass piece.

[00:32:45]Chris Piazza: Whoa.

[00:32:48] 75.

[00:32:51]Kellan Finney: Kelly a Honda. I think, I mean, I just think that consuming cannabis goes hand in hand with owning glass and they may, [00:33:00] they may not use the glass every, every day. They might prefer vaporizing it or like using a volcano or something like that. But they’ll, they’ll, they’ll definitely own a glass piece. I mean, it’s just as part of cannabis consumption and.

[00:33:14] Sorry,

[00:33:15]Chris Piazza: go ahead. Can you send us your resume by, by chance

[00:33:21]Kellan Finney: you got it? I don’t know if

[00:33:23]Bryan Fields: I’d say a hundred, right? Like of course a hundred is, is never the one that would take, but I was going to say probably four out of five, right? I think around 80% of people will have that. I think it’s just a cleaner experience plus it’s fast, but I think that there’s some people who consume.

[00:33:37] Who enjoy the process of just the rolling experience. And I think you never going to take that away from them, but I think they might have a glass piece of the same aspect for those times where they don’t want to roll it. So I think for sure, as we continue to progress forward and becomes, you know, a way more traditional mechanism, I think it will become very popular.

[00:33:56]Kellan Finney: One more question. This is, I don’t know why we didn’t ask this book [00:34:00] sooner. I’ve always been curious about the ball jar manufacturing. Method, how complex is it? Is it really like bat crazy that they’re like, what makes ball jars? Cause like ballparks, every one of the whole industry uses ball charts, but, and ball, I mean, they started an aerospace company because their glass manufacturing capabilities.

[00:34:18] Is there something special about that in terms of how they manufacture their targets?

[00:34:21]Chris Piazza: Honestly, I wish I could give you more. I that’s one that I don’t know a ton about. So I don’t, I like to speak on things that I know I don’t like to, you know, so, um, Yeah, no. I mean

[00:34:32]Kellan Finney: like, cause like ball jars and Curt guards, there’s only those two brands.

[00:34:35] And I mean, like I cannot even imagine how much money ball makes from the industry. Just, I mean, like everyone uses ball jars,

[00:34:45]Chris Piazza: I would say Majesta. So I just, I wouldn’t speak on it, but I would, I would assume that it had something to do more about the ceiling side than it had to do about the glass itself.

[00:34:55] Yeah.

[00:34:55]Kellan Finney: I mean, Who is like every single jar is within like two or three grams of each other when you [00:35:00] tear them. So it’s a very accurate manufacturing process that they have dialed down for sure.

[00:35:05]Chris Piazza: Nice. Nice. All right. That was my last question.

[00:35:08]Bryan Fields: That’s something that never kind of, uh, popped in my head. So I’m glad you got a chance to share that.

[00:35:14] So Chris, for our listeners, they want to get in touch. They want to learn more. Where can they find you in your.

[00:35:19]Chris Piazza: So Canon devices.com, C a N N a D E V I C S. Um, that’s the best place. There’s a little, a contact form. If there’s any questions or any of that, um, you know, uh, Instagram, Canon devices, and then, uh, I’m on LinkedIn.

[00:35:37] Chris Piazza. I believe it’s crispy. AZA. I L um, yeah, just change my profile picture. So I’ll actually look like this a little bit more nice short hair hold on. Was like along like, yeah, but, um, LinkedIn is a good place for it and, uh, yeah, that’s about it. Cool. We’ll link it all up

[00:35:56]Bryan Fields: in the show notes. Thanks for taking the time, Chris.

[00:35:58]Chris Piazza: Awesome. Well, thank you guys for the [00:36:00] opportunity. Absolutely.

Share and Enjoy !

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!